Clinical trial NCT02527746
Conditions: Neutropenia Breast Cancer
Sponsor: EVIVE Biotechnology
Start date: 2012-12-01; Completion date: 2013-12-01
Enrollment: 18 participants; Allocation: NON_RANDOMIZED; Intervention model: PARALLEL

Brief summary:
A Phase I, dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of F-627 in female breast cancer patients who received up to 4 cycles of Epirubicin and Cyclophosphamide. 18 patients (6 patients each cohort) were assigned to three escalated dose cohorts of 80, 240 and 320 µg/kg.

Detailed description:
A Phase I, dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of F-627 in female breast cancer patients receiving 4 cycles of EC (Epirubicin plus Cyclophosphamide) chemotherapy.

18 patients (6 patients each cohort) were assigned to three sequential doses cohort of F-627 at the dose of 80, 240 and 320 µg/kg. The patients received chemotherapy (100 mg/m\^2 epirubicin and 600 mg/m\^2 cyclophosphamide) administrated by i.v. injection on Day 1 and F-627 by s.c. injection on Day 3 of each cycle for 4 cycles. If no dose-limiting toxicity (DLT) was observed in 6 patients during first cycle, the next cohort was escalated.

Blood samples were collected for completed blood counts with differential, serum F-627 concentration and safety evaluation at different point following F-672 injection.

The decision to proceed to the next higher dose was made jointly by the sponsor's medical expert and the investigator based upon the review of safety data in the first cycle treatment.

Arms: arm 1: F-627 at the dose of 80 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles. arm 2: F-627 at the dose of 240 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles. arm 3: F-627 at the dose of 320 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
Interventions: intervention 1: F-627 intervention 2: EC regimen
Intervention descriptions: intervention 1: F-627 subcutaneous injection on Day 3 of each cycle for 4 cycles. Dose-escalation method was used. intervention 2: Epirubicin 100 mg/m\^2 (in vein) and Cyclophosphamide 600 mg/m\^2 (in vein) on Day 1 of each cycle for 4 cycles.

Protocol documents:
Prot_000.pdf: 
F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 1 of 54  
 
Title Page 
 
 
 
 
 
 
 
Clinical Study Protocol 
 
 
 
A Single-Center, Open-Label, Dose-Escalation Phase I Clinical Trial of Recombinant Human 
Granulocyte Colony Stimulating Factor-Fc Fusion Protein for Injection as an Adjuvant to 
Chemotherapy in Subjects with Breast Cancer 
 
 
 
 
Protocol Number: 
2012-F-627-CH1 
Investigational Drug: 
Recombinant human granulocyte colony stimulating factor-Fc fusion 
protein (F-627) 
Clinical Phase: 
Phase I 
Current Version No.: 
Amendment 1.0 
Issue Date of Current 
Version: 
May 13, 2013 
Original Version No./ 
Issue Date: 
Final Version: 2.5/Dec. 3, 2012 
Study Site: 
Fudan University Shanghai Cancer Center 
Address: No. 270 Dong’an Road,  
Shanghai, China 
Postal Code: 200032 
Principal Investigator 
Professor Cao Junning  
Tel.: +86-021-61733900 
Sponsor 
Generon (Shanghai) Corporation Ltd. 
Address: Building 9, No. 787 Kangqiao  
Road, Shanghai, China  
Postal Code: 201315 
Contact 
Huang Cheng  
Tel.: +86-021-61760866 
 
 
 
 
 
 
 
Statement of ownership: This protocol is the property of Generon (Shanghai) Corporation Ltd. 
and may not be distributed, copied, or published by any individual or entity without authorization. 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 1


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 2 of 54  
 
Summary of Amendments of Protocol 
 
 
 
Amendments of this protocol include: 
 
1. 
In Section 4.1, "dose delay and one-time reduction due to toxicities other than myelotoxicity 
(such as cardiotoxicity) are permitted" was changed to "Dose delay and one dose reduction due to 
chemotherapy-induced toxicities (such as cardiotoxicity) are permitted". 
 
2. 
Item 4 of the inclusion criteria "Absolute neutrophil count (ANC) ≥ 2.0 × 109/L, hemoglobin (Hb) 
≥ 11.5 g/dL, and platelet (PLT) ≥ 100 × 109/L prior to chemotherapy" was changed to "Absolute 
neutrophil count (ANC) ≥ 2.0 × 109/L, hemoglobin (Hb) ≥ 11.0 g/dL, and platelet (PLT) ≥ 100 × 
109/L prior to chemotherapy". 
 
3. 
Exclusion criteria 11 "history of TB; or history of TB exposure, unless negative for tuberculin test; 
TB patients undergoing treatment; or suspected TB evaluated by chest x-ray" was changed to 
"With active tuberculosis (TB); history of TB exposure, unless negative for tuberculin test; 
TB patients undergoing treatment; or suspected TB evaluated by chest x-ray". 
 
4. 
The window for examination on the first day of cycles 2–4, namely day 22, day 43 and day 64 of 
the study, was set to 3 days. 
 
5. 
Administration time of the study drug was changed from morning (08:00 ± 1:00) to morning 
(09:00 ± 1:00). 
 
6. 
Blood sampling points were added on day 16 (± 24 hrs) and day 21 (± 24 hrs) for pharmacokinetics 
(PK) in cycle 1 and cycle 3. 
 
7. 
Time points for serum antibody collection were changed from each day 8, day 13 and day 21 in 
cycles 1–4 to each day 1, day 8 and day 13 in cycles 1–4 and day 22 in cycle 4. 
 
8. 
"The recommended concentration of F-627 is 2.0 mg/mL" was deleted from Section 5.5; "See the 
drug preparation procedure manual" was added. 
 
9. 
In Section 6.2, "For chemotherapy cycles 2–4 (day 3–day 21 of each chemotherapy cycle, i.e., day 
23–day 84 of the study), starting on each day 2 of cycles 2–4, oral temperature measurement and 
routine blood test will be performed every other day" was changed to "For chemotherapy cycles 
2–4 (days 3–21 of each chemotherapy cycle, i.e., days 23–84 of the study), starting from day 3, 
oral temperature measurement and routine blood test will be performed every other day". 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 2


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 3 of 54  
 
Signature Page 
 
 
 
 
A Single-Center, Open-Label, Dose-Escalation Phase I Clinical Trial of Recombinant Human 
Granulocyte Colony Stimulating Factor-Fc Fusion Protein for Injection as an Adjuvant to 
Chemotherapy in Subjects with Breast Cancer 
 
 
Protocol Number: 2012-F-627-CH1    
 
 
I confirm that I have read, understood and agreed to abide by all provisions in the Clinical Study 
Protocol (Number: 2012-F-627-CH1, Date: May 13, 2013). I shall carefully carry out my duties 
in accordance with the Good Clinical Practice. 
 
 
 
 
Principal Investigator 
 
 
 
Cao Junning 
 
 
 
Signature 
Date 
 
 
Cao Junning 
 
 
Principal Investigator (Printed Name) 
 
 
 
 
Sponsor 
 
 
Huang Cheng 
 
 
 
Signature 
Date 
 
 
Huang Cheng 
 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 3


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 4 of 54  
 
Emergency Contacts of Generon (Shanghai) Corporation Ltd. 
 
 
 
 
In case of a medical emergency, the clinical study leading official may be contacted. If the 
director is not available, the protocol writer or the clinical research associate (CRA) may be 
contacted via the information shown in the table below. 
 
 
 
Name 
Contact Number 
Project leading official 
Huang Cheng 
021-6176-0866 
or 18621697558 
Protocol Writer 
Tang Kaiyang/Huang 
Cheng 
021-6176-0866 
or 18621697558 
24-Hour Emergency 
Contact Number 
Huang Cheng 
021-6176-0866 
or 18621697558 
 
 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 4


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 5 of 54  
Synopsis of Phase I Clinical Study Protocol 
Investigational Drug 
Recombinant human granulocyte colony stimulating factor-Fc fusion protein for injection 
Protocol No. 
2012-F-627-CH1 
Title 
A single-center, open-label, dose-escalation phase I clinical trial of recombinant human 
granulocyte colony stimulating factor-Fc fusion protein for injection as an adjuvant to 
chemotherapy in subjects with breast cancer 
Mechanism of 
Drug Action 
The recombinant human granulocyte colony stimulating factor (rhG-CSF)-Fc fusion protein 
is a long-acting rhG-CSF expressed in CHO cells. Each molecule of rhG-CSF-Fc fusion 
protein contains two G-CSF dimer molecules, which may overcome the weak bioactivity of 
pegfilgrastim and produce a stronger receptor activation signal, thereby accelerating the 
differentiation and proliferation of neutrophils in bone marrow. Also, preclinical studies have 
shown that the pharmacokinetic and pharmacodynamic properties of rhG-CSF-Fc is different 
from or superior to pegfilgrastim, and therefore it decreases the severity of neutropenia and 
reduces the duration of severe neutropenia in cancer patients after chemotherapy. 
Study Site 
Fudan University Shanghai Cancer Center 
Pharmacokinetic 
Analysis Site 
Covance Pharmaceutical Research and Development (Shanghai) Co., Ltd. 
Number of Planned 
Enrollment 
It is planned to enroll 18 subjects 
Study Population 
Female postoperative patients with breast cancer who receive adjuvant chemotherapy will be 
enrolled in this study. Eligible patients should have received no chemotherapy or only one 
chemotherapy. 
The chemotherapy used for this trial is EC→P or EC→T, that is: epirubicin 100 mg/m2, i.v. + 
cyclophosphamide 600 mg/m2, i.v. on day 1, repeat cycle every 21 days for 4 cycles. After 
completing the evaluation for all 4 cycles, subjects will receive 4 subsequent cycles of 
sequential chemotherapy (either paclitaxel or docetaxel) and supportive care according to 
routine practice. 
Objectives 
Primary Objective: 
To evaluate the safety and tolerability of recombinant human granulocyte colony stimulating 
factor-Fc fusion protein for injection (F-627) in treatment of female postoperative breast cancer 
patients who require adjuvant chemotherapy in a single-center, open-label, single-dose and 
repeated-dose, dose-escalation phase I clinical trial. 
Secondary Objectives: 
1. 
To evaluate the pharmacokinetics of F-627 by determining the serum drug concentrations 
of F-627 at different time points after dosing; 
2. 
To evaluate the pharmacodynamics of F-627 by analyzing the relationship between serum 
drug concentrations of F-627 and neutrophil counts in blood at different time points after 
dosing, and to provide a recommended dose for phase II clinical trial. 
Exploratory Objectives: 
1. 
To observe the number of days in which absolute neutrophil count is less than 0.5 × 109/L 
in cycle 1 of chemotherapy, the average time of ANC recovery, and the number of 
days in which absolute neutrophil count is less than 1 × 109/L, and to provide guiding 
significance for phase II clinical trial. 
2. 
To evaluate the potential immunogenicity of F-627 by testing anti-F-627 antibodies 
(IgG and IgM) in serum. 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 5


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 6 of 54  
Dosage and 
Administration 
This study includes 3 dose cohorts, 80, 240, and 320 µg/kg, each of which will enroll 6 patients 
with breast cancer sequentially receiving adjuvant chemotherapy. Subjects in each cohort will 
receive a single-dose of F-627 by subcutaneous injection approximately 48 hours after the 
completion of chemotherapy. Blood samples are then collected at multiple time points during 
the subsequent follow-up visits, to evaluate the pharmacokinetics, pharmacodynamics, and 
safety of the drug. If dose-limiting toxicities are not observed before the start of cycle 2, then 
the same dose of F-627 is to be given at approximately 48 hours after each chemotherapy in 
cycles 2-4. 
Dose-Escalation 
The starting dose is 80 µg/kg. Only after 6 subjects have completed the treatment and observation 
of the first cycle, the sponsor and investigator will determine whether to proceed to the next 
higher dose based on the safety evaluation. This is also applicable to the 240 µg/kg cohort. Dose 
escalation is not pursued after 6 subjects in the 320 µg/kg cohort complete the evaluation. Dose 
escalation should be stopped if 2 cases of DLTs are observed in the first cycle in each cohort. 
Rationale for 
Dose Selection 
Results from 3-month repeat dosing toxicity studies showed that the no-observed-adverse- 
effect-levels (NOAEL) of F-627 was 1000 µg/kg in rats and 675 µg/kg in cynomolgus 
monkeys. F-627 is a recombinant fusion protein with a molecular weight of 95000 Daltons. 
Results from preclinical studies showed that the toxicity of F-627 was due to the amplification 
of pharmacodynamics, which is closely associated with the dose (expressed in mg/kg) in 
various different species. The maximum safe starting dose of F-627 was calculated to be 
67.5 µg/kg when converted using mg/kg, which is one-tenth of the NOAEL in cynomolgus 
monkeys. In a phase I clinical trial in healthy volunteers, male subjects received a single-dose 
of F-627 by subcutaneous injection at doses of 30, 60, 120, 240, and 360 µg/kg. Results 
showed that neutrophil increased across all dose cohort up to 96 hours following the 
administration of F-627. The maximum dose of 360 µg/kg was safe and no serious adverse 
events observed. Higher incidence rate of adverse event was observed with the increasing dose. 
Low dose was better tolerated than high dose. According to the animal studies and phase I 
clinical trial, 80 µg/kg is safe as the starting dose for patients. Firstly, the maximum dose 
should not exceed the maximum dose determined in the phase I clinical trial. Secondly,  
the G-CSF mole number of 240 µg/kg F-627 is comparable to that of 100 µg/kg pegfilgrastim. 
Finally, 60 µg/kg cohort exhibited superior pharmacodynamics than the 150 µg/kg cohort in 
treating the chemotherapy-induced neutropenia in monkey models. 
Dose-Limiting 
Toxicity 
Dose-limiting toxicity (DLT) refers to an intolerable toxicity that is experienced during the 
treatment with investigational drug and limits the further dose escalations. DLT is defined as 
any grade 3 or greater adverse event related to the investigational drug that observed in cycle 1 
(21 days). Adverse events will be assessed according to NCI CTCAE V4.03 criteria. 
After 6 subjects in each dose of F-627 cohort have completed the treatment and observation 
of first cycle, the trial may proceed into the next dose cohort only if less than 2 subjects 
develop DLT. If a grade 3 or greater adverse event related to the investigational drug is 
observed in cycles 2-4, then the investigator and sponsor will determine together whether the 
adverse event would affect further dose escalations. 
Safety Evaluation 
Safety endpoints include laboratory measurements, physical examinations, vital signs, and 
performance status, as well as adverse events. The incidence rate and severity of adverse events 
(AEs) will be assessed according to NCI CTCAE 4.03 criteria. 
Salvage Therapy 
During the study, an approved G-CSF treatment should be given to the patient as salvage therapy 
in the case of febrile neutropenia (defined as ANC < 1.0 × 109/L; a single measurement of body 
temperature > 38.3 °C or a fever ≥ 38.0 °C sustained for longer than 1 h; Note: temperature 
measurements is based on oral temperature or equivalent armpit/rectal temperature) or grade 
4 neutropenia lasting greater than 3 days. The sponsor recommends GRAN® (filgrastim) at a dose 
equivalent to 5 µg/kg/day of G-CSF, once daily for ≤ 2 weeks or until neutrophil count recovers 
to 1.0 × 109/L. 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 6


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 7 of 54  
Inclusion Criteria 
All of the following conditions must be met: 
1) 18-75 years old; 
2) Female postoperative breast cancer patients who require adjuvant chemotherapy, 
and are planned to receive 4 cycles of EC chemotherapy; 
3) ECOG performance status of 0-1; 
4) Absolute neutrophil count (ANC) ≥ 2.0 × 109/L, hemoglobin (Hb) ≥ 11.0 g/dL, 
and platelet (PLT) ≥ 100 × 109/L prior to chemotherapy 
5) Hepatic and renal function within the normal range; 
6) Left ventricular ejection fraction greater than 50%; 
7) Willing to sign the informed consent form and able to comply with protocol requirements; 
Exclusion Criteria 
Subjects who meet any of the following must be excluded from this study: 
1) 
Women in pregnancy or breastfeeding; Women of child–bearing potential have a positive 
pregnancy test result prior to the first dose; 
2) 
Life expectancy less than 12 months; 
3) 
Radiation therapy within 4 weeks prior to enrollment; 
4) 
Breast cancer patients who have received neoadjuvant chemotherapy before radical 
mastectomy; 
5) 
Prior bone marrow or stem cell transplant; 
6) 
With other malignant tumors other than breast cancer; 
7) 
Have received G-CSF treatment within 6 weeks prior to enrollment; 
8) 
Diagnosed with acute congestive heart failure, cardiomyopathy, or myocardial infarction 
by clinical diagnosis, ECG or other approaches; 
9) 
With any disease that may cause splenomegaly; 
10) With acute infection, chronic active Hepatitis B within 1 year (unless patients tested 
negative for HBsAg prior to enrollment), or Hepatitis C; 
11) With active tuberculosis (TB); history of TB exposure, unless negative for tuberculin test; 
TB patients undergoing treatment; or suspected TB evaluated by chest x-ray; 
12) Known HIV positive or AIDS; 
13) With sickle cell anemia; 
14) With alcohol or drug abuse that may affect the compliance with the study; 
15) With known hypersensitivity to E. coli derived proteins, G-CSF, or excipients; 
16) Has received any other investigational drug within 4 weeks prior to enrollment; 
17) Patients with diseases or symptoms unsuitable for participating in the clinical trial based 
on the investigator's judgment; 
Criteria for 
Terminating Study 
1) Incidence rate and severity of serious adverse events (SAEs) indicate the study should be 
terminated early as determined by the investigators and the sponsor; 
2) The dose-limiting toxicity of the subjects does not recover or cannot be relieved; 
3) The investigators question the safety of the drug and believe that the continuation of the 
study may pose serious risks to the subjects; 
4) The maximum dose set in the clinical trial has been reached; 
5) Data fraud, or inaccurate/incomplete collection of data; 
Criteria for Subject 
Withdrawal 
Subjects will withdraw from the study with a written explanation when the following 
conditions occur. 
1) Subject withdraws voluntarily during the trial; 
2) The investigator considers that withdrawal is for the best interest of the subject; 
3) The investigator or subject believes that to continue the trial may result in intolerable 
adverse events; 
4) Complications or worsening co-morbidities affecting subject's participation occur; 
5) Subject is found to violate protocol after enrollment, or a major protocol violation occurs 
during the trial; 
6) When a safety concern regarding the investigational drug arises, but data is yet unknown, 
resulting in potential risks if subjects continue the trial; 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 7


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 8 of 54  
Drop-Out Criteria 
Determination of drop-outs: Eligible subjects who have signed the informed consent form 
and been enrolled have the right to withdraw from the study at any time. Subjects who do not 
complete the entire observation are considered drop-outs regardless of the time or reason of the 
withdrawal. A replacement should be implemented immediately according to the original plan 
when a drop-out occurs. Blood samples from drop-out subjects should be retained. 
Evaluations: 
Safety Evaluation 
Medical consultation, physical examinations, vital signs, laboratory measurements (hematology, 
clinical chemistry, routine urinalysis, etc.), weight, ECG, abdominal ultrasound and adverse 
event evaluation. 
Pharmacokinetic 
Evaluation 
Serum: Cmax, Tmax, MRT, Vd, Kel, Tl/2z, AUClast, AUC, CL/F, Vz/F 
Pharmacodynamic 
Evaluation 
Absolute neutrophil count (ANC) after dosing, as well as the number of days in which ANC 
is less than 0.5 × 109/L, the number of days in which ANC is less than 1.0 × 109/L, and the 
time ANC recovers to 1.0 × 109/L after chemotherapy in cycles 1 and 2-4 are observed. 
Statistical Analysis: 
Descriptive statistics will be summarized for all variables obtained at various observation time points by dose cohorts, 
unless the protocol specifies that statistical analysis at a particular time point is not required. Overall, continuous 
variables (such as age) will be descriptively summarized with observed numbers, mean, median, standard deviation, 
minimum, and maximum. Categorical variables will be descriptively summarized with frequency and percentage based 
on each category. Continuous safety analysis of adverse events related to the investigational drug and other safety 
endpoints will be performed. 
The analysis dataset includes all enrolled subjects who have received at least one dose of the study drug. This dataset 
is available for all analyses. Statistical methods are detailed in the Statistical Analysis Plan. 
Pharmacokinetics 
Two phases (single-dose and repeated dose); All PK parameters will be summarized using 
descriptive statistics by dose cohorts. The non-compartmental analysis of blood concentration 
data will be performed by the central laboratory using WinNonlin Enterprise. 
Cmax (natural logarithm), AUC(0-inf), AUCt, and AUClast of the single-dose and repeated-dose 
phase were analyzed using one-way ANOVA, with dose cohort as the fixed factor. The least 
squares mean difference between the two dose cohorts and the 90% confidence intervals are 
obtained from the analysis of variance, then the least squares geometric means ratio and the 
90% confidence intervals are obtained by taking the antilog. 
Pharmacodynamic 
Evaluation 
The number of days in which ANC is less than 0.5 × 109/L, the number of days in which ANC 
is less than 1 × 109/L, and the mean time of ANC recovery to 1.0 × 109/L in chemotherapy of 
cycles 1 and 2-4 of chemotherapy are calculated for each dose cohort. ANC profiles in various 
dose cohorts are plotted. 
Safety Evaluation 
All adverse events are listed by patient, and coded by MedDRA as per System Organ Class 
and Preferred Term. Inferential statistics are not required for safety endpoints. Abnormal values 
of laboratory measurements, vital signs, ECG, and other safety endpoints need to be noted. The 
incidence rate and severity of adverse events (AEs) will be assessed according to NCI CTCAE 
4.03 criteria. 
 
 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 8


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 9 of 54  
 
Table of Contents 
 
1. 
STUDY BACKGROUND ............................................................................................................ 13 
1.1 
Introduction to F-627 ......................................................................................................... 13 
1.1.1 
Name, structure, and physicochemical properties ............................................................. 13 
1.1.2 
Mechanism of action .......................................................................................................... 14 
1.1.3 
Preclinical pharmacokinetics study .................................................................................... 15 
1.1.4 
Preclinical toxicology study ............................................................................................... 15 
1.1.5 
Preclinical pharmacodynamic study .................................................................................. 16 
1.1.6 
Previous clinical studies ..................................................................................................... 17 
1.2 
Overall Evaluation of Adjuvant Measures and Efficacy of Chemotherapy for Cancer ..... 20 
2. 
STUDY OBJECTIVES ................................................................................................................ 21 
2.1 
Primary Objective .............................................................................................................. 21 
2.2 
Secondary Objectives ......................................................................................................... 21 
2.3 
Exploratory Objectives ...................................................................................................... 21 
3. 
STUDY PLAN AND METHODOLOGY ................................................................................... 21 
3.1 
Overall Study Design and Schedule of Study Procedures ................................................. 21 
3.2 
Evidence for Dose Determination ...................................................................................... 23 
3.3 
Single Dose and Repeated Dose ........................................................................................ 24 
3.4 
Dose Escalation .................................................................................................................. 24 
3.5 
Dose-Limiting Toxicity (DLT) .......................................................................................... 25 
3.6 
Risk, Benefit and Ethical Evaluations................................................................................ 25 
4. 
STUDY POPULATION ............................................................................................................... 26 
4.1 
Study Population and Number of Subjects ........................................................................ 26 
4.2 
Inclusion Criteria................................................................................................................ 26 
4.3 
Exclusion Criteria .............................................................................................................. 27 
4.4 
Criteria for Terminating Study ........................................................................................... 27 
4.5 
Criteria for Subject Withdrawal ......................................................................................... 28 
4.6 
Drop-Out Criteria ............................................................................................................... 28 
4.7 
Withdrawal-Related Procedures and Handling .................................................................. 28 
5. 
INVESTIGATIONAL DRUG AND TREATMENT ................................................................ 28 
5.1 
Source................................................................................................................................. 28 
5.2 
Strength and Expiration Date ............................................................................................. 29 
5.3 
Labeling ............................................................................................................................. 29 
5.4 
Storage ............................................................................................................................... 29 
5.5 
Drug Preparation ................................................................................................................ 29 
5.6 
Administration and Precautions ......................................................................................... 30 
5.7 
Salvage Therapy ................................................................................................................. 30 
5.8 
Drug Management.............................................................................................................. 30 
5.9 
Principles and Methods for Treatment of Drug Toxicities ................................................ 31 
5.10 
Treatment Compliance ....................................................................................................... 31 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 9


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 10 of 54  
6. 
EVALUATIONS AND ENDPOINTS ........................................................................................ 31 
6.1 
Evaluations During Screening ........................................................................................... 31 
6.2 
Clinical Evaluations During and After F-627 Treatment ................................................... 32 
6.3 
Pharmacokinetic (PK) Evaluations .................................................................................... 34 
6.3.1 
Determination and analysis of PK serum samples ............................................................. 34 
6.3.2 
Collection, handling, and storage of PK blood samples .................................................... 34 
6.3.3 
Blood sampling of single-dose and repeated-dose PK studies .......................................... 34 
6.4 
Pharmacodynamic Evaluation............................................................................................ 35 
6.5 
Safety Evaluation ............................................................................................................... 35 
6.6 
Serum Antibody Assays and Evaluations .......................................................................... 36 
7. 
ADVERSE EVENTS .................................................................................................................... 36 
7.1 
Adverse Events (AEs) and Abnormal Values of Laboratory Measurements .................... 36 
7.1.1 
Clinical adverse events....................................................................................................... 36 
7.1.2 
Treatment and follow-up of adverse events ....................................................................... 38 
7.1.3 
Abnormal values of laboratory measurements ................................................................... 38 
7.2 
Adverse Event Management .............................................................................................. 39 
8. 
STATISTICAL METHODS AND ANALYSIS ........................................................................ 40 
8.1 
Pharmacokinetic Evaluation .............................................................................................. 40 
8.2 
Pharmacodynamics Evaluation .......................................................................................... 41 
8.3 
Statistical Analysis of Safety Data ..................................................................................... 41 
9. 
DATA MANAGEMENT ............................................................................................................. 41 
9.1 
Data Filling-In by Investigator ........................................................................................... 41 
9.2 
Requirement of Data Monitoring by Clinical Research Associate .................................... 42 
9.3 
Data Entry, Recording and Management ........................................................................... 42 
9.4 
Audits and Inspections ....................................................................................................... 43 
9.5 
Personnel Training ............................................................................................................. 43 
10. STUDY PROTOCOL REVISIONS ........................................................................................... 43 
11. STUDY MANAGEMENT ........................................................................................................... 43 
11.1 
Clinical Study Agreement .................................................................................................. 43 
11.2 
Study Schedule and Requirements for Early Termination ................................................. 44 
12. ETHICS ......................................................................................................................................... 44 
12.1 
Ethics of Clinical Study ..................................................................................................... 44 
12.2 
Independent Ethics Committee (IEC) ................................................................................ 44 
12.3 
Informed Consent Form (ICF) ........................................................................................... 45 
12.4 
Privacy Protection .............................................................................................................. 45 
13. QUALITY CONTROL OF CLINICAL TRIAL ....................................................................... 45 
14. DATA STORAGE AND USE ..................................................................................................... 46 
15. REFERENCES ............................................................................................................................. 46 
Appendix 1 
Analysis of Causality Between Drugs and Adverse Events ....................................... 47 
Appendix 2 
ECOG Performance Status Scoring Standard ............................................................. 48 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 10


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 11 of 54  
 
List of Tables 
 
Table 30-1. Comparison of PK parameters between F-627 and pegfilgrastim. ...................................... 15 
Table 30-2. Summary of F-627 preclinical safety evaluation tests......................................................... 15 
Table 30-3. Summary of adverse events in the phase I clinical trial. ..................................................... 17 
Table 30-4. Human PK parameters in phase I clinical trial. ................................................................... 18 
Table 30-5. Summary of pharmacodynamics in phase I clinical trial. ................................................... 19 
Table 30-6. Schedule of F-627 study procedures. .................................................................................. 22 
Table 30-7. Rationale for F-627 doses in clinical trials. ......................................................................... 24 
Table 30-8. Blood sampling time of single-dose and repeated-dose PK studies. ................................... 35 
 
 
List of Figures 
 
Figure 30-1. Semi-logarithmic plot of concentration-time (hours) after different doses of  
F-627 in healthy male subjects........................................................................................... 19 
Figure 30-2. Mean ANC in subjects after administration of different doses of F-627. .......................... 19 
 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 11


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 12 of 54  
Abbreviations and Terms 
 
Abbreviations and Terms Definitions 
AEs 
Adverse Events 
ALP 
Alkaline Phosphatase 
ANC 
Absolute Neutrophil Count 
AUC 
Area Under Concentration-Time Curve 
CL/F 
Total Clearance 
Cmax 
Maximum Serum Concentration 
DHL 
Lactate Dehydrogenase 
ECG 
Electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
ED50 
Median Effective Dose 
EMEA 
European Medicines Agency 
FDA 
U.S. Food & Drug Administration 
GCP 
Good Clinical Practice 
Kel 
Elimination rate constant 
MRT 
Mean Residence Time 
NCI CTC 
National Cancer Institute Common Terminology Criteria 
NOAEL 
No-Observed-Adverse-Effect Level 
PK/PD 
Pharmacokinetics/Pharmacodynamics 
Pubmed 
PubMed search system developed by the National Institutes of Health 
rhG-CSF-Fc 
Recombinant human granulocyte colony stimulating factor-Fc fusion protein 
SFDA 
State Food and Drug Administration 
Tmax 
Time to Peak 
Vd 
Apparent Volume of Distribution 
Vz/F 
Volume of Distribution 
WBC 
White Blood Cell 
WHO 
World Health Organization 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 12


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 13 of 54  
 
1. 
STUDY BACKGROUND 
1.1 
Introduction to F-627 
1.1.1 
Name, structure, and physicochemical properties 
All recombinant human granulocyte colony stimulating factors (rhG-CSF) that have already been 
approved for marketing in China and other countries, and the more than 10 rhG-CSFs in clinical and 
pre-clinical studies, are monomeric G-CSFs (Pharmaproject ref). This rhG-CSF-Fc fusion protein, is a 
rhG-CSF dimer expressed in CHO cells, based on the technology of Fc fusion, whose IP is protected by 
Chinese patents. The Fc fragment is derived from human immunoglobulin with prolonged effects. The 
half-life of IgG immunoglobulins may be up to 3 weeks in human blood. Recombinant protein drugs 
generated using the Fc fusion protein technology such as Enbrel (for rheumatoid arthritis, soluble 
TNFα receptor and IgG1) and chimeric monoclonal antibodies such as Remicade (for rheumatoid 
arthritis, anti-TNFα IgG1) and Abciximab (for platelet aggregation, anti-GPIIb/IIIa IgG1) have been 
successfully marketed. In addition, D-Mab (for osteoporosis, anti-RANKL IgG2) has been approved for 
marketing by FDA. The safety and efficacy of Fc fusion protein have been validated for clinical 
application. 
 
The Fc region of human immunoglobulin mediates effector functions, such as antibody-dependent 
cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and plays an important 
role in the immune defense. ADCC refers to the phagocytosis or killing of target cells, which is 
mediated by the specific binding of antibody or the Fc fusion protein via the Fc region to the Fcγ 
receptor expressed on the surface of effector cells, such as natural killer cells and macrophages. CDC 
refers to the killing of target cells by the activation of complements, which is mediated by the specific 
binding of antibody or the Fc fusion protein via the Fc region to plasma proteins, such as complement 
proteins C1q, C3 and C4. 
 
The effector function of the Fc fragment in rhG-CSF-Fc is reduced and eliminated by two methods 
(U.S. Patent: 6797493, Chinese Patent: 02126839.8). Among the four human IgGs, IgG2 has a weaker 
effector function. In regard to FcγRI and FcγRIIB, the affinity of FcγRI for the four human IgGs is in 
the order of: IgG1, IgG3 > IgG4 >> IgG2. The affinity of FcγRIIB for the four human IgGs is: IgG3 > 
IgG1 > IgG4 > IgG2 (Van Sorge et al 2003, Tissue Antigens. Vol. 61:189–202). Therefore, IgG2 Fc 
was used for the making of the fusion protein. Given the substitution of proline (a proven functional 
residue in CDC) at position 331 of IgG2 with serine, the fusion protein generated by this method no 
longer has any effector function. The above amino acid number (e.g. position 331) was calculated using 
the EU numbering system described by Kabat et al. (Sequence of Proteins of Immunological Interest, 
edition5, United States Department of Health and Human Services, 1991). 
 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 13


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 14 of 54  
In the construction of the G-CSF-Fc fusion protein, a peptide linker comprising 16 amino acids was 
added between G-CSF and IgG2-Fc. The sequence of this linker is: 
GlySerGlyGlyGlySerGlyGlyGlyGlySerGlyGlyGlyGlySer. The purpose is to keep the Fc domain of the 
fusion protein away from the G-CSFR binding site and improve its bioactivity. In addition, the peptide 
linker may also allow one G-CSF to be distant from another G-CSF, and produce rhG-CSF in a dimeric 
form with two G-CSF molecules on a single Fc fragment. The rhG-CSF-Fc dimer may cause a stronger 
receptor activation compared with a rhG-CSF monomer, and thereby the bioactivity of the fusion 
protein can be further improved. 
1.1.2 
Mechanism of action 
The human granulocyte colony stimulating factor receptor (G-CSF receptor, G-CSFR) is a specific, 
812-amino acid single-chain receptor with high affinity to G-CSF. During neutrophil development, 
each cell expresses about 50–500 G-CSFR. The more mature neutrophils are, the higher the density of 
G-CSFR on their surfaces Tamada et al. performed a 2.8Ao diffraction analysis of the G-CSF: G-CSFR 
crystal (PNAS, 2008, Vol. 103: 3135-3140) and found that this complex exists in a 2:2 ratio, i.e., 
2 ligands with 2 receptors (Fig. 3-2). Each G-CSF molecule binds to one receptor. Only when two 
receptors binding to the G-CSF ligands interact with each other to form a 2:2 dimer, the C-terminal of 
the G-CSF receptor may activate the downstream signaling molecule, JAK2 (Janus tyrosine kinase). 
JAK2 then initiates gene transcription by activating STAT3, resulting in cell proliferation. 
Theoretically, dimeric ligands may be able to activate downstream signaling pathways faster and 
stronger than monomeric ligands. 
 
G-CSF receptors on neutrophils can not only transmit G-CSF signal, but also regulate the G-CSF 
concentration in the blood. During an infection or a neutropenic period, G-CSF concentrations in the 
blood will increase to stimulate the production of neutrophils. When absolute neutrophil count 
increases, the binding of G-CSF in the blood also increases, thereby maintaining a relatively stable G-
CSF concentration in vivo. 
 
Furthermore, in a clinical study of rhG-CSF (Schwinger et al, 1993, Bone Marrow Transplantation, Vol. 
11:489-492), it was found that peripheral blood precursor cells and peripheral blood stem cells increase 
drastically after the injection of rhG-CSF, which is called peripheral blood precursor cell (PBPC) 
and/or peripheral blood stem cell (PBSC) mobilization. Many hematopoietic growth factors such as 
SCF, FL, GM-CSF, and IL-3, as well as reagents affecting the character of bone marrow matrix 
proteins and adhesion molecules have the similar function of PBPC and/or PBSC mobilization. 
Therefore, peripheral blood cells collected after rhG-CSF injection, are enriched with PBPCs and 
PBSCs, and are widely used as donor cells for conventional bone marrow transplantation in developed 
countries. 
 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 14


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 15 of 54  
1.1.3 
Preclinical pharmacokinetics study 
Pharmacokinetics studies of F-627 in rats and cynomolgus monkeys showed that F-627 is a long-acting 
drug in vivo. F-627 demonstrated nonlinear pharmacokinetics. Blood drug concentration and ANC 
increase (PD response) is dose-dependent. In the study of F-627 (100 µg/kg) subcutaneous injection in 
rats, T1/2 was 7.6 ± 1.3 hours, Cmax was 162 ng/mL, and AUC was 4217 ± 641 ng/mL·*hr. In the study 
of pegfilgrastim (Neulasta, 100 µg/kg) in rats, T1/2 was 7.1 hours (Zamboni W.C, 2003, 
Pharmacotherapy, Vol.23 (8 pt2):9S-14S) and AUC was 1600 ng/mL·*hr (FDA IND). In cynomolgus 
monkey models with cyclophosphamide-induced neutropenia, the PK parameters of F-627 and 
pegfilgrastim at the equivalent dose were comparable (as shown in Table 30-1). However, F-627 
resulted in a faster neutrophil recovery compared with pegfilgrastim. 
 
Table 30-1. Comparison of PK parameters between F-627 and pegfilgrastim. 
 
Dose 60 µg/kg 
Tmax (hr) 
Cmax (ng/mL) 
AUC (ng/mL·hr) 
T½ (hr) 
F-627 (Female) 
8.0 
776 ± 155 
21289 ± 5744 
8.9 
F-627 (Male) 
8.0 
566 ± 162 
14515 ± 7324 
11 
Pegfilgrastim (Female) 
12.0 
482 ± 88 
25571 ± 474 
8.2 
Pegfilgrastim (Male) 
8.0 
574 ± 87 
21894 ± 2616 
8.7 
Note: The table shows the PK data after the first dose in the cynomolgus monkey model with cyclophosphamide-induced 
neutropenia. 
1.1.4 
Preclinical toxicology study 
A systematic preclinical safety evaluation of F-627 has been conducted according to SFDA's 
registration categories of biological products and requirements for submission dossiers. Refer to Table 
30-2 for the details of safety evaluation tests. In the repeat dosing toxicity studies in rats and 
cynomolgus monkeys, application requirements of FDA were taken into account by increasing the 
number of animals and the number of organs dissected. Meanwhile, the validation of PK/TK analysis 
method was in accordance with the application requirements of FDA/EMEA. In the 3-month repeat 
dosing toxicity studies, the no-observed-adverse-event-level (NOAEL) of F-627 was 1000 µg/kg in rats 
and 675 µg/kg in cynomolgus monkeys, which were the high dose selected in the dose design. 
 
Table 30-2. Summary of F-627 preclinical safety evaluation tests. 
 
Animal 
Study Title 
Dose (µg/kg) 
Administration 
Observation Time 
NOAEL 
µg/kg 
Rat 
Acute toxicity study 
100,500,2500,7500 
Single 
2 weeks 
 
Rat 
Dose range finding 
toxicity study 
30,100,300,1500 
Repeat 
4 weeks 
 
Rat 
Repeat dosing toxicity 
study 
100,300,1000 
Repeat 
Administration: 
3 months 
Recovery period: 
1 month 
1000 
Cynomolgus 
monkey 
Acute toxicity study 
300,3000 
Single 
2 weeks 
 
Cynomolgus 
Repeat dosing toxicity 
75,225,675 
Repeat 
Administration: 
675 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 15


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 16 of 54  
Animal 
Study Title 
Dose (µg/kg) 
Administration 
Observation Time 
NOAEL 
µg/kg 
monkey 
study 
3 months 
Recovery period: 
1 month 
Mouse 
Safety pharmacology 
study - spontaneous 
activity 
30,120,480 
Single 
10 minutes 
 
Mouse 
Safety pharmacology 
study - synergy of 
sodium pentobarbital 
hypnotic effect in mice 
30,120,480 
Single 
30 minutes 
 
Mouse 
Safety pharmacology 
study - hypnotic effect 
of sodium pentobarbital 
of subthreshold dose 
30,120,480 
Single 
30 minutes 
 
Rabbit 
Muscular irritation 
study 
400,1600 
Single 
48 hours, 16 days 
 
Rabbit 
Vascular irritation 
study 
400,1600 
Single 
48 hours, 16 days 
 
Guinea Pig 
Active anaphylaxis test Sensitization phase: 
100, 500; 
Challenge phase: 
sensitization dose × 2 
Sensitization for 
5 times 
once every other 
day 
30 minutes, 3 hours 
Rabbit 
RBC in vitro hemolysis 
test 
1000 µg/mL 
In vitro 
incubation 
3 hours 
 
 
Results from 3-month repeat dosing toxicity studies showed that the no-observed-adverse-effect-level 
(NOAEL) of F-627 was 1000 µg/kg in rats and 675 µg/kg in cynomolgus monkeys. F-627 is a 
recombinant fusion protein with a molecular weight of 95000 Daltons. Results from preclinical studies 
showed that the toxicity of F-627 was due to the exaggerated pharmacology effects, which is closely 
associated with the dose (expressed in mg/kg) in various different species. Based on the guideline 
issued by the FDA in 2005, the maximum safe starting dose of F-627 was calculated to be 67.5 µg/kg 
using mg/kg conversion, which is one-tenth of the NOAEL in cynomolgus monkeys. Based on the dose 
in the phase I clinical trial conducted in Australia, 80 µg/kg is a safe starting dose. 
1.1.5 
Preclinical pharmacodynamic study 
In vitro bioactivity study of F-627 
The in vitro bioactivity study of F-627 showed that the ED50 of F-627 was 0.68 ng/mL (7.58 pM) in the 
proliferative response of M-NFS-60 cell line. The proliferation effects of F-627 on M-NFS-60 was 
neutralized by anti-human G-CSF monoclonal antibodies. The activation of intracellular signaling 
pathways following G-CSF ligand-receptor binding was studied by detecting G-CSF-activated 
phosphorylated STAT3. Similar with filgrastim (Neupogen, Amgen) and pegfilgrastim (Neulasta, 
Amgen; Neulastim, Roche), F-627 can effectively activate phosphorylated STAT3 signaling and 
stimulate cell proliferation in M-NFS-60 cell line. 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 16


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 17 of 54  
In vivo pharmacodynamics study of F-627 
In vivo bioactivity study of F-627 showed that: a single subcutaneous injection of F-627 in mice, rats, 
and cynomolgus monkeys resulted in increases of peripheral blood white blood cell count (WBC) and 
absolute neutrophil count (ANC) in a dose-dependent manner. The minimum effective dose of F-627 in 
rats was 3.0 μg/kg. A single subcutaneous injection of F-627 100 μg /kg in mice showed that, 
phosphorylated STAT3 levels in bone marrow cells increased 17 folds compared to baseline levels. 
Peak ANC in peripheral blood appeared at 48 hr after the dose, and recovered to normal levels at 72 hr. 
F-627 was significantly superior to Neulasta and rhG-CSF, at the same molar dose of G-CSF, in terms 
of ANC increase and duration. 
 
In cynomolgus monkey models with cyclophosphamide-induced neutropenia, F-627 not only shorten 
the recovery time of ANC, but also reduced the ANC decrease compared to filgrastim (rhG-CSF) and 
pegfilgrastim (Neulasta), thereby preventing the occurrence of severe neutropenia. F-627 demonstrated 
superior pharmacodynamic effects over the same dose (60 μg/kg) of pegfilgrastim. 
1.1.6 
Previous clinical studies 
The phase I clinical trial was conducted at the Alfred Medical Center in Melbourne, Australia. The 
clinical study protocol was approved by the Ethics Committee of the hospital on May 4, 2010, and the 
first subject received F-627 treatment on Jun. 1, 2010. 
 
The starting dose of this study was 30 µg/kg, and the dose was escalated sequentially to 60, 120, 240, 
and 360 µg/kg. In each dose cohort, 6 healthy adult male subjects were enrolled, which means totally 
30 subjects in five cohorts. One to three Asian subjects were recruited to each dose cohort except for 
the 360 µg/kg cohort. Each subject received a single-dose of F-627 by subcutaneous injection. Blood 
samples were then collected at multiple time points in the 14-day follow-up visits to evaluate the 
pharmacokinetics, pharmacodynamics (including WBC, ANC, and CD34 analysis), and safety of the 
drug. The starting dose of F-627 was 30 µg/kg. Dose escalation was conducted only after it was 
confirmed to be safe by the principal investigators and medical experts of the sponsor. 
 
All subjects completed dose administration. F-627 subcutaneous injection was well-tolerated. There 
were no serious adverse events (SAEs) or deaths among the 30 subjects. All adverse events are 
summarized in Table 30-3. No abnormalities were observed in the vital signs, electrocardiograms 
(ECGs), abdominal ultrasound, serum biomarkers and urinalysis parameters of subjects in all dose 
cohorts. The most common adverse events were manifested as musculoskeletal disorders, including 
mild to moderate muscle soreness, bone pain and lumbago. 
 
Table 30-3. Summary of adverse events in the phase I clinical trial. 
 
Adverse Events 
30 µg/kg 
60 µg/kg 
120 µg/kg 
240 µg/kg 
360 µg/kg 
Total 
Number 
Description 
Headache 
1 
2 
1 
1 
2 
7 
2 moderate 
events 
Injection-Site Pain 
2 
 
 
0 
 
2 
1 moderate 
events 
Bone Pain 
 
2 
 
3 
 
5 
3 moderate 
events 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 17


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 18 of 54  
Adverse Events 
30 µg/kg 
60 µg/kg 
120 µg/kg 
240 µg/kg 
360 µg/kg 
Total 
Number 
Description 
Back Pain 
2 
1 
4 
4 
4 
15 
6 moderate 
events 
Leg Pain 
 
1 
 
1 
2 
4 
3 moderate 
events 
Abdominal 
Discomfort/Pain 
 
1 
 
1 
 
2 
1 moderate 
events 
Dry Skin 
 
1 
 
 
 
1 
1 moderate 
events 
Hunger 
 
 
1 
 
 
1 
 
Urinary Tract 
Infection 
 
 
 
1 
 
2 
 
Diarrhea 
 
 
 
2 
 
2 
 
Feeling Abnormal 
 
 
 
1 
 
1 
 
Tiredness 
 
 
 
 
1 
1 
 
Respiratory 
Tract Irritation 
 
 
 
1 
 
1 
 
Photophobia 
 
 
 
1 
 
1 
 
All moderate adverse events were noted, others were mild events. 
 
Results are shown in Table 30-4. The 5 dose cohorts, 30, 60, 120, 240, and 360 μg/kg, demonstrated 
dose-dependent pharmacodynamics, i.e., WBC, ANC, and CD34 count increased with increasing dose. 
The lowest dose cohort (30 μg/kg) demonstrated significant ANC elevation. The time to initial onset of 
effect was 4 hours for all dose cohorts. In the lowest dose cohort, ANC at 4 hours after administration 
(5.05 ± 2.00) was significantly higher than that before administration (2.79 ± 0.40, p = 0.02). Tmax of 
ANC was 36 hours for two low dose cohorts and 72 hours for two high dose cohorts. The peak ANC in 
these four dose cohorts increased 4.1, 4.4, 5.8, and 8.6 folds compared to the pre-dose ANC. CD34 
peaked at 72–96 hours, respectively. CD34 reached 38.7 ± 11.7 in the 120 μg/kg cohort. Results 
showed a good dose-effect relationship of F-627 in healthy male subjects. 
 
Table 30-4. Human PK parameters in phase I clinical trial. 
 
Parameters 
30 µg/kg 
（n=6） 
60 µg/kg 
（n=6） 
120 µg/kg 
（n=6） 
240 µg/kg 
（n=6） 
360 µg/kg 
（n=6） 
Cmax (ng/mL) 
21.3(10.3) 
44.6(17.7) 
219.9(76.6) 
759(160) 
693(243) 
Tmax (hr) 
8(8-16) 
8(8-16) 
16(16-36) 
36(36) 
16(16-48) 
T1/2 (hr) 
43.9(9.3) 
56.1(23.3) 
59.3(23.5) 
62.8(10.8) 
71.4(27.3) 
AUC(0-∞) (ng·hr/mL) 
720(214) 
1756(673) 
8374(2789) 
46580(17255) 
44009(18266) 
CL/F (mL/hr/kg) 
41.4(12.8) 
36.8(14.6) 
18.5(7.7) 
5.7(2.0) 
12.0/11.9 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 18


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 19 of 54  
Figure 30-1. Semi-logarithmic plot of concentration-time (hours) after different doses of F-627 in 
healthy male subjects. 
 
 
Table 30-5. Summary of pharmacodynamics in phase I clinical trial. 
 
F-627 Dose 
ANC Elevation (Tmax) 
Peak ANC 
ANC Recovery 
CD34 Tmax 
µg/kg 
hrs 
(Increased Folds) 
hrs 
(CD34 Count) 
30 
4 (36) 
11.52 (4.1) 
144 
96 (7.83 ± 2.32) 
60 
4 (36) 
12.32 (4.4) 
240 
72 (21.5 ± 23.9) 
120 
4 (72) 
22.31 (5.8) 
288 
72 (38.67 ± 11.71) 
240 
4 (72) 
26.98 (8.6) 
240 
96 ( 37.83 ± 9.7) 
360 
5(96) 
34.97(10.9) 
To be 
supplemented 
120(52.7 ± 19.0) 
ANC units: 1 × 109/L; ANC recovery: ANC < 5 × 109/L; CD34 count units: 1 × 103/mL, n = 6. 
 
Figure 30-2. Mean ANC in subjects after administration of different doses of F-627. 
 
 
Time (hours) 
Serum F-627 in healthy adult males 
(ng/mL) 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 19


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 20 of 54  
Clinical studies of long-acting rhG-CSF (pegfilgrastim, i.e. PEGylated G-CSF) were primarily 
conducted by Amgen Inc. The new drug approval documents of pegfilgrastim included two phase I 
clinical trials that examined the PK/PD and safety of the drug in healthy human; four phase II clinical 
trials that determined the effective dose of the drug in patients with different cancers, including post-
chemotherapy lymphoma, lung cancer and breast cancer; and two phase III clinical trials that examined 
the efficacy and safety of 100 µg/kg pegfilgrastim. Pegfilgrastim was approved for marketing by the 
FDA in 2002 and is mainly used in Europe, U.S. and other western countries. Pegfilgrastim is a first-
line supportive therapy for post-chemotherapy cancer patients. It is used to treat neutropenia caused by 
radiation therapy and chemotherapy. 
 
There has been a substantial number of clinical studies of pegfilgrastim in recent years. A total of 
107 clinical studies could be found in the Pubmed database using pegfilgrastim or Neulasta as 
keywords for title and abstract. Long-acting pegfilgrastim is favorable for patients as it is administered 
once per chemotherapy cycle and its efficacy is equal to that of the short-acting Filgrastim administered 
daily. However, most blood cancer patients, such as those with lymphoma or acute leukemia, are in a 
state of severe neutropenia for a considerable period of time (2-3 weeks) even with post-chemotherapy 
administration of filgrastim or pegfilgrastim. Therefore, this is the medical challenge facing the 
application of the existing recombinant human G-CSF monomers. 
 
The clinical side effects of long-acting Pegfilgrastim are similar with those of short-acting Filgrastim. 
These side effects are primarily manifested as musculoskeletal disorders including muscle soreness, 
bone pain, lumbago and chest pain, and gastrointestinal disorders including inappetence or increased 
ALT/AST in liver. Some patients may develop fever, headache, asthenia, rash and ALP/LDH elevation, 
and a small fraction of patients may experience shock, interstitial pneumonia, adult respiratory distress 
syndrome, and increased immature granulocyte count. Pegfilgrastim is prohibited for individuals with 
severe liver, kidney, heart and lung disorders. Pegfilgrastim is not recommended for myeloid leukemia 
patients without significant reduction in immature granulocytes in the bone marrow or with immature 
granulocytes in the peripheral blood. 
1.2 
Overall Evaluation of Adjuvant Measures and Efficacy of Chemotherapy for Cancer 
Cancer is currently still a threat to human health and its incidence rate continues to increase (Nature 
Review Cancer, 2006, vol 6: 63-74). In 2002, there were 10.9 million new cancer patients worldwide. 
The number of new cancer patients worldwide is estimated to reach 16.5 million in 2020 and 
27.0 million in 2050. According to the statistics from the Ministry of Health of the PRC, the incidence 
rate of cancer had increased to 127 in 100000 people in the 1990s. In recent years, the number of new 
cancer patients per year has reached 1.6–1.7 million, totaling about 4.5 million cancer patients. In terms 
of cancer treatment, chemotherapeutic and cytotoxic agents are still first-line therapy. Some new small 
molecule targeted drugs still cannot be used as first-line drugs for curing cancer. Therefore, there is still 
much to be done for the adjuvant therapy of chemotherapy. Although first- and second-generation G-
CSF has partially shortened the duration of chemotherapy-induced neutropenia, how to alleviate 
neutropenia and shorten the duration of severe neutropenia are still the challenges in the treatment of 
chemotherapy-induced severe neutropenia. The development and study of F-627 have provided 
theoretical and practical feasibility for the treatment of this problem. As an independent global 
innovation, F-627 is expected to become the best adjuvant therapy for enhancing the efficacy of 
chemotherapy drugs in cancer patients. 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 20


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 21 of 54  
2. STUDY OBJECTIVES 
2.1 
Primary Objective 
To evaluate the safety and tolerability of recombinant human granulocyte colony stimulating factor-Fc 
fusion protein for injection (F-627) in treatment of female postoperative breast cancer patients who 
require adjuvant chemotherapy in a single-center, open-label, single-dose and repeated-dose, dose-
escalation phase I clinical trial. 
2.2 
Secondary Objectives 
1) 
To evaluate the pharmacokinetics (PK) of F-627 by determining the serum drug concentrations of 
F-627 at different time points after dosing; 
2) 
To evaluate the pharmacodynamics of F-627 by analyzing the relationship between serum drug 
concentrations of F-627 and neutrophil counts in blood at different time points after dosing, and to 
provide a recommended dose for phase II clinical trial. 
2.3 
Exploratory Objectives 
1) 
To observe the number of days in which absolute neutrophil count is less than 0.5 × 109/L in cycle 
1 of chemotherapy, the average time of ANC recovery, and the number of days in which absolute 
neutrophil count is less than 1 × 109/L, and to provide insights for phase II clinical trial. 
2) 
To evaluate the potential immunogenicity of F-627 by testing anti-F-627 antibodies (IgG and 
IgM) in serum. 
3. STUDY PLAN AND METHODOLOGY 
3.1 
Overall Study Design and Schedule of Study Procedures 
This is a single-center, open-label, dose-escalation, single-dose and repeated-dose phase I clinical trial 
in treatment of female postoperative breast cancer patients who require adjuvant chemotherapy. 
Eligible patients are those who have not received chemotherapy. The adjuvant chemotherapy regimen 
for this trial is EC→P or EC→T, that is: epirubicin 100 mg/m2, i.v. + cyclophosphamide 600 mg/m2, 
i.v. on day 1, repeat cycle every 21 days for 4 cycles. After completing the evaluation for all 4 cycles, 
subjects will receive 4 subsequent cycles of sequential chemotherapy (either paclitaxel or docetaxel) 
and supportive care according to routine clinical practice. The investigator must ensure that the first 
cycle of treatment follows the recommended chemotherapy regimen; in chemotherapy cycles 2–4, 
treatment regimen and dose are permitted to be individualized based on subject conditions. Dose delay 
and one dose reduction due to toxicities other than myelotoxicity (such as cardiotoxicity) are permitted 
in this trial. If the subject requires a second dose reduction, the investigator and sponsor must decide 
together whether the subject should continue the treatment with study drug. 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 21


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 22 of 54  
Subjects who have signed the informed consent form and have passed the screening are enrolled in the 
trial. 
 
This study includes 3 dose cohorts, 80, 240, and 320 µg/kg, each of which will enroll 6 subjects 
sequentially. Subjects in each cohort will receive a single-dose of F-627 by subcutaneous injection 
approximately 48 hours after the completion of chemotherapy. Blood samples are then collected at 
multiple time points in the subsequent follow-up visits to evaluate the pharmacokinetics, 
pharmacodynamics, and safety of the drug. If dose-limiting toxicities (DLT, see Section 3.4) are not 
observed before the start of cycle 2, then the same dose of F-627 is to be given at approximately 
48 hours after each chemotherapy in cycles 2–4. 
 
Only after 6 subjects in each cohort have completed the treatment and observation of the first cycle will 
the sponsor and investigator determine whether to proceed to the next higher dose based on the safety 
evaluation. 
 
Schedule of study procedures is detailed in Table 30-6. 
 
Table 30-6. Schedule of F-627 study procedures. 
 
 
1–15 Days 
Before 
Enrollment 
Day 1, Day 22, Day 
43, and Day 64 of 
the Study (Window 
Phase: 3 Days 
Before Dosing)6 
Day 3, Day 
24, Day 45, 
and Day 66 
of the Study 1 
Cycle 1 of 
Chemotherapy  
(Day 3–Day 21)4 
Cycles 2–4 of 
Chemotherapy  
(Day 3–Day 21)5 
End of 
Study  
(Day 84)7 
Signing Informed 
Consent Form 
X 
 
 
 
 
 
History of Cancer 
X 
 
 
 
 
 
Complete Physical 
Examination 
X 
 
 
 
 
X 
Physical 
Examination 
 
X 
X 
 
 
 
Abdominal 
Ultrasound2 
X 
X 
 
 
 
X 
Chemotherapy 
 
X 
 
 
 
 
Urinalysis2 
X 
X 
 
 
 
X 
Administration1 
 
 
X 
 
 
 
12-Lead ECG3 
X 
 
 
 
 
X 
Color Doppler 
Echocardiography 
X 
 
 
 
 
 
Chest X-Ray 
X 
 
 
 
 
X 
Height and Weight2 
X 
X 
 
 
 
 
Body Temperature 
X 
X 
X 
X 
X 
X 
Routine Blood Test 
(Including ANC) 
X 
X 
X 
X 
X 
X 
Clinical Chemistry2 
X 
X 
 
 
 
X 
Serum Pregnancy 
Test 
X 
 
 
 
 
X 
Blood Pressure and 
Heart Rate 
X 
X 
 
 
 
X 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 22


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 23 of 54  
 
1–15 Days 
Before 
Enrollment 
Day 1, Day 22, Day 
43, and Day 64 of 
the Study (Window 
Phase: 3 Days 
Before Dosing)6 
Day 3, Day 
24, Day 45, 
and Day 66 
of the Study 1 
Cycle 1 of 
Chemotherapy  
(Day 3–Day 21)4 
Cycles 2–4 of 
Chemotherapy  
(Day 3–Day 21)5 
End of 
Study  
(Day 84)7 
Pharmacokinetics8 
 
 
X 
X 
X 
 
Serum Antibody9 
 
X 
X 
X 
X 
X 
AEs and Combined 
Medications9 
 
X 
X 
X 
X 
X 
1. 
Three dose cohorts for F-627 (80 μg/kg, 240 μg/kg and 320 μg/kg); 
2. 
Examination should be completed upon enrollment and the start of each chemotherapy cycle. Body height is measured 
upon enrollment only, while body weight is measured on day 1 of each cycle; for abdominal ultrasound, a retest on day 
1 of cycle 1 is not required and the baseline result can be used; for routine blood test and clinical chemistry before the 
start of cycle 1, results within 7 days are acceptable; 
3. 
12-lead ECG should be repeated at the last visit of the study; 
4. 
Starting on day 3 of cycle 1, oral temperature measurement and routine blood test will be performed daily until ANC 
recovers from its nadir to > 1.0 × 109/L, and once every 3 days thereafter until the next cycle; 
5. 
For chemotherapy cycles 2–4 (day 3–day 21 of each chemotherapy cycle, i.e., day 24–day 84 of the study), starting on 
each day 3 of cycles 2–4, oral temperature measurement and routine blood test will be performed every other day until 
ANC recovers from its nadir to > 1.0 × 109/L, and once every 3 days thereafter until the next cycle; 
6. 
Only when ANC of a subject recovers to > 1.0 × 109/L as judged by the investigator, can the next cycle start; 
7. 
The last visit is on day 84, and the subjects should complete a follow-up visit by telephone on day 114 (30 days after 
the last visit); 
8. 
In cycle 1 and cycle 3, blood samples are collected for PK at time points shown in Table 30-8; 
9. 
Blood samples will be collected for serum antibody assays on days 1, 8, and 13 of each cycle as well as day 22 of 
cycle 4. 
 
Remark: All laboratory measurements will be performed at a central laboratory assigned by the investigator. In case of any 
toxicities related to chemotherapy, subsequent treatment can be modified according to common diagnosis and treatment 
practice in the judgment of the investigator. 
3.2 
Evidence for Dose Determination 
Results from 3-month repeat dosing toxicity studies showed that the no-observed-adverse-effect-level 
(NOAEL) of F-627 was 1000 µg/kg in rats and 675 µg/kg in cynomolgus monkeys. F-627 is a 
recombinant fusion protein with a molecular weight of 95000 Daltons. Results from preclinical studies 
showed that the toxicity of F-627 was due to the amplification of pharmacodynamics, which is closely 
associated with the dose (expressed in mg/kg) in various different species. Based on the guideline 
issued by the FDA in 2005, the maximum safe starting dose of F-627 was calculated to be 67.5 µg/kg 
using mg/kg conversion, which is one-tenth of the NOAEL in cynomolgus monkeys. Based on the dose 
for healthy volunteers in the phase I clinical trial, 80 µg/kg is a safe starting dose. 
 
The pharmacokinetic parameters in cynomolgus monkeys, such as T1/2, AUC, CL and MRT, were 
comparable between F-627 and pegfilgrastim. In the 3-month repeat dosing toxicity studies of 
pegfilgrastim and F-627 in rats and cynomolgus monkeys based on subcutaneous injection, the no-
observed-adverse-effect-levels (NOAELs) of drugs in rats were comparable to those in cynomolgus 
monkeys. In addition, the phase I clinical trial involving healthy volunteers used an F-627 dose that is 
less than 5% of the NOAEL in monkeys (Table 30-6). F-627 demonstrated good safety and tolerability 
in all five dose cohorts (30, 60, 120, 240 and 360 µg/kg). For F-627, 240 µg/kg was equivalent to 
96 µg/kg of pegfilgrastim (calculated by the molarity of G-CSF). The phase I of this study plans to 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 23


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 24 of 54  
include three dose cohorts, namely 80, 240 and 320 µg/kg. Firstly, all doses should not exceed the 
maximum dose in the phase I clinical trial. Secondly, the G-CSF molarity of 240 µg/kg F-627 is 
comparable to that of 100 µg/kg pegfilgrastim. Finally, 60 µg/kg of F-627 showed pharmacodynamics 
superior than 150 µg/kg in the cynomolgus monkey models of chemotherapy-induced neutropenia. 
Therefore, using 80 µg/kg in the low-dose cohort will ensure that the drug may be effective for the 
subjects. The highest dose (320 µg/kg) for subjects is slightly lower than the maximum dose 
(360 µg/kg) tested in healthy subjects. 
 
Table 30-7. Rationale for F-627 doses in clinical trials. 
 
 
Pegfilgrastim 
F-627 
Repeat Dosing Toxicity Study in Rats 
100, 300, and 1000µg/kg, once a week 
for 3/6 months 
100, 300 and 1000 µg/kg, once a week 
for 3 months, followed by a recovery 
period of 1 month 
NOAEL in rats 
1000 µg/kg 
1000 µg/kg 
Repeat Dosing Toxicity Study in 
Monkeys 
75, 250, and 750 µg/kg, once a week for 
1 month, followed by a recovery period 
of 1 month 
75, 225, and 675 µg/kg, once a week for 
3 months, followed by a recovery period 
of 1 month 
NOAEL in Monkeys 
750 µg/kg 
675 µg/kg 
Starting Dose of Healthy Subjects in 
Phase I Clinical Trial 
30 µg/kg 
30 µg/kg 
Dose of Healthy Subjects in Phase I 
Clinical Trial 
30, 60, 100, 300 µg/kg 
30, 60, 120, 240, 360 µg/kg 
Post-Chemotherapy Dose for Breast 
Cancer in Clinical Trial 
60, 100, 300 µg/kg 
Planned: 80, 240 and 320 µg/kg 
Recommended Dose for Clinical Trials 
100 µg/kg 
TBD 
3.3 
Single Dose and Repeated Dose 
This study includes 3 dose cohorts, 80, 240, and 320 µg/kg, each of which will enroll 6 patients with 
breast cancer sequentially receiving adjuvant chemotherapy. Subjects in each cohort will receive a 
single-dose of F-627 by subcutaneous injection approximately 48 hours after the completion of 
chemotherapy. Blood samples are then collected at multiple time points in the subsequent follow-up 
visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. If dose-limiting 
toxicities (DLT, see Section 3.4) are not observed before the start of cycle 2, then the same dose of F-
627 is to be given at approximately 48 hours after each chemotherapy in cycles 2–4. 
3.4 
Dose Escalation 
Doses that will be used in this study are 80, 240 and 320 µg/kg, and 6 subjects will be enrolled in each 
dose cohort. The starting dose is 80 µg/kg. Only after 6 subjects have completed the treatment and 
observation of the first cycle will the sponsor and investigator determine whether to proceed to the next 
higher dose based on the safety evaluation. Likewise, the 240 µg/kg cohort will enroll 6 subjects, and 
only after 6 subjects have completed the treatment and observation of the first cycle will the sponsor 
and investigator determine whether to proceed to the next higher dose based on the safety evaluation. 
The 320 µg/kg cohort will enroll 6 subjects, but dose escalation will not be conducted after all 6 
subjects have completed the treatment and observation. 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 24


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 25 of 54  
 
Dose Cohort 
Dose 
Number of Subjects 
1 
80 µg/kg 
6 
2 
240 µg/kg 
6 
3 
320 µg/kg 
6 
 
Dose escalation should be stopped in each dose cohort if 2 dose-limiting toxicities (DLT, see Section 
3.5 for definition) are observed in subjects in cycle 1 of chemotherapy 
3.5 
Dose-Limiting Toxicity (DLT) 
Dose-limiting toxicity (DLT) refers to an intolerable toxicity that is observed in the treatment with 
investigational drug and limits the further dose escalations. DLT is defined as any grade 3 or greater 
adverse event related to the investigational drug that observed in cycle 1 (21 days). Adverse events will 
be assessed according to NCI CTCAE V4.03 criteria. 
 
After 6 subjects in each F-627 dose cohort have completed the treatment and observation of first cycle, 
the trial may proceed into the next dose cohort only if less than 2 subjects develop DLT. If a grade 3 or 
greater adverse event related to the investigational drug is observed in cycles 2–4, then the investigator 
and sponsor will determine together whether the adverse event would affect further dose escalations. 
3.6 
Risk, Benefit and Ethical Evaluations 
The rhG-CSF-Fc fusion protein is a long-acting rhG-CSF expressed in CHO cells. Each molecule of 
rhG-CSF-Fc fusion protein contains two G-CSF dimer molecules, which may overcome the weak 
bioactivity of pegfilgrastim and produce a stronger receptor activation signal, thereby accelerating the 
differentiation and proliferation of neutrophils in bone marrow. Also, preclinical studies have shown 
that the pharmacokinetic and pharmacodynamic properties of rhG-CSF-Fc is different from or superior 
to pegfilgrastim, and therefore it decreases the severity of neutropenia and reduces the duration of 
severe neutropenia in cancer patients after chemotherapy. For the phase I clinical trial, patients with 
breast cancer will be enrolled as subjects to evaluate the safety, tolerability and pharmacodynamic 
properties of F-627. Phase I clinical trial of pegfilgrastim showed that subcutaneous injection of 30, 60, 
100 and 300 µg/kg of pegfilgrastim resulted in no significant toxicity. The dose of F-627 will also be 
controlled within this range to ensure the safety of the subjects. Phase I clinical trial of F-627 in 
Australia already demonstrated that no serious adverse event is observed within this dose range and 
subjects had good treatment compliance. 
 
In this study, the safety of the subjects will be closely monitored, including clinical symptoms, vital 
signs, routine blood test, clinical chemistry, urinalysis and any adverse event. Once an adverse event is 
observed, it will be handled in accordance with the national regulations. Safety evaluation of the phase 
I clinical trial on healthy subjects showed that adverse events observed under the above doses were all 
within controllable range. Emergency medical events and handling procedures are described in Section 
11 of this document. 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 25


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 26 of 54  
4. STUDY POPULATION 
4.1 
Study Population and Number of Subjects 
Female postoperative patients with breast cancer who receive adjuvant chemotherapy will be enrolled 
in this study. Eligible subject should be chemotherapy naïve patient. 
 
The selection of chemotherapy drug is one of the key considerations in the design of this protocol. 
Among the adjuvant chemotherapy regimens that are recommended by the NCCN 2010 guideline for 
breast cancer, the preferred regimens include TAC, dose-dense AC → dose-dense paclitaxel, AC → 
paclitaxel, TC, EC, and AC. At present, AC/EC→P or AC/EC→T are the commonly used regimens in 
China. 
 
The adjuvant chemotherapy regimen for this trial is EC→P or EC→T, that is: 100 mg/m2 epirubicin i.v. 
+ 600 mg/m2 cyclophosphamide i.v. on day 1, repeat cycle every 21 days for 4 cycles. After 
completing the evaluation for all 4 cycles, subjects will receive 4 subsequent cycles of sequential 
chemotherapy (either paclitaxel or docetaxel) and supportive care according to routine clinical practice. 
 
The investigator must ensure that the first cycle of treatment follows the recommended chemotherapy 
regimen; in chemotherapy cycles 2–4, treatment regimen and dose are permitted to be individualized 
based on subject conditions. Dose delay and one dose reduction due to chemotherapy-induced toxicities 
(such as cardiotoxicity) are permitted in this trial. If the subject requires a second dose reduction, the 
investigator and sponsor must decide together whether the subject should continue the treatment with 
study drug. 
 
This study includes 3 dose cohorts, 80, 240, and 320 µg/kg, each of which will enroll 6 subjects, 
totaling 18 subjects. 
4.2 
Inclusion Criteria 
1) 18-75 years old; 
2) Female postoperative breast cancer patients who require adjuvant chemotherapy, and are planned 
to receive 4 cycles of EC chemotherapy; 
3) ECOG performance status of 0-1; 
4) Absolute neutrophil count (ANC) ≥ 2.0 × 109/L, hemoglobin (Hb) ≥ 11.0 g/dL, and platelet (PLT) 
≥ 100 × 109/L prior to chemotherapy; 
5) Hepatic and renal function within the normal range; 
6) Left ventricular ejection fraction greater than 50% 
7) Willing to sign the informed consent form and able to comply with protocol requirements; 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 26


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 27 of 54  
4.3 
Exclusion Criteria 
Subjects who meet any of the following must be excluded from this study: 
 
1) Women in pregnancy or breastfeeding; women of child–bearing potential have a positive pregnancy 
test result prior to the first dose; 
2) Life expectancy less than 12 months; 
3) Radiation therapy within 4 weeks prior to enrollment; 
4) Patients with breast cancer who have received neoadjuvant chemotherapy before radical 
mastectomy; 
5) Prior bone marrow or stem cell transplant; 
6) With other malignant tumors other than breast cancer; 
7) Have received G-CSF treatment within 6 weeks prior to enrollment; 
8) Diagnosed with acute congestive heart failure, cardiomyopathy, or myocardial infarction by 
clinical diagnosis, ECG or other approaches 
9) With any disease that may cause splenomegaly; 
10) With acute infection, chronic active Hepatitis B within 1 year (unless patients tested negative for 
HBsAg prior to enrollment) or Hepatitis C; 
11) With active tuberculosis (TB); history of TB exposure, unless negative for tuberculin test; or TB 
patients undergoing treatment; or suspected TB evaluated by chest x-ray; 
12) Known HIV positive or AIDS; 
13) With sickle cell anemia; 
14) With alcohol or drug abuse that may affect the compliance with the study; 
15) With known hypersensitivity to E. coli derived proteins, G-CSF, or excipients; 
16) Has received any other study drug within 4 weeks prior to enrollment; 
17) Patients with diseases or symptoms unsuitable for participating in the trial based on the 
investigator's judgment; 
4.4 
Criteria for Terminating Study 
1) Incidence rate and severity of serious adverse events (SAEs) indicate the study should be 
terminated early as determined by the investigators and the sponsor; 
2) The dose-limiting toxicity of the subjects does not recover or cannot be relieved; 
3) The investigators question the safety of the drug and believe that the continuation of the study may 
pose serious risks to the subjects; 
4) The maximum dose set in the clinical trial has been reached; 
5) Data fraud, or inaccurate/incomplete collection of data; 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 27


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 28 of 54  
4.5 
Criteria for Subject Withdrawal 
Subjects will prematurely withdraw from the study with a written explanation when the following 
conditions occur. 
 
1) Subjects voluntarily withdraw during the study; 
2) The investigator considers that withdrawal is for the best interest of the subject; 
3) The investigator or subject believes that continuing the trial may result in intolerable adverse 
events; 
4) Complications or worsening co-morbidities affecting subject's participation occur; 
5) Safety issues of the study drug in the absence of data, subject will be exposed to potential risks if 
continues the participation in the study; 
6) When a safety concern regarding the study drug arises, but data is yet unknown, resulting in 
potential risks if subjects continue the trial; 
4.6 
Drop-Out Criteria 
Determination of drop-outs: Eligible subjects who have signed the informed consent form and been 
enrolled have the right to withdraw from the study at any time. Subjects who do not complete the entire 
observation are considered drop-outs regardless of the time or reason of the withdrawal. A replacement 
should be implemented immediately according to the original plan when a drop-out occurs. Blood 
samples from drop-out subjects should be retained and tested and processed by the sponsor. 
4.7 
Withdrawal-Related Procedures and Handling 
The investigator should ask the withdrawn subject for the reason of withdrawal and whether there is 
an adverse event, and record the length of treatment and dose. If possible, the investigator should 
perform corresponding observation and evaluation of the withdrawn subject and conduct a follow-up 
for adverse events within 30 days of the last dosing. If a subject withdraws from the study due to 
suspected grade 2, 3 or 4 infection according to WHO risk classification criteria, then his/her 
biological samples must not be sent to a laboratory, and instead, should be destructed as per 
operating practice of the study site. 
5. INVESTIGATIONAL DRUG AND TREATMENT 
5.1 
Source 
F-627 is provided by Generon (Shanghai) Corporation Ltd. 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 28


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 29 of 54  
5.2 
Strength and Expiration Date 
The recombinant human granulocyte colony stimulating factor-Fc fusion protein for injection (F-627) 
is securely packaged and sealed by Generon (Shanghai) Corporation Ltd. 
 
Dosage Form 
Strength 
Formulation 
Mode of 
Administration 
Expiration 
Date 
Lyophilized Powder 
for Injection 
1 mg 
F-627 (rhG-CSF-Fc) 
1.0 mg 
Subcutaneous 
injection 
2 years 
(tentative) 
Sucrose  
20.0 mg 
Mannitol 
50.0 mg 
Polysorbate 80 
0.05 mg 
Sodium phosphate dibasic 
0.92 mg 
Sodium phosphate monobasic 
0.42 mg 
Lyophilized Powder 
for Injection 
5 mg 
F-627 (rhG-CSF-Fc) 
5.0 mg 
Subcutaneous 
injection 
2 years 
(tentative) 
Sucrose  
20.0 mg 
Mannitol 
50.0 mg 
Polysorbate 80 
0.05 mg 
Sodium phosphate dibasic 
0.92 mg 
Sodium phosphate monobasic 
0.42 mg 
5.3 
Labeling 
The recombinant human granulocyte colony stimulating factor-Fc fusion protein for injection (F-627) 
is stored as lyophilized powder in tubular vials (1.0 mg/2 mL vial and 5.0 mg/2 mL vial). The drug 
label includes the following information: investigational drug name, study number, study protocol 
number, storage conditions, contents, mode of administration, batch number, expiration date, and the 
standard notes "For clinical trials only" and "Keep out of reach of children". 
5.4 
Storage 
The drug should be stored as specified in a sealed container at 2–8 °C away from light, and under the 
management of designated personnel. If the temperature exceeds the storage condition during transport 
and storage, record and report the incident to the sponsor. 
5.5 
Drug Preparation 
The pharmacist is responsible for preparing the drugs and the nurse is responsible for reviewing. 
During drug preparation, inject 0.5 mL of water for injection slowly into the vial along the wall, let the 
vial stand for 1–2 minutes, and perform subcutaneous injection after the powder is completely 
dissolved. The injection should be used within 1 hour after preparation. See the drug preparation 
procedure manual. The drug is generally injected in the morning (09:00 ± 1:00). The subject should 
remain in a sitting or walking position within two hours after the injection. 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 29


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 30 of 54  
5.6 
Administration and Precautions 
Subjects must sign the informed consent forms prior to enrollment. After being screened and confirmed 
to be enrolled, subjects will be numbered in strict order. If a subject withdraws from the study, the 
same subject number must not be reused. Subjects who have withdrawn are not allowed to participate 
in this study again. According to the study protocol, subjects are allocated to different dose cohorts and 
will enter the study in the order of enrollment. 
 
The investigator should be present during administration and within 1 hour after administration to 
provide guidance and supervision, and be prepared to administer first aid or emergency treatment 
whenever needed. The specific time and date of dosing, and the drug labels should be documented in 
the subject's source data files and case report forms. 
 
Subjects will receive a chemotherapy of EC on day 1 of each cycle, and a subcutaneous injection of  
F-627 on day 3, that is, 48 ± 2 hours after the start of chemotherapy. During the treatment, subjects 
should avoid strenuous physical activity or long periods of bed rest, and keep relaxed. 
5.7 
Salvage Therapy 
In the study, an approved G-CSF treatment should be given to the patient as salvage therapy in the case 
of febrile neutropenia (defined as ANC < 1.0 × 109/L; a single measurement of body temperature > 
38.3 °C or a fever ≥ 38.0 °C lasting for longer than 1 hour; note: body temperature measurement is 
based on oral temperature or equivalent armpit/rectal temperature) or grade 4 neutropenia for longer 
than 3 days. The sponsor recommends GRAN® (filgrastim) at a dose of 5 µg/kg/day of G-CSF, once 
daily for ≤ 2 weeks or until neutrophil count recovers to 1.0 × 109/L. 
5.8 
Drug Management 
Registration and recording of the investigational drug should be in the charge of designated personnel. 
The study site should establish a set of systematic operating procedures to ensure that the drugs are 
received by designated personnel, the distribution of the drugs is accurately documented, and the drugs 
are used and stored properly. 
 
1) Drug registration form: 
a. The type of drug received from the sponsor; 
b. Dosage form and strength; 
c. Batch number and expiration date; 
d. The dosage form, dose, quantity, and date of drug dispensed to the investigator (signed by both 
dispensers and recipients). 
2) Individual drug administration record: subject name, package number, administration time, dose 
and mode of administration, signature of operator, and return of packaging. 
3) Detailed record of drug administration, loss, scattering, and misuse. 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 30


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 31 of 54  
4) Unused drugs should be stored in accordance with storage requirements. Storage conditions should 
be checked regularly by the same designated personnel. 
5) After the study is completed, all remaining drugs should be returned and recorded, and be disposed 
according to the GCP by the site together with the sponsor. 
5.9 
Principles and Methods for Treatment of Drug Toxicities 
If a subject develops a mild drug toxicity after receiving F-627 injection, symptoms should be 
monitored with the treatment continued. Intervention is usually not required. Toxicities related to 
chemotherapy should be handled according to clinical guidelines and the prescribing information of the 
chemotherapy drugs. Serious or life-threatening symptoms must be treated immediately, and the 
clinical trial for this case must be terminated. 
 
Refer to Table 30-3 for all adverse events observed in phase I clinical trial: these symptoms do not need 
to be treated. At present, serious adverse events have not been observed for F-627. High-risk serious 
adverse events for long-acting G-CSF that have been reported include: 
 
• 
Acute splenomegaly: incidence rate is around 1–10%, while the likelihood of splenic rupture is less 
than 1 in 10000. Patients who develop abdominal pain and were found to have splenomegaly upon 
physical examination or ultrasonic inspection should be treated immediately. The drugs should be 
discontinued. 
• 
Adult respiratory distress syndrome (ARDS): Rare cases have been reported with clinical use of 
long-acting G-CSF. Treat immediately and discontinue the drugs if present. 
5.10 Treatment Compliance 
Administer according to subject's dosage allocation under the guidance and supervision of the 
investigator. The actual time and date of administration should be accurately documented for each 
subject. Any protocol violations should be documented in subject's source data file and case report 
form. 
6. EVALUATIONS AND ENDPOINTS 
6.1 
Evaluations During Screening 
Prior to enrollment, the evaluation carried out within 2 weeks before dose administration (1–14 days 
before enrollment) includes: 
 
1) Record of subject demographics: date of birth, gender, ethnicity, etc.; 
2) Medical history collection, including history of cancer and history of chemotherapy; 
3) Record of concomitant diseases and combined medication, surgical history, etc.; 
4) Record of pathological diagnosis confirmed in tumor histology or cytology; 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 31


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 32 of 54  
5) Tumor staging (TNM); 
 Complete physical examination, height, weight, vital signs (temperature, pulse, respiratory 
rate, blood pressure), and heart rate; 
6) ECOG PS score, weight evaluation; 
7) Hematologic examination: red blood cell, hemoglobin, white blood cell, platelet count, differential 
blood count (neutrophils, lymphocytes, monocytes, basophils and eosinophils), hematocrit, mean 
corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), mean corpuscular hemoglobin 
concentration (MCHC), etc.; 
8) Clinical chemistry: including total protein (TP), albumin (ALB), globulin (G), blood glucose, 
blood urea nitrogen, creatinine, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), 
pancreatic amylase, total bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), Ca, 
P, Mg, K, Na, Cl, etc.; 
9) Urinalysis: including pH, specific gravity, protein, cast, blood cell, urine glucose, ketones, etc.; 
10) 12-lead ECG; 
11) Color doppler echocardiography 
12) Pregnancy test within 7 days before dose administration; 
13) Chest x-ray (PA and lateral); 
14) Signing informed consent form; 
15) Abdominal ultrasound (liver, gallbladder, spleen, kidney, and pancreas) 
Note: Only results of routine blood test and clinical chemistry conducted within 1 week before 
enrollment are accepted. 
6.2 
Clinical Evaluations During and After F-627 Treatment 
Evaluations on day 1 of each chemotherapy cycle (day 1, day 22, day 43, and day 64 of the study) 
include: 
 
1) Abdominal ultrasound; 
2) Chemotherapy; 
3) Urinalysis; 
4) Height, weight; 
5) Body temperature; 
6) Routine blood test (including ANC) 
7) Clinical chemistry; 
8) Blood pressure and heart rate; 
9) Serum antibody assay (IgG and IgM) 
10) Adverse events and combined medication; 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 32


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 33 of 54  
Evaluations on day 3 of each chemotherapy cycle (day 3, day 24, day 45, and day 66 of the study) 
include: 
 
1) Physical examination 
2) Investigational Drug; 
3) Temperature; 
4) Routine blood test (including ANC); 
5) Adverse events and combined medication; 
 
According to different time in the chemotherapy cycle, for cycle 1 (days 1–21 of both the cycle and the 
study), starting from day 3, oral temperature measurement and routine blood test will be performed 
daily until ANC recovers from nadir to > 1.0 × 109/L, and once every 3 days thereafter until the next 
cycle. Evaluations include: 
 
1) Temperature; 
2) Routine blood test (including ANC); 
3) Adverse events and combined medication; 
 
For chemotherapy cycles 2–4 (days 3–21 of each chemotherapy cycle, i.e., days 23–84 of the study), 
starting from day 3, oral temperature measurement and routine blood test will be performed every other 
day until ANC recovers from its nadir to > 1.0 × 109/L, and once every 3 days thereafter until the next 
cycle. Evaluations include: 
 
1) Physical examination; 
2) Temperature; 
3) Routine blood test (including ANC); 
4) Serum antibody assay (IgG and IgM); 
5) Adverse events and combined medication 
 
Evaluations upon the end (day 84) or withdrawal include: 
 
1) Physical examination; 
2) Abdominal ultrasound; 
3) Urinalysis; 
4) 12-lead ECG; 
5) Chest x-ray; 
6) Temperature; 
7) Routine blood test (including ANC) 
8) Clinical chemistry; 
9) Serum pregnancy test; 
10) Blood pressure and heart rate; 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 33


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 34 of 54  
11) Antibody test (IgG and IgM); 
12) Adverse events and combined medication 
 
Subjects who withdraw from the study should be followed for adverse events 30 days after the last dose. 
 
The subjects should complete telephone visits (on day 114, i.e., 30 days after the last visits). 
6.3 
Pharmacokinetic (PK) Evaluations 
6.3.1 
Determination and analysis of PK serum samples 
The concentrations of drugs and metabolites in blood samples will be determined by the validated 
central laboratory (Covance Pharmaceutical Research and Development (Shanghai) Co., Ltd.). The 
specific method of determining serum drug concentrations will be decided by the laboratory and will be 
described in detail in the clinical study report. 
6.3.2 
Collection, handling, and storage of PK blood samples 
According to the time points specified in the study protocol, baseline blood samples are collected 
within 1 hour before dose administration. Refer to 30-8 for the blood collection interval. The actual 
blood collection time should be documented after each intravenous blood sampling. The sampling date 
and collection tube number should be documented in the case report form (CRF). The collect tube label 
should include the following information: study number, subject initials, cycle number, day, sampling 
time (hour), etc. Each time a total of 2.5 mL of blood is collected, transferred to a labeled serum 
separator tube, placed for about 30 minutes, and centrifuged at 1000 g for 15 minutes at room 
temperature. Aliquot the serum into two clean 1.5 mL EP tubes (approximately 0.3 mL of serum each), 
close the lid tightly and immediately transfer to ≤ –70 °C for storage. The entire sampling and serum 
collection process must be completed within 60 minutes. Samples must be transferred in a constant 
temperature box with dry ice. 
6.3.3 
Blood sampling of single-dose and repeated-dose PK studies 
PK analysis of F-627 in the phase I clinical trial showed that mean time to peak was 30–36 hours and 
plasma elimination half-life was 46–72 hours, longer in the high-dose cohort. For example, in the 
240 µg/kg cohort, Tmax  was 36 hours, T1/2  was 62.8 hours, MRT was 43.5 ± 6.0 hours, Cmax  was 758 ± 
160 ng/mL, AUC was 46580 ± 17255 ng/mL*hr, and CLz/F was 5.72 ± 2.0 mL/hr/kg. 
 
Taking into account the above results from animal PK studies, this phase I clinical trial plans to collect 
blood samples at different time points following single-dose and repeated-dose administration. See 
Table 30-8 for detailed blood sampling time. 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 34


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 35 of 54  
Table 30-8. Blood sampling time of single-dose and repeated-dose PK studies. 
 
Study Process 
Days of 
Study 
Days of 
Dosing 
Blood Sampling Time 
Point of Cycle 1 
(hours: minutes) 
Blood Sample 
Number 
Blood Sampling 
Time Point of Cycle 3 
(hours: minutes) 
Blood 
Sample 
Number 
F-627 PK Study 
(2.5 mL) 
F-627 PK 
Study 
(2.5 mL) 
Study Process 
3 
1 
–01:00±0.1:00 
PK 1 
00:00±0.1:00 
PK 1 
 
 
02:00±0.3:00 
PK 2 
02:00±0.3:00 
PK 2 
 
 
06:00±0.5:00 
PK 3 
06:00±0.5:00 
PK 3 
 
 
12:00±0.5:00 
PK 4 
12.00±0.5:00 
PK 4 
4 
2 
24:00±0.5:00 
PK 5 
24:00±0.5:00 
PK 5 
 
 
36:00±0.5:00 
PK 6 
36:00±0.5:00 
PK 6 
5 
3 
48:00±1:00 
PK 7 
48:00±1:00 
PK 7 
6 
4 
72:00±1:00 
PK 8 
72:00±1:00 
PK 8 
7 
5 
96:00±1:00 
PK 9 
96:00±1:00 
PK 9 
8 
6 
120:00±1:00 
PK 10 
120:00±1:00 
PK 10 
9 
7 
144:00±1:00 
PK 11 
144:00±1:00 
PK 11 
11 
9 
192:00±2:00 
PK 12 
192:00±2:00 
PK 12 
13 
11 
240:00±2:00 
PK 13 
240:00±2:00 
PK 13 
16 
14 
312:00±2 4:00 
PK 14 
312:00±24:00 
PK 14 
21 
19 
432:00±2 4:00 
PK 15 
432:00±24:00 
PK 15 
Number of Blood Samples Collected on Each Subject 
15 
 
15 
Total Volume of Blood Samples Collected on Each Subject 
37.5mL 
 
37.5 mL 
6.4 
Pharmacodynamic Evaluation 
While evaluating the safety, tolerability and pharmacokinetic characteristics of F-627, the ANC-time 
profile after treatment is observed to investigate the effects of different dosages on neutrophil count and 
to determine a recommended dose for phase II trials. 
 
Pharmacodynamic evaluation of F-627 is carried out at the study site. For cycle 1, starting from day 3, 
oral temperature measurement and routine blood test will be performed daily until ANC recovers from 
its nadir to a value not less than 10 × 109/L, and once every 3 days thereafter until the next cycle; for 
chemotherapy cycles 2–4 (days 3–21 of each chemotherapy cycle, i.e., days 24–84 of the study), 
starting from each day 3 of cycles 2–4, oral temperature measurement and routine blood test will be 
performed every other day until ANC recovers from its nadir to > 10 × 109/L, and once every 3 days 
thereafter until the next cycle. Refer to Table 30-6 for specific procedures. 
6.5 
Safety Evaluation 
Safety evaluations include all observed and recorded adverse events and serious adverse events, 
changes in complete physical examinations, vital signs, performance status, routine blood test, routine 
urinalysis, chemistry indicators, echocardiogram, and ECG. 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 35


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 36 of 54  
Refer to Section 7 for the definition of adverse events, which are graded according to NCI CTCAE 
V4.03. The investigator should take appropriate treatment measures on the adverse events, report the 
event in the corresponding form of CRFs, and determine the relationship between the adverse event or 
serious adverse event and the drugs. If a serious safety issue occurs during the trial, the sponsor and 
investigator must decide together whether to terminate the trial. The sponsor may also request to 
terminate the clinical trial according to the situation. 
6.6 
Serum Antibody Assays and Evaluations 
This study will evaluate the potential immunogenicity of F-627 by testing serum anti-F-627 antibodies 
(IgG and IgM) in serum. 
 
Serum antibody assays will be carried out at the laboratory of Generon (Shanghai) Corporation Ltd. 
Specific assay methods will be determined by the laboratory and will be described in detail in the 
clinical study report. 
 
According to the study protocol, blood samples will be collected during screening (baseline value), and 
on days 8, 13, and 21 of each cycle. A total of 2.5 mL of blood will be collected. 
 
Each time a total of 2.5 mL of blood is collected, transferred to a labeled serum separator tube, placed 
for about 30 minutes, and centrifuged at 1000 g for 15 minutes at room temperature. Aliquot the serum 
into two clean 1.5 mL EP tubes (approximately 0.3 mL of serum each), close the lid tightly and 
immediately transfer to ≤ –70 °C for storage. The entire sampling and serum collection process must be 
completed within 60 minutes. Samples must be transferred in a constant temperature box with dry ice. 
The collect tube label should include the following information: study number, subject initials, cycle 
number, day, sampling time (hour), etc. 
7. ADVERSE EVENTS 
7.1 
Adverse Events (AEs) and Abnormal Values of Laboratory Measurements 
7.1.1 
Clinical adverse events 
An AE is defined as any untoward medical condition in a patient or clinical study subject administered 
a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptoms, or disease temporally associated with the use of a medicinal product 
(investigational drug), whether or not considered related to the medicinal product. 
 
If an elective surgery/treatment has been scheduled prior to the study, then it is not considered as an AE. 
However, if the disease worsens during the trial (e.g. surgery/treatment is required earlier than 
scheduled), then the elective surgery/treatment due to disease worsening is considered as an AE. 
 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 36


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 37 of 54  
AEs and corresponding severity during the trial should be recorded in the CRFs. Refer to Section 
7.1.1.1 for detailed severity. A causality evaluation between AEs and treatment should also be 
performed. 
7.1.1.1 Severity 
AEs are graded according to NCI CTCAE v4.03. 
 
Investigators should use the following guidelines to assess the severity of AEs that are not graded by 
NCI CTCAE: 
 
Mild 
The AE causes discomfort but does not affect activities of daily living 
Moderate 
The AE causes discomfort and affects activities of daily living 
Severe 
The subject cannot work or perform activities of daily living 
Life-Threatening The AE is life-threatening 
7.1.1.2 Causality 
The investigator will use "probably related", "possibly related", "unlikely related", and "unrelated" to 
assess the causality between adverse events and treatment. The evaluation criteria are shown in 
Appendix 1 (classification of causality between adverse events and drugs). 
7.1.1.3 Serious adverse events 
An AE meeting any one of the followings is considered as an SAE. The investigator should report the 
SAE to the sponsor and regulatory authorities according to relevant regulations within 24 hours of 
learning of the event. 
 
Death 
An adverse event that causes the death (reporting of deaths resulting from progression of 
disease is exempted) 
Life-Threatening 
An AE in which the subject is at immediate risk of death at the time of event if no medical 
interventions are taken as judged by the investigator, not an event that hypothetically might 
cause death or worsening. 
Hospitalization 
An AE that leads to hospitalization, excluding emergency or outpatient visits. 
Prolonged Hospitalization An AE occurs during the hospitalization and results in prolonged hospitalization. 
Congenital Anomaly 
An abnormality present at birth or after birth, or any malformations leading to abortion. 
Permanent or Significant 
Disability/Incapacity 
An AE that has important effect on the subject's daily life. Incapacity does not include 
medical events of relative minor importance, such as headache, nausea, vomiting, diarrhea, 
influenza, or accidental injury (e.g. ankle sprains). 
Important medical events 
requiring pharmaceutical 
or surgical interventions 
to prevent serious medical 
events 
Important medical events may not be immediately life-threatening, or result in death or 
hospitalization, but may jeopardize the subject and require pharmaceutical or surgical 
interventions to prevent any of the above outcomes (i.e., death, life threat, hospitalization 
or prolonged hospitalization, and congenital anomaly). These events may include allergic 
bronchospasm requiring treatment in an emergency room or at home, convulsions not 
requiring hospitalization, or drug dependence or abuse. 
A severe AE refers to the severity of the event, and is not necessarily an SAE, e.g. persistent vomiting 
for several hours is considered as a severe AE, but not an SAE clinically. 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 37


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 38 of 54  
After the initial report of an SAE, medical history, autopsy report, and other necessary documents 
should be provided as required. 
 
The severity, causality with the drugs, interventions taken and outcome of an SAE should be included 
in the report. 
7.1.2 
Treatment and follow-up of adverse events 
An investigational drug-related AE should be followed until it returns to the baseline level or is stabilized. 
If an AE does not return to the baseline level or cannot be stabilized, a reasonable explanation should be 
recorded in the CRF. 
7.1.3 
Abnormal values of laboratory measurements 
7.1.3.1 Laboratory measurements 
Results of laboratory measurement/vital signs should be recorded in the CRF. Abnormal values of 
laboratory measurements that meet the criteria for SAEs should be recorded in the SAE reports and the 
CRFs as AEs simultaneously. 
 
Clinically significant abnormal values of laboratory measurements/vital signs should be recorded in 
CRFs as independent AEs if at least one of the followings are met: 
 
• 
Accompanied by clinical symptoms 
• 
Resulting in changes in administration (such as dose adjustment, treatment suspension, or 
permanent discontinuation) 
• 
Requiring changes in combined treatment (such as the addition, suspension, discontinuation of, or 
changes to combined medication or treatment) 
• 
Resulting in treatment interruption 
• 
The investigator insists on reporting as an adverse event: If an abnormality in laboratory 
measurement/vital signs is associated with clinical symptoms/sign, the corresponding clinical 
symptom/sign should be reported as an adverse event, and the abnormal lab result or vital sign 
should be recorded in the case report form as supplemental information. 
7.1.3.2 Follow-up of abnormal values of laboratory measurements 
Any clinically significant abnormal values of laboratory measurements that cannot be explained should 
be retested and followed until returning to the baseline levels, or provided with a reasonable 
explanation and recorded in the CRFs. 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 38


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 39 of 54  
7.2 
Adverse Event Management 
7.2.1 
Adverse event reporting 
The investigator should closely monitor the clinical and laboratory evidence of each AE in the study. 
All AEs should be evaluated and recorded in detail, including the date of onset, symptoms, severity, 
outcome, duration, result of the event, relationship to the investigational drug, the diagnosis of the AE, 
and measures taken. The investigator should provide other potential information on causes of SAEs 
that are considered possibly unrelated to the investigational drug. 
 
For an AE considered intermittent, the nature and severity should be similar between each occurrence. 
All AEs should be recorded, regardless of whether they are collected from the subject's medical history, 
investigator's observation, or self-reporting by the subject. 
 
All AEs should be followed until satisfactory resolution. 
 
All adverse events and serious adverse events that occur from the signing of the informed consent form 
to 30 days after stopping the investigational drug should be collected, regardless of whether the event is 
observed by the investigator or self-reported by the subject. 
7.2.2 
Serious adverse event reporting (immediate) 
If any clinical AEs or laboratory abnormalities that occur from the study to 30 days after the last dose 
are considered as SAEs, the investigator must report the SAEs to the sponsor and regulatory authorities 
in accordance with applicable regulations within 24 hours after learning of the event, regardless of 
whether interventions are given. 
 
For SAEs occurring within the above-mentioned period, those considered related to the investigational 
drug should also be reported. 
7.2.3 
Special non-serious adverse event reporting 
Progression of Disease 
Tumor progression should not be reported as an AE or SAE. A second cancer can be instead. 
 
Lack of Treatment Efficacy 
When the disease treated by the investigational drug worsens, it may not be possible to determine 
whether it is due to lack of treatment efficacy or an adverse event. In this case, it is generally 
considered to be due to lack of treatment efficacy rather than an adverse event unless the investigator 
believes that the exacerbation is related to the investigational drug. 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 39


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 40 of 54  
Infusion Reaction 
Other than reporting an "infusion reaction", symptoms and AEs associated with the investigational drug 
or chemotherapy should also be reported. An AE may be related to the infusion if the event occurs 
during or within 24 hours from the chemotherapy infusion. 
The following data should be collected: 
• 
Special symptoms to be recorded in the CRFs; 
• 
Severity of each AE; 
• 
Symptoms that occur within 24 hours from the infusion, e.g. fever, chills, and hypotension. 
 
Overdose 
An overdose (whether accidental or intentional) must be reported according to procedures of treating 
the overdose, regardless of whether there are symptoms related to the overdose. All overdose-related 
symptoms should be reported as AEs. 
7.2.4 
Pregnancy 
Subjects who become pregnant during the study must immediately notify the investigator. The 
investigational drug and chemotherapy drug must be discontinued. Subjects who become pregnant 
within 90 days after the completion of treatment should also notify the investigator. The investigator 
must report the pregnancy to the sponsor within 24 hours. The investigator should discuss with the 
subject about the risks of continuing pregnancy and potential effects on the fetus. The pregnancy 
should be followed until satisfactory resolution. 
8. STATISTICAL METHODS AND ANALYSIS 
Descriptive statistics will be summarized for all variables obtained at various observation time points 
by dose cohorts, unless the protocol specifies that statistical analysis at a particular time point is not 
required. Overall, continuous variables (such as age) will be descriptively summarized with observed 
numbers, mean, median, standard deviation, minimum, and maximum. Categorical variables will be 
descriptively summarized with frequency and percentage based on each category. Continuous safety 
analysis of adverse events related to the investigational drug and other safety endpoints will be 
performed to determine how to achieve dose escalation. 
 
The analysis dataset includes all enrolled subjects who have received at least one dose of the study drug. 
This dataset is available for all analyses. Statistical methods are detailed in the Statistical Analysis Plan. 
8.1 
Pharmacokinetic Evaluation 
Two phases (single-dose and repeated dose); All PK parameters will be summarized using descriptive 
statistics by dose cohorts. The non-compartmental analysis of blood drug concentration data will be 
performed by the central laboratory using WinNonlin Enterprise. 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 40


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 41 of 54  
For Cmax (natural logarithm) of the single-dose and repeated-dose phase, AUC(0-inf), AUCt, and AUClast 
will be analyzed by one-way ANOVA, with dose cohort as the fixed factor. The least squares mean 
difference between the two dose cohorts and the 90% confidence intervals are obtained from the 
analysis of variance, and then the least squares geometric means ratio and the 90% confidence intervals 
are obtained by taking the antilog. 
8.2 
Pharmacodynamics Evaluation 
Absolute neutrophil count (ANC) after administration in different dose cohorts, as well as the number 
of days of ANC less than 0.5 × 109/L, the number of days of ANC less than 1.0 × 109/L, and the time of 
ANC recovered to 1.0 × 109/L after the completion of chemotherapy in cycles 1 and 2–4 are observed. 
8.3 
Statistical Analysis of Safety Data 
All adverse events are listed by patient, and coded using MedDRA as per physiologic system and 
standard terminology. Inferential statistics are not required for safety endpoints. Abnormal values 
laboratory measurements, vital signs, ECG, and other safety endpoints need to be noted. 
9. DATA MANAGEMENT 
This study will be monitored in accordance with International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP). The clinical 
research associate will have direct access to source data and will verify the data by comparing data in 
case report forms with the data in the original medical records (patient's permitting the clinical research 
associate to directly access the data is part of the informed consent). This data verification process is an 
important part of ensuring the quality of the study. During this process, the investigator will be urged to 
correct any transcription errors and omissions. Also, the demographic data in case report forms are also 
considered as source data and should be verified before being transferred to the data management 
department. 
9.1 
Data Filling-In by Investigator 
1) All parts of the case report forms should be carefully and detailedly filled in for subjects who 
signed the informed consent forms and are eligible to participate in the trial, with no blanks or 
omissions (blank spaces should be crossed out); 
2) Data in the case report forms should be verified with medical records to ensure accuracy; 
3) Case report forms are considered as source data. When making changes, the investigator should 
cross out incorrect data, write down the correct data, then sign and date the change; 
4) Data that are significantly higher or beyond reference ranges should be verified and explained by 
the investigator; 
5) Refer to the instructions for filling in case report forms (CRFs). 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 41


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 42 of 54  
9.2 
Requirement of Data Monitoring by Clinical Research Associate 
1) The clinical research associate should check subjects' informed consent and screening procedures 
during the course of the trial; 
2) Ensure that case report forms are filled out correctly and consistent with source data; 
3) All errors or omissions have been corrected or noted, and signed and dated by the investigator; 
4) Dose modifications, treatment changes, combined medications, and intercurrent diseases should be 
confirmed and documented for each subject; 
5) Verify that withdrawal and loss to follow-up of enrolled subjects are explained in the case report 
forms; 
6) Ensure that all adverse events have been documented, and serious adverse events have been 
documented and reported; 
7) Verify whether the drugs are supplied, stored, dispensed, and returned in accordance with 
applicable regulations, and documented accordingly; 
8) CRF must be completed for each enrolled patient; 
9) CRF is filled out by the investigator and must be completed for each enrolled patient. After the 
completed CRF is reviewed by the clinical research associate, the original copy is handed over to 
the data management personnel of the statistical teaching and research section for data entry and 
data management, the middle copy is handed over to the sponsor for archiving, and the bottom 
copy is archived at the clinical pharmacological center. 
9.3 
Data Entry, Recording and Management 
This study will use paper case report forms (pCRFs). Subject data will be clearly documented on the 
case report forms using blue or black ink. Correction fluid or tape must not be used. The clinical 
research associate of Generon (Shanghai) Corporation Ltd. will verify data during monitoring visits. 
The investigator should ensure that the data in the case report forms are accurate, complete, and clear. 
Data in the case report forms will be entered into the F-627 clinical study database and validated under 
the direction of data management personnel. Data in the case report forms that are missing, abnormal, 
or inconsistent will be presented to the investigator in data query forms and documented accordingly. 
The database is locked only after all queries have been resolved. The statistics department is 
responsible for data entry and management. The data manager will use software-compiled data entry 
programs for data entry and management. Double entry and proofreading should be performed by two 
data entry personnel independently to ensure the accuracy of data. The clinical research associate 
should submit any queries regarding case report forms to the investigator in data query forms. The 
investigator should respond and return the query as soon as possible. The medical statistician will then 
modify, confirm, and enter the data based on the investigator's response. The data query form can be 
issued again if necessary. 
The revision and inquiry of the data query form should be documented. The data query form is an 
extension to the CRF and must be kept carefully. 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 42


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 43 of 54  
9.4 
Audits and Inspections  
The authorized representative of Generon (Shanghai) Corporation Ltd., regulatory departments, 
independent ethics committee may audit or inspect the study site, including source data verification. 
The purpose of audits or inspections is to systematically and independently check all study-related 
procedures and documents to ensure that procedures have been implemented and data have been 
recorded, analyzed, and accurately reported in accordance with study protocol, GCP, ICH guidelines, 
and other laws and regulations. The investigator should immediately contact Generon (Shanghai) 
Corporation Ltd. when an inspection of the study site has been requested by the regulatory department. 
9.5 
Personnel Training 
The principal investigator should maintain a study work record of study-related personnel (doctors, 
nurses, and other personnel). The principal investigator must ensure that all personnel have received 
appropriate training related to the study, and any new information related to the study has been 
communicated to the relevant personnel. 
10. STUDY PROTOCOL REVISIONS 
The study protocol and study procedures must not be modified without the consent of both the principal 
investigator and Generon (Shanghai) Corporation Ltd. If the study protocol must be modified, the 
amendments or new version of the protocol (revised protocol) must be reviewed and approved in 
writing by the ethics committee prior to being implemented. If applicable, it must be submitted to or 
approved by the local drug regulatory authorities according to local regulations. 
 
If there is an administrative amendment, the change must be submitted to or approved in writing by the 
ethics committee as required. Generon (Shanghai) Corporation Ltd. and the ethics committee of the 
study site must be notified if amendments to the study protocol require changes to the study site's 
informed consent form. The application of the revised informed consent form must be approved by 
Generon (Shanghai) Corporation Ltd. and the ethics committee in writing. 
 
Generon (Shanghai) Corporation Ltd. will distribute the protocol amendments and the new version of 
the study protocol to each principal investigator. The principal investigators will then be responsible for 
providing these documents to the ethics committee and other personnel at the study site. 
11. STUDY MANAGEMENT 
11.1 Clinical Study Agreement 
The principal investigator of the study site must comply with all the terms and responsibilities of this 
clinical study agreement. The investigator must follow the study protocol when there are contradictions 
between the study protocol and the study agreement. 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 43


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 44 of 54  
11.2 Study Schedule and Requirements for Early Termination 
The study is scheduled to begin in December 2012 and end in October 2013. If the sponsor decides to 
terminate or suspend the study, the investigator and regulatory authorities must be notified in writing 
and the reason for early termination or suspension must be provided. The principal 
investigator/investigator must immediately explain the situation to subjects in this study, provide 
appropriate treatment, take necessary measures, and document the treatment measures in the source 
documents and case report forms. 
12. ETHICS 
12.1 Ethics of Clinical Study 
The study must not be initiated before the protocol is approved by the Institutional Review Board (IRB) 
or ethics committee (EC). The composition of the IRB or EC must be in accordance with State Food 
and Drug Administration (SFDA) requirements and fulfill all duties required by the SFDA. The ethics 
committee approval should include comments on the review or approval, as well as the name, gender, 
and occupation of the committee members. The clinical research associate must first receive a copy of 
the ethics committee approval before distributing the drugs to the investigator. The investigator must 
receive the ethics committee approval before enrolling subjects. 
 
According to applicable regulations of national regulatory authorities, in case of any amendments to the 
study protocol, the principal investigator is responsible for submitting to and obtaining written approval 
from the ethics committee for all study protocol amendments. The ethics committee must review 
advertisements for subject recruitment. The ethics committee must also re-approve the study protocol 
annually as required by local regulations. All SAEs or unexpected events that occur in the study must 
be reported to the EC as subject safety and the conduct of the trial may be affected. Consult the EC if 
the ethical aspects of the study need to be re-evaluated. 
 
This study must be conducted in strict accordance with the requirements of SFDA "Good Clinical 
Practice" and the "Declaration of Helsinki". 
12.2 Independent Ethics Committee (IEC) 
Before the clinical study can begin, the trial protocol, informed consent form, and other materials 
provided to subjects must be reviewed and approved by the ethics committee. Relevant approvals must 
be provided to the sponsor. 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 44


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 45 of 54  
12.3 Informed Consent Form (ICF) 
The principal investigator of the study site must ensure that subjects receive adequate oral and written 
information regarding the nature, purpose, potential risks and benefits of the study, and must inform 
subjects that they may voluntarily withdraw from the study at any time. Subjects must be given the 
opportunity to ask questions and time to consider these information. The informed consent form must 
be signed and dated by each subject before the trial is initiated. The original copy must be kept by the 
investigator as part of the trial documents. A copy of the signature page is retained by the subject. The 
subject must be informed that the sponsor's designee may review the relevant medical records. 
12.4 Privacy Protection 
The informed consent form will state (or sometimes with separate documents) compliance with 
applicable data protection and privacy regulations. Based on this statement, subjects are required to 
authorize the investigator or other personnel who need to know the information to collect, use, and 
publish their data. The informed consent form will state that the study data are stored in a computer 
database and kept confidential in accordance with the applicable laws. In the database, subjects are 
only identified based on random number/study number/subject name initials. The informed consent 
form will also state that for the purpose of data verification, the sponsor's designee, regulatory 
authorities, and the ethics committee have direct access to hospital or medical records related to this 
study, including patient medical records. 
13. QUALITY CONTROL OF CLINICAL TRIAL 
In the study, the clinical research associate assigned by the sponsor will regularly conduct on-site 
monitoring visits to the study hospital to ensure that all parts of the study protocol are strictly 
implemented and the accuracy of study data. 
 
The personnel participating in the study must receive uniform training, make unified records and adopt 
the same evaluation criteria. The investigator must fill out all parts of the CRF truthfully, detailedly, 
and carefully according to requirements to ensure that the contents of the case report form is authentic 
and reliable. The evaluation criteria for abnormalities in laboratory measurement should be based on 
the normal reference ranges provided by the measurer. 
 
All observations and findings in the trial should be verified to ensure data reliability and to ensure that 
conclusions from the trial are derived from source data. Appropriate data management measures should 
be set in place during the clinical trial and data processing phases. Active measures should be taken to 
maintain a drop-out rate of < 20%. 
 
 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 45


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 46 of 54  
14. Data Storage and Use 
The investigator must agree to store all study data, including confirmation of all participating subjects 
(different records, such as CRFs and hospital source data, can be effectively verified), original 
informed consent forms of all patients, CRFs, and detailed drug dispensation records. 
 
All data from this clinical trial are owned by Generon (Shanghai) Corporation Ltd. and must not be 
provided to persons unrelated to this trial in any form without the consent of the sponsor. Data from 
this study may be published only after the consent of the sponsor. 
15. REFERENCES 
1 
National Comprehensive Cancer Network(NCCN), Version 2010. 
2 
L Roskos, B B Yang et al. Pharmacokinetic/Pharmacodynamic Modeling of Pegfilgrastim in 
Healthy Subjects. J. Clin Pharmacol 2006; 46: 747-757 
3 
F. A. Holmes, S. E. Jones, J. O’Shaughnessy et al. Comparable efficacy and safety profiles of 
once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: 
a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002 ;13:903-9. 
4 
Stephen E. Jones, Michael A. Savin et al. Phase III Trial Comparing Doxorubicin Plus 
Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable 
Breast Cancer. J Clin Oncol. 2006;24:5381-5387. 
5 
Martin M, Pienkowski P, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. 
N Engl J Med 2005;352:2302-2313. 
6 
Nobuyuki Yamamoto, Ikuo Sekine, Kazuhiko Nakagawa, et al. A Pharmacokinetic and Dose 
Escalation Study of Pegfilgrastim (KRN 125) in Lung Cancer Patients with Chemotherapy-induced 
Neutropenia. Jpn J Clin Oncol 2009;39(7):425-430 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 46


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 47 of 54  
Appendix 
Appendix 1 Analysis of Causality Between Drugs and Adverse Events 
1) Probably related: 
 
This category applies to AEs that are considered highly likely to be caused by the drugs. The event is 
considered probably related if three of the followings are met: 
 
a) Plausible time relationship to administration. 
b) Cannot be reasonably explained by known signs and symptoms, environmental or toxic 
factors, or other treatments received. 
c) The AE resolved or improved after treatment suspension or dose reduction (with one 
exception where the AE does not resolve while drug-related toxicities persists after 
suspending treatment, such as (1) myelosuppression, (2) delayed dyskinesia). 
d) Consistent with the recognized toxicity of the suspected drug. 
e) Positive rechallenge. 
 
2) Possibly related 
 
This category applies to AEs that are not likely to be caused by the drugs, but cannot be ruled out with 
certainty. The AE is considered possibly related if two of the followings are met: 
 
a) Plausible time relationship to administration. 
b) Can be explained by disease, environmental or toxic factors, or other treatments received. 
c) Consistent with the recognized toxicity of the suspected drug. 
 
3) Unlikely related (meet 2 criteria) 
 
This category of adverse events generally meet the following criteria: 
 
a) Implausible time relationship to administration. 
b) Plausibly explained by disease, environmental or toxic factors, or other treatments received. 
c) Not consistent with the recognized toxicity of the suspected drug. 
d) Negative rechallenge. 
 
4) Unrelated 
 
This category applies to AEs that are clearly caused by other factors (disease, environment, etc.) and 
does not meet the criteria for "unlikely related", "possibly related", or "probably related". 
 
 
Probably Related 
Possibly Related Unlikely related 
Unrelated 
Clearly Caused by Other Factors 
– 
– 
– 
+ 
Plausible Time Relationship to Administration 
+ 
+ 
– 
– 
May be Explained by Disease 
– 
+ 
+ 
+ 
Recognized Toxicity of the Suspected Drug 
+ 
+ 
– 
– 
Positive Dechallenge 
+ 
– 
– 
– 
Positive Rechallenge 
+ 
– 
– 
– 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 47


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 48 of 54  
Appendix 2 ECOG Performance Status Scoring Standard 
Score 
Performance Status 
0 
Fully active, able to carry on all pre-disease performance without restriction 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light nature or office 
work 
2 
Ambulatory and capable of all self care but unable to carry out any work activities; confined to bed for no more 
than 50% of waking hours 
3 
Capable of only limited self care; confined to bed or chair for more than 50% of waking hours 
4 
Completely disabled; cannot carry on any self care; totally confined to bed or chair 
5 
Death 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 48


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 49 of 54  
Appendix 3 Summary of Protocol Amendments 
 
Protocol Synopsis of Phase I Clinical Trial, Inclusion Criteria 4 (page 7)  
 
Previous Text: 
4) Absolute neutrophil count (ANC) ≥ 2.0 × 109/L, hemoglobin (Hb) ≥ 11.5 g/dL, and platelet (PLT) 
≥ 100 × 109/L prior to chemotherapy. 
Revised Text: 
 
4) Absolute neutrophil count (ANC) ≥ 2.0 × 109/L, hemoglobin (Hb) ≥ 11.0 g/dL, and platelet (PLT) 
≥ 100 × 109/L prior to chemotherapy. 
 
Protocol Synopsis of Phase I Clinical Trial, Exclusion Criteria 11 (page 8) Previous Text: 
 
11)  History of tuberculosis (TB); history of TB exposure, unless negative for tuberculin test; 
TB patients undergoing treatment; or suspected TB evaluated by chest x-ray; 
 
Revised Text: 
 
11)  With active tuberculosis (TB); history of TB exposure, unless negative for tuberculin test; 
TB patients undergoing treatment; or suspected TB evaluated by chest x-ray; 
 
3.1 Overall Study Design and Schedule of Study Procedures, Figure 30-6 Schedule of F-627 
study procedures (page 30) 
 
Previous Text: 
 
1–15 Days 
Before 
Enrollment 
Day 1, Day 22, 
Day 43, and 
Day 64 of 
the Study6 
Day 3, Day 24, 
Day 45, 
and Day 66 of 
the Study1 
Cycle 1 of 
Chemotherapy 
(Day 3– 
Day 21)4 
Cycles 2–4 of 
Chemotherapy 
(Day 3– 
Day 21)5 
End of Study  
(Day 84)7 
Signing Informed 
Consent Form 
X 
 
 
 
 
 
History of Cancer 
X 
 
 
 
 
 
Complete Physical 
Examination 
X 
 
 
 
 
X 
Physical 
Examination 
 
X 
X 
 
 
 
Abdominal 
Ultrasound2 
X 
X 
 
 
 
X 
Chemotherapy 
 
X 
 
 
 
 
Urinalysis2 
X 
X 
 
 
 
X 
Administration1 
 
 
X 
 
 
 
12-Lead ECG3 
X 
 
 
 
 
X 
Color Doppler 
Echocardiography 
X 
 
 
 
 
 
Chest X-Ray 
X 
 
 
 
 
X 
Height and Weight2 
X 
X 
 
 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 49


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 50 of 54  
 
1–15 Days 
Before 
Enrollment 
Day 1, Day 22, 
Day 43, and 
Day 64 of 
the Study6 
Day 3, Day 24, 
Day 45, 
and Day 66 of 
the Study1 
Cycle 1 of 
Chemotherapy 
(Day 3– 
Day 21)4 
Cycles 2–4 of 
Chemotherapy 
(Day 3– 
Day 21)5 
End of Study  
(Day 84)7 
Body Temperature 
X 
X 
X 
X 
X 
X 
Routine Blood Test 
(including ANC) 
X 
X 
X 
X 
X 
X 
Clinical Chemistry2 
X 
X 
 
 
 
X 
Serum Pregnancy 
Test 
X 
 
 
 
 
X 
Blood Pressure 
and Heart Rate 
X 
X 
 
 
 
X 
Pharmacokinetics8 
 
 
X 
X 
X 
 
Serum Antibody9 
 
X 
X 
X 
X 
X 
AEs and Combined 
Medications9 
 
X 
X 
X 
X 
X 
1. 
Three dose cohorts for F-627 (80 μg/kg, 240 μg/kg and 320 μg/kg); 
2. 
Examination should be completed upon enrollment and the start of each chemotherapy cycle. Body height is measured 
upon enrollment only, while body weight is measured on day 1 of each cycle; for abdominal ultrasound, a retest on day 
1 of cycle 1 is not required and the baseline result can be used; for routine blood test and clinical chemistry before the 
start of cycle 1, results within 7 days are acceptable; 
3. 
12-lead ECG should be repeated at the last visit of the study; 
4. 
For chemotherapy cycle 1, starting from day 3, oral temperature measurement and routine blood test will be performed 
daily until ANC recovers to > 1.0 × 109/L from nadir, and once every 3 days thereafter until the next cycle; 
5. 
For chemotherapy cycles 2–4 (day 3–day 21 of each chemotherapy cycle, i.e., day 24–day 84 of the study), starting on 
each day 3 of cycles 2–4, oral temperature measurement and routine blood test will be performed every other day until 
ANC recovers from its nadir to > 1.0 × 109/L, and once every 3 days thereafter until the next cycle; 
6. 
Only when ANC of a subject recovers to > 1.0 × 109/L as judged by the investigator, can the next cycle start; 
7. 
The last visit is on day 84, and the subjects should complete a follow-up visit by telephone on day 114 (30 days after 
the last visit); 
8. 
In cycle 1 and cycle 3, blood samples are collected for PK at time points shown in Table 30-8; 
9. 
Blood samples will be collected for serum antibody assays during screening or before treatment with the drugs, as well 
as on days 8, 13, and 21 of each cycle. 
 
Remark: All laboratory measurements will be performed at a central laboratory assigned by the investigator. In case of any 
toxicities related to chemotherapy, subsequent treatment can be modified according to common diagnosis and treatment 
practice in the judgment of the investigator. 
 
Revised Text: 
 
 
1–15 Days 
Before 
Enrollment 
Day 1, Day 22, 
Day 43, and 
Day 64 of the 
Study (Window 
Phase: 3 Days 
Before 
Dosing)6 
Day 3, Day 24, 
Day 45, and 
Day 66 of 
the Study1 
Cycle 1 of 
Chemotherapy 
(Day 3– 
Day 21)4 
Cycles 2–4 of 
Chemotherapy 
(Day 3– 
Day 21)5 
End of Study 
(Day 84)7 
Signing 
Informed 
Consent Form 
X 
 
 
 
 
 
History of Cancer 
X 
 
 
 
 
 
Complete Physical 
Examination 
X 
 
 
 
 
X 
Physical 
Examination 
 
X 
X 
 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 50


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 51 of 54  
 
1–15 Days 
Before 
Enrollment 
Day 1, Day 22, 
Day 43, and 
Day 64 of the 
Study (Window 
Phase: 3 Days 
Before 
Dosing)6 
Day 3, Day 24, 
Day 45, and 
Day 66 of 
the Study1 
Cycle 1 of 
Chemotherapy 
(Day 3– 
Day 21)4 
Cycles 2–4 of 
Chemotherapy 
(Day 3– 
Day 21)5 
End of Study 
(Day 84)7 
Abdominal 
Ultrasound2 
 
X 
 
X 
 
 
 
 
X 
Chemotherapy 
 
X 
 
 
 
 
Urinalysis2 
X 
X 
 
 
 
X 
Administration1 
 
 
X 
 
 
 
12-Lead ECG3 
X 
 
 
 
 
X 
Color Doppler 
Echocardiography 
X 
 
 
 
 
 
Chest X-Ray 
X 
 
 
 
 
X 
Height and Weight2 
X 
X 
 
 
 
 
Body Temperature 
X 
X 
X 
X 
X 
X 
Routine Blood Test 
(including ANC) 
X 
X 
X 
X 
X 
X 
Clinical Chemistry2 
X 
X 
 
 
 
X 
Serum Pregnancy 
Test 
X 
 
 
 
 
X 
Blood Pressure and 
Heart Rate 
X 
X 
 
 
 
X 
Pharmacokinetics8 
 
 
X 
X 
X 
 
Serum Antibody9 
 
X 
X 
X 
X 
X 
AEs and Combined 
Medications9 
 
 
X 
 
X 
 
X 
 
X 
 
X 
1. 
Three dose cohorts for F-627 (80 μg/kg, 240 μg/kg and 320 μg/kg); 
2. 
Examination should be completed upon enrollment and the start of each chemotherapy cycle. Body height is measured 
upon enrollment only, while body weight is measured on day 1 of each cycle; for abdominal ultrasound, a retest on day 
1 of cycle 1 is not required and the baseline result can be used; for routine blood test and clinical chemistry before the 
start of cycle 1, results within 7 days are acceptable; 
3. 
12-lead ECG should be repeated at the last visit of the study; 
4. 
For chemotherapy cycle 1, starting from day 3, oral temperature measurement and routine blood test will be performed 
daily until ANC recovers to > 1.0 × 109/L from nadir, and once every 3 days thereafter until the next cycle; 
5. 
For chemotherapy cycles 2–4 (days 3–21 of each chemotherapy cycle, i.e., days 24–84 of the study), starting from 
each day 3 of cycles 2–4, oral temperature measurement and routine blood test will be performed every other day until 
ANC recovers from its nadir to > 1.0 × 109/L, and once every 3 days thereafter until the next cycle; 
6. 
The investigator may decide to start next cycle only when ANC recovers to > 1.0 × 109/L; 
7. 
The last visit is on day 84, and the subjects should complete a follow-up visit by telephone on day 114 (30 days after 
the last visit); 
8. 
In cycle 1 and cycle 3, blood samples are collected for PK at time points shown in Table 30-8; 
9. 
Blood samples will be collected for serum antibody assays on days 1, 8, and 13 of each cycle as well as day 22 of 
chemotherapy cycle 4. 
 
Remark: All laboratory measurements will be performed at a central laboratory assigned by the investigator. In case of any 
toxicities related to chemotherapy, subsequent treatment can be modified according to common diagnosis and treatment 
practice in the judgment of the investigator. 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 51


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 52 of 54  
4.1 Study Population and Number of Subjects (page 30) 
Previous Text: 
The investigator must ensure that the first cycle of treatment follows the recommended chemotherapy 
regimen; in chemotherapy cycles 2–4, treatment regimen and dose are permitted to be individualized 
based on subject conditions. Dose delay and one dose reduction due to toxicities other than 
myelotoxicity (such as cardiotoxicity) are permitted in this trial. If the subject requires a second dose 
reduction, the investigator and sponsor must decide together whether the subject should continue the 
treatment with the drugs. 
 
Revised Text: 
 
The investigator must ensure that the first cycle of treatment follows the recommended chemotherapy 
regimen; in chemotherapy cycles 2–4, treatment regimen and dose are permitted to be individualized 
based on subject conditions. Dose delay and one dose reduction due to chemotherapy-induced toxicities 
(such as cardiotoxicity) are permitted in this trial. If the subject requires a second dose reduction, the 
investigator and sponsor must decide together whether the subject should continue the treatment with 
the drugs. 
4.2 Inclusion Criteria 4 (page 30)  
Previous Text: 
4) Absolute neutrophil count (ANC) ≥ 2.0 × 109/L, hemoglobin (Hb) ≥ 11.5 g/dL, and platelet (PLT) 
≥ 100 × 109/L prior to chemotherapy. 
Revised Text: 
 
4) Absolute neutrophil count (ANC) ≥ 2.0 × 109/L, hemoglobin (Hb) ≥ 11.0 g/dL, and platelet (PLT) 
≥ 100 × 109/L prior to chemotherapy. 
4.3 Exclusion Criteria 11 (page 31)  
Previous Text: 
11)  History of tuberculosis (TB); history of TB exposure, unless negative for tuberculin test; 
TB patients undergoing treatment; or suspected TB evaluated by chest x-ray; 
 
Revised Text: 
 
11)  With active tuberculosis (TB); history of TB exposure, unless negative for tuberculin test; 
TB patients undergoing treatment; or suspected TB evaluated by chest x-ray; 
5.5 Drug Preparation (pages 32–33) 
Previous Text: 
The pharmacist is responsible for preparing the drugs and the nurse is responsible for reviewing. 
During drug preparation, inject 0.5 mL of water for injection slowly into the vial along the wall, let the 
vial stand for 1–2 minutes, and perform subcutaneous injection after the powder is completely 
dissolved. The injection should be used within 1 hour after preparation. The recommended 
concentration for F-627 is 2.0 mg/mL. The drug is generally injected in the morning (08:00 ± 1:00). 
The subject should remain in a sitting or walking position within two hours after the injection. 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 52


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 53 of 54  
Revised Text: 
 
The pharmacist is responsible for preparing the drugs and the nurse is responsible for reviewing. 
During drug preparation, inject 0.5 mL of water for injection slowly into the vial along the wall, let the 
vial stand for 1–2 minutes, and perform subcutaneous injection after the powder is completely 
dissolved. The injection should be used within 1 hour after preparation. See the drug preparation 
procedure manual. The drug is generally injected in the morning (09:00 ± 1:00). The subject should 
remain in a sitting or walking position within two hours after the injection. 
6.3 Clinical Evaluationss During and After F-627 Treatment (page 35) 
Previous Text: 
For chemotherapy cycles 2–4 (days 3–21 of each chemotherapy cycle, i.e., days 23–84 of the study), 
starting from day 2, oral temperature measurement and routine blood test will be performed every other 
day until ANC recovers from its nadir to > 1.0 × 109/L, and once every 3 days thereafter until the next 
cycle. Evaluations include: 
 
Revised Text: 
 
For chemotherapy cycles 2–4 (days 3–21 of each chemotherapy cycle, i.e., days 23–84 of the study), 
starting from day 3, oral temperature measurement and routine blood test will be performed every other 
day until ANC recovers from its nadir to > 1.0 × 109/L, and once every 3 days thereafter until the next 
cycle. Evaluations include: 
6.3.3 
Blood sampling of single-dose and repeated-dose PK studies, Table 30-8 (page 38) 
Previous Text: 
 
Study Process 
Days of 
Study 
Days of 
Dosing 
Blood Sampling 
Time Point of 
Cycle 1 
(hours: minutes) 
Blood Sample 
Number 
Blood Sampling 
Time Point of 
Cycle 3 
(hours: minutes) 
Blood Sample 
Number 
F-627 PK Study (2.5 
mL) 
F-627 PK 
Study 
(2.5 mL) 
Study Process 
3 
1 
–01:00±0.1:00 
PK 1 
00:00±0.1:00 
PK 1 
 
 
02:00±0.3:00 
PK 2 
02:00±0.3:00 
PK 2 
 
 
06:00±0.5:00 
PK 3 
06:00±0.5:00 
PK 3 
 
 
12:00±0.5:00 
PK 4 
12.00±0.5:00 
PK 4 
4 
2 
24:00±0.5:00 
PK 5 
24:00±0.5:00 
PK 5 
 
 
36:00±0.5:00 
PK 6 
36:00±0.5:00 
PK 6 
5 
3 
48:00±1:00 
PK 7 
48:00±1:00 
PK 7 
6 
4 
72:00±1:00 
PK 8 
72:00±1:00 
PK 8 
7 
5 
96:00±1:00 
PK 9 
96:00±1:00 
PK 9 
8 
6 
120:00±1:00 
PK 10 
120:00±1:00 
PK 10 
9 
7 
144:00±1:00 
PK 11 
144:00±1:00 
PK 11 
11 
9 
192:00±2:00 
PK 12 
192:00±2:00 
PK 12 
 
13 
11 
240:00±2:00 
PK 13 
240:00±2:00 
PK 13 
Number of Blood Samples Collected on Each Subject 
13 
 
13 
Total Volume of Blood Samples Collected on Each Subject 
32.5mL 
 
32.5 mL 
 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 53


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 54 of 54  
Revised Text: 
 
Study Process 
Days of 
Study 
Days of 
Dosing 
Blood Sampling 
Time Point of 
Cycle 1 
(hours: minutes) 
Blood Sample 
Number 
Blood Sampling 
Time Point of 
Cycle 3 
(hours: minutes) 
Blood Sample 
Number 
F-627 PK Study 
(2.5 mL) 
F-627 PK 
Study 
(2.5 mL) 
Study Process 
3 
1 
–01:00±0.1:00 
PK 1 
00:00±0.1:00 
PK 1 
 
 
02:00±0.3:00 
PK 2 
02:00±0.3:00 
PK 2 
 
 
06:00±0.5:00 
PK 3 
06:00±0.5:00 
PK 3 
 
 
12:00±0.5:00 
PK 4 
12.00±0.5:00 
PK 4 
4 
2 
24:00±0.5:00 
PK 5 
24:00±0.5:00 
PK 5 
 
 
36:00±0.5:00 
PK 6 
36:00±0.5:00 
PK 6 
5 
3 
48:00±1:00 
PK 7 
48:00±1:00 
PK 7 
6 
4 
72:00±1:00 
PK 8 
72:00±1:00 
PK 8 
7 
5 
96:00±1:00 
PK 9 
96:00±1:00 
PK 9 
8 
6 
120:00±1:00 
PK 10 
120:00±1:00 
PK 10 
9 
7 
144:00±1:00 
PK 11 
144:00±1:00 
PK 11 
11 
9 
192:00±2:00 
PK 12 
192:00±2:00 
PK 12 
13 
11 
240:00±2:00 
PK 13 
240:00±2:00 
PK 13 
16 
14 
312:00±2 4:00 
PK 14 
312:00±24:00 
PK 14 
21 
19 
432:00±2 4:00 
PK 15 
432:00±24:00 
PK 15 
Number of Blood Samples Collected on Each Subject 
15 
 
15 
Total Volume of Blood Samples Collected on Each Subject 
37.5 mL 
 
37.5 mL 
 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 54


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
 
Title Page 
 
 
 
 
 
 
 
Clinical Study Protocol 
 
 
 
A Single-Center, Open-Label, Dose-Escalation Phase I Clinical Trial of Recombinant Human 
Granulocyte Colony Stimulating Factor-Fc Fusion Protein for Injection as an Adjuvant to 
Chemotherapy in Subjects with Breast Cancer 
 
 
 
 
Protocol Number: 
2012-F-627-CH1 
Investigational Drug: 
Recombinant human granulocyte colony stimulating factor-Fc fusion 
protein (F-627) 
Clinical Phase: 
Phase I 
Current Version No.: 
2.5 
Issue Date of Current 
Version: 
Dec. 3, 2012 
Original Version No./ 
Issue Date: 
0.0/Apr. 25, 2010 
Study Site: 
Fudan University Shanghai Cancer Center 
Address: No. 270 Dong’an Road,  
Shanghai, China 
Postal Code: 200032 
Principal Investigator 
Professor Cao Junning  
Tel.: +86-021-61733900 
Sponsor 
Generon (Shanghai) Corporation Ltd. 
Address: Building 9, No. 787 Kangqiao  
Road, Shanghai, China  
Postal Code: 201315 
Contact 
Huang Cheng  
Tel.: +86-021-61760866 
 
 
 
 
 
 
 
Statement of ownership: This protocol is the property of Generon (Shanghai) Corporation Ltd. 
and may not be distributed, copied, or published by any individual or entity without authorization. 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 1 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 55


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
 
Signature Page 
 
 
 
 
Protocol Title: A Single-Center, Open-Label, Dose-Escalation Phase I Clinical Trial of 
Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein for Injection as 
an Adjuvant to Chemotherapy in Subjects with Breast Cancer 
 
 
Protocol Number: 2012-F-627-CH1 
 
 
I confirm that I have read, understood and agreed to abide by all provisions in the Clinical Study 
Protocol (Number: 2012-F-627-CH1, Date: Dec. 3, 2012). I shall carefully carry out my duties in 
accordance with the Good Clinical Practice. 
 
 
 
 
Principal Investigator 
 
 
 
Cao Junning 
 
 
 
Signature 
Date 
 
 
Cao Junning 
 
 
Principal Investigator (Printed Name) 
 
 
 
 
Sponsor 
 
 
Huang Cheng 
 
 
 
Signature 
Date 
 
 
Huang Cheng 
 
 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 2 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 56


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
 
Emergency Contacts of Generon (Shanghai) Corporation Ltd. 
 
 
 
 
In case of a medical emergency, the clinical study leading official may be contacted. If the 
director is not available, the protocol writer or the clinical research associate (CRA) may be 
contacted via the information shown in the table below. 
 
 
 
Name 
Contact Number 
Project leading official 
Huang Cheng 
021-6176-0866 
or 18621697558 
Protocol Writer 
Tang Kaiyang/ 
Huang Cheng 
021-6176-0866 
or 18621697558 
24-Hour Emergency 
Contact Number 
Huang Cheng 
021-6176-0866 
or 18621697558 
 
 
 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 3 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 57


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Synopsis of Phase I Clinical Study Protocol 
Investigational Drug 
Recombinant human granulocyte colony stimulating factor-Fc fusion protein for injection 
Protocol No. 
2012-F-627-CH1 
Title 
A single-center, open-label, dose-escalation phase I clinical trial of recombinant human 
granulocyte colony stimulating factor-Fc fusion protein for injection as an adjuvant to 
chemotherapy in subjects with breast cancer 
Mechanism of 
Drug Action 
The recombinant human granulocyte colony stimulating factor (rhG-CSF)-Fc fusion protein 
is a long-acting rhG-CSF expressed in CHO cells. Each molecule of rhG-CSF-Fc fusion 
protein contains two G-CSF dimer molecules, which may overcome the weak bioactivity of 
pegfilgrastim and produce a stronger receptor activation signal, thereby accelerating the 
differentiation and proliferation of neutrophils in bone marrow. Also, preclinical studies have 
shown that the pharmacokinetic and pharmacodynamic properties of rhG-CSF-Fc is different 
from or superior to pegfilgrastim, and therefore it decreases the severity of neutropenia and 
reduces the duration of severe neutropenia in cancer patients after chemotherapy. 
Study Site 
Fudan University Shanghai Cancer Center 
Pharmacokinetic 
Analysis Site 
Covance Pharmaceutical Research and Development (Shanghai) Co., Ltd. 
Number of Planned 
Enrollment 
It is planned to enroll 18 subjects 
Study Population 
Female postoperative patients with breast cancer who receive adjuvant chemotherapy will be 
enrolled in this study. Eligible patients should have received no chemotherapy or only one 
chemotherapy. 
The chemotherapy used for this trial is EC→P or EC→T, that is: epirubicin 100 mg/m2, i.v. + 
cyclophosphamide 600 mg/m2, i.v. on day 1, repeat cycle every 21 days for 4 cycles. After 
completing the evaluation for all 4 cycles, subjects will receive 4 subsequent cycles of 
sequential chemotherapy (either paclitaxel or docetaxel) and supportive care according to 
routine practice. 
Objectives 
Primary Objective: 
To evaluate the safety and tolerability of recombinant human granulocyte colony stimulating 
factor-Fc fusion protein for injection (F-627) in treatment of female postoperative breast cancer 
patients who require adjuvant chemotherapy in a single-center, open-label, single-dose and 
repeated-dose, dose-escalation phase I clinical trial. 
Secondary Objectives: 
1. 
To evaluate the pharmacokinetics of F-627 by determining the serum drug concentrations 
of F-627 at different time points after dosing; 
2. 
To evaluate the pharmacodynamics of F-627 by analyzing the relationship between serum 
drug concentrations of F-627 and neutrophil counts in blood at different time points after 
dosing, and to provide a recommended dose for phase II clinical trial. 
Exploratory Objectives: 
1. 
To observe the number of days in which absolute neutrophil count is less than 0.5 × 109/L 
in cycle 1 of chemotherapy, the average time of ANC recovery, and the number of 
days in which absolute neutrophil count is less than 1 × 109/L, and to provide guiding 
significance for phase II clinical trial. 
2. 
To evaluate the potential immunogenicity of F-627 by testing anti-F-627 antibodies 
(IgG and IgM) in serum. 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 4 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 58


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Dosage and 
Administration 
This study includes 3 dose cohorts, 80, 240, and 320 µg/kg, each of which will enroll 6 patients 
with breast cancer sequentially receiving adjuvant chemotherapy. Subjects in each cohort will 
receive a single-dose of F-627 by subcutaneous injection approximately 48 hours after the 
completion of chemotherapy. Blood samples are then collected at multiple time points during 
the subsequent follow-up visits, to evaluate the pharmacokinetics, pharmacodynamics, and 
safety of the drug. If dose-limiting toxicities are not observed before the start of cycle 2, then 
the same dose of F-627 is to be given at approximately 48 hours after each chemotherapy in 
cycles 2-4. 
Dose-Escalation 
The starting dose is 80 µg/kg. Only after 6 subjects have completed the treatment and observation 
of the first cycle, the sponsor and investigator will determine whether to proceed to the next 
higher dose based on the safety evaluation. This is also applicable to the 240 µg/kg cohort. Dose 
escalation is not pursued after 6 subjects in the 320 µg/kg cohort complete the evaluation. Dose 
escalation should be stopped if 2 cases of DLTs are observed in the first cycle in each cohort. 
Rationale for 
Dose Selection 
Results from 3-month repeat dosing toxicity studies showed that the no-observed-adverse- 
effect-levels (NOAEL) of F-627 was 1000 µg/kg in rats and 675 µg/kg in cynomolgus 
monkeys. F-627 is a recombinant fusion protein with a molecular weight of 95000 Daltons. 
Results from preclinical studies showed that the toxicity of F-627 was due to the amplification 
of pharmacodynamics, which is closely associated with the dose (expressed in mg/kg) in 
various different species. The maximum safe starting dose of F-627 was calculated to be 
67.5 µg/kg when converted using mg/kg, which is one-tenth of the NOAEL in cynomolgus 
monkeys. In a phase I clinical trial in healthy volunteers, male subjects received a single-dose 
of F-627 by subcutaneous injection at doses of 30, 60, 120, 240, and 360 µg/kg. Results 
showed that neutrophil increased across all dose cohort up to 96 hours following the 
administration of F-627. The maximum dose of 360 µg/kg was safe and no serious adverse 
events observed. Higher incidence rate of adverse event was observed with the increasing dose. 
Low dose was better tolerated than high dose. According to the animal studies and phase I 
clinical trial, 80 µg/kg is safe as the starting dose for patients. Firstly, the maximum dose 
should not exceed the maximum dose determined in the phase I clinical trial. Secondly,  
the G-CSF mole number of 240 µg/kg F-627 is comparable to that of 100 µg/kg pegfilgrastim. 
Finally, 60 µg/kg cohort exhibited superior pharmacodynamics than the 150 µg/kg cohort in 
treating the chemotherapy-induced neutropenia in monkey models. 
Dose-Limiting 
Toxicity 
Dose-limiting toxicity (DLT) refers to an intolerable toxicity that is experienced during the 
treatment with investigational drug and limits the further dose escalations. DLT is defined as 
any grade 3 or greater adverse event related to the investigational drug that observed in cycle 1 
(21 days). Adverse events will be assessed according to NCI CTCAE V4.03 criteria. 
After 6 subjects in each dose of F-627 cohort have completed the treatment and observation 
of first cycle, the trial may proceed into the next dose cohort only if less than 2 subjects 
develop DLT. If a grade 3 or greater adverse event related to the investigational drug is 
observed in cycles 2-4, then the investigator and sponsor will determine together whether the 
adverse event would affect further dose escalations. 
Safety Evaluation 
Safety endpoints include laboratory measurements, physical examinations, vital signs, and 
performance status, as well as adverse events. The incidence rate and severity of adverse events 
(AEs) will be assessed according to NCI CTCAE 4.03 criteria. 
Salvage Therapy 
During the study, an approved G-CSF treatment should be given to the patient as salvage therapy 
in the case of febrile neutropenia (defined as ANC < 1.0 × 109/L; a single measurement of body 
temperature > 38.3 °C or a fever ≥ 38.0 °C sustained for longer than 1 h; Note: temperature 
measurements is based on oral temperature or equivalent armpit/rectal temperature) or grade 
4 neutropenia lasting greater than 3 days. The sponsor recommends GRAN® (filgrastim) at a dose 
equivalent to 5 µg/kg/day of G-CSF, once daily for ≤ 2 weeks or until neutrophil count recovers 
to 1.0 × 109/L. 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 5 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 59


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Inclusion Criteria 
All of the following conditions must be met: 
1) 18-75 years old; 
2) Female postoperative breast cancer patients who require adjuvant chemotherapy, 
and are planned to receive 4 cycles of EC chemotherapy; 
3) ECOG performance status of 0-1; 
4) Absolute neutrophil count (ANC) ≥ 2.0 × 109/L, hemoglobin (Hb) ≥ 11.5 g/dL, and platelet 
(PLT) ≥ 100 × 109/L prior to chemotherapy 
5) Hepatic and renal function within the normal range; 
6) Left ventricular ejection fraction greater than 50%; 
7) Willing to sign the informed consent form and able to comply with protocol requirements; 
Exclusion Criteria 
Subjects who meet any of the following must be excluded from this study: 
1) 
Women in pregnancy or breastfeeding; Women of child–bearing potential have a positive 
pregnancy test result prior to the first dose; 
2) 
Life expectancy less than 12 months; 
3) 
Radiation therapy within 4 weeks prior to enrollment; 
4) 
Breast cancer patients who have received neoadjuvant chemotherapy before radical 
mastectomy; 
5) 
Prior bone marrow or stem cell transplant; 
6) 
With other malignant tumors other than breast cancer; 
7) 
Have received G-CSF treatment within 6 weeks prior to enrollment; 
8) 
Diagnosed with acute congestive heart failure, cardiomyopathy, or myocardial infarction 
by clinical diagnosis, ECG or other approaches; 
9) 
With any disease that may cause splenomegaly; 
10) With acute infection, chronic active Hepatitis B within 1 year (unless patients tested 
negative for HBsAg prior to enrollment), or Hepatitis C; 
11) History of tuberculosis (TB); history of TB exposure, unless negative for tuberculin test; 
TB patients undergoing treatment; or suspected TB evaluated by chest x-ray; 
12) Known HIV positive or AIDS; 
13) With sickle cell anemia; 
14) With alcohol or drug abuse that may affect the compliance with the study; 
15) With known hypersensitivity to E. coli derived proteins, G-CSF, or excipients; 
16) Has received any other investigational drug within 4 weeks prior to enrollment; 
17) Patients with diseases or symptoms unsuitable for participating in the clinical trial based 
on the investigator's judgment; 
Criteria for 
Terminating Study 
1) Incidence rate and severity of serious adverse events (SAEs) indicate the study should be 
terminated early as determined by the investigators and the sponsor; 
2) The dose-limiting toxicity of the subjects does not recover or cannot be relieved; 
3) The investigators question the safety of the drug and believe that the continuation of the 
study may pose serious risks to the subjects; 
4) The maximum dose set in the clinical trial has been reached; 
5) Data fraud, or inaccurate/incomplete collection of data; 
Criteria for Subject 
Withdrawal 
Subjects will withdraw from the study with a written explanation when the following 
conditions occur. 
1) Subject withdraws voluntarily during the trial; 
2) The investigator considers that withdrawal is for the best interest of the subject; 
3) The investigator or subject believes that to continue the trial may result in intolerable 
adverse events; 
4) Complications or worsening co-morbidities affecting subject's participation occur; 
5) Subject is found to violate protocol after enrollment, or a major protocol violation occurs 
during the trial; 
6) When a safety concern regarding the investigational drug arises, but data is yet unknown, 
resulting in potential risks if subjects continue the trial; 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 6 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 60


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Drop-Out Criteria 
Determination of drop-outs: Eligible subjects who have signed the informed consent form 
and been enrolled have the right to withdraw from the study at any time. Subjects who do not 
complete the entire observation are considered drop-outs regardless of the time or reason of the 
withdrawal. A replacement should be implemented immediately according to the original plan 
when a drop-out occurs. Blood samples from drop-out subjects should be retained. 
Evaluations: 
Safety Evaluation 
Medical consultation, physical examinations, vital signs, laboratory measurements (hematology, 
clinical chemistry, routine urinalysis, etc.), weight, ECG, abdominal ultrasound and adverse 
event evaluation. 
Pharmacokinetic 
Evaluation 
Serum: Cmax, Tmax, MRT, Vd, Kel, Tl/2z, AUClast, AUC, CL/F, Vz/F 
Pharmacodynamic 
Evaluation 
Absolute neutrophil count (ANC) after dosing, as well as the number of days in which ANC 
is less than 0.5 × 109/L, the number of days in which ANC is less than 1.0 × 109/L, and the 
time ANC recovers to 1.0 × 109/L after chemotherapy in cycles 1 and 2-4 are observed. 
Statistical Analysis: 
Descriptive statistics will be summarized for all variables obtained at various observation time points by dose cohorts, 
unless the protocol specifies that statistical analysis at a particular time point is not required. Overall, continuous 
variables (such as age) will be descriptively summarized with observed numbers, mean, median, standard deviation, 
minimum, and maximum. Categorical variables will be descriptively summarized with frequency and percentage based 
on each category. Continuous safety analysis of adverse events related to the investigational drug and other safety 
endpoints will be performed. 
The analysis dataset includes all enrolled subjects who have received at least one dose of the study drug. This dataset 
is available for all analyses. Statistical methods are detailed in the Statistical Analysis Plan. 
Pharmacokinetics 
Two phases (single-dose and repeated dose); All PK parameters will be summarized using 
descriptive statistics by dose cohorts. The non-compartmental analysis of blood concentration 
data will be performed by the central laboratory using WinNonlin Enterprise. 
Cmax (natural logarithm), AUC(0-inf), AUCt, and AUClast of the single-dose and repeated-dose 
phase were analyzed using one-way ANOVA, with dose cohort as the fixed factor. The least 
squares mean difference between the two dose cohorts and the 90% confidence intervals are 
obtained from the analysis of variance, then the least squares geometric means ratio and the 
90% confidence intervals are obtained by taking the antilog. 
Pharmacodynamic 
Evaluation 
The number of days in which ANC is less than 0.5 × 109/L, the number of days in which ANC 
is less than 1 × 109/L, and the mean time of ANC recovery to 1.0 × 109/L in chemotherapy of 
cycles 1 and 2-4 of chemotherapy are calculated for each dose cohort. ANC profiles in various 
dose cohorts are plotted. 
Safety Evaluation 
All adverse events are listed by patient, and coded by MedDRA as per System Organ Class 
and Preferred Term. Inferential statistics are not required for safety endpoints. Abnormal values 
of laboratory measurements, vital signs, ECG, and other safety endpoints need to be noted. The 
incidence rate and severity of adverse events (AEs) will be assessed according to NCI CTCAE 
4.03 criteria. 
 
 
 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 7 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 61


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
 
Table of Contents 
 
1. 
STUDY BACKGROUND ............................................................................................................ 12 
1.1 
Introduction to F-627 ......................................................................................................... 12 
1.1.1 
Name, structure, and physicochemical properties ............................................................. 12 
1.1.2 
Mechanism of action .......................................................................................................... 13 
1.1.3 
Preclinical pharmacokinetics study .................................................................................... 14 
1.1.4 
Preclinical toxicology study ............................................................................................... 14 
1.1.5 
Preclinical pharmacodynamic study .................................................................................. 15 
1.1.6 
Previous clinical studies ..................................................................................................... 16 
1.2 
Overall Evaluation of Adjuvant Measures and Efficacy of Chemotherapy for Cancer ..... 19 
2. 
STUDY OBJECTIVES ................................................................................................................ 20 
2.1 
Primary Objective .............................................................................................................. 20 
2.2 
Secondary Objectives ......................................................................................................... 20 
2.3 
Exploratory Objectives ...................................................................................................... 20 
3. 
STUDY PLAN AND METHODOLOGY ................................................................................... 20 
3.1 
Overall Study Design and Schedule of Study Procedures ................................................. 20 
3.2 
Evidence for Dose Determination ...................................................................................... 22 
3.3 
Single Dose and Repeated Dose ........................................................................................ 23 
3.4 
Dose Escalation .................................................................................................................. 23 
3.5 
Dose-Limiting Toxicity (DLT) .......................................................................................... 24 
3.6 
Risk, Benefit and Ethical Evaluations................................................................................ 24 
4. 
STUDY POPULATION ............................................................................................................... 24 
4.1 
Study Population and Number of Subjects ........................................................................ 25 
4.2 
Inclusion Criteria................................................................................................................ 25 
4.3 
Exclusion Criteria .............................................................................................................. 25 
4.4 
Criteria for Terminating Study ........................................................................................... 26 
4.5 
Criteria for Subject Withdrawal ......................................................................................... 26 
4.6 
Drop-Out Criteria ............................................................................................................... 27 
4.7 
Withdrawal-Related Procedures and Handling .................................................................. 27 
5. 
INVESTIGATIONAL DRUG AND TREATMENT ................................................................ 27 
5.1 
Source................................................................................................................................. 27 
5.2 
Strength and Expiration Date ............................................................................................. 28 
5.3 
Labeling ............................................................................................................................. 28 
5.4 
Storage ............................................................................................................................... 28 
5.5 
Drug Preparation ................................................................................................................ 28 
5.6 
Administration and Precautions ......................................................................................... 29 
5.7 
Salvage Therapy ................................................................................................................. 29 
5.8 
Drug Management.............................................................................................................. 29 
5.9 
Principles and Methods for Treatment of Drug Toxicities ................................................ 30 
5.10 
Treatment Compliance ....................................................................................................... 30 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 8 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 62


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
6. 
EVALUATIONS AND ENDPOINTS ........................................................................................ 30 
6.1 
Evaluations During Screening ........................................................................................... 30 
6.2 
Clinical Evaluations During and After F-627 Treatment ................................................... 31 
6.3 
Pharmacokinetic (PK) Evaluations .................................................................................... 33 
6.3.1 
Determination and analysis of PK serum samples ............................................................. 33 
6.3.2 
Collection, handling, and storage of PK blood samples .................................................... 33 
6.3.3 
Blood sampling of single-dose and repeated-dose PK studies .......................................... 33 
6.4 
Pharmacodynamic Evaluation............................................................................................ 34 
6.5 
Safety Evaluation ............................................................................................................... 34 
6.6 
Serum Antibody Assays and Evaluations .......................................................................... 35 
7. 
ADVERSE EVENTS .................................................................................................................... 35 
7.1 
Adverse Events (AEs) and Abnormal Values of Laboratory Measurements .................... 35 
7.1.1 
Clinical adverse events....................................................................................................... 35 
7.1.2 
Treatment and follow-up of adverse events ....................................................................... 37 
7.1.3 
Abnormal values of laboratory measurements ................................................................... 37 
7.2 
Adverse Event Management .............................................................................................. 38 
8. 
STATISTICAL METHODS AND ANALYSIS ........................................................................ 39 
8.1 
Pharmacokinetic Evaluation .............................................................................................. 39 
8.2 
Pharmacodynamics Evaluation .......................................................................................... 40 
8.3 
Statistical Analysis of Safety Data ..................................................................................... 40 
9. 
DATA MANAGEMENT ............................................................................................................. 40 
9.1 
Data Filling-In by Investigator ........................................................................................... 40 
9.2 
Requirement of Data Monitoring by Clinical Research Associate .................................... 41 
9.3 
Data Entry, Recording and Management ........................................................................... 41 
9.4 
Audits and Inspections ....................................................................................................... 42 
9.5 
Personnel Training ............................................................................................................. 42 
10. STUDY PROTOCOL REVISIONS ........................................................................................... 42 
11. STUDY MANAGEMENT ........................................................................................................... 42 
11.1 
Clinical Study Agreement .................................................................................................. 42 
11.2 
Study Schedule and Requirements for Early Termination ................................................. 43 
12. ETHICS ......................................................................................................................................... 43 
12.1 
Ethics of Clinical Study ..................................................................................................... 43 
12.2 
Independent Ethics Committee (IEC) ................................................................................ 43 
12.3 
Informed Consent Form (ICF) ........................................................................................... 44 
12.4 
Privacy Protection .............................................................................................................. 44 
13. QUALITY CONTROL OF CLINICAL TRIAL ....................................................................... 44 
14. DATA STORAGE AND USE ..................................................................................................... 45 
15. REFERENCES ............................................................................................................................. 45 
Appendix 1 
Analysis of Causality Between Drugs and Adverse Events ....................................... 46 
Appendix 2 
ECOG Performance Status Scoring Standard ............................................................. 47 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 9 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 63


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
 
List of Tables 
 
Table 30-1. Comparison of PK parameters between F-627 and pegfilgrastim. ...................................... 14 
Table 30-2. Summary of F-627 preclinical safety evaluation tests......................................................... 14 
Table 30-3. Summary of adverse events in the phase I clinical trial. ..................................................... 16 
Table 30-4. Human PK parameters in phase I clinical trial. ................................................................... 17 
Table 30-5. Summary of pharmacodynamics in phase I clinical trial. ................................................... 18 
Table 30-6. Schedule of F-627 study procedures. .................................................................................. 21 
Table 30-7. Rationale for F-627 doses in clinical trials. ......................................................................... 23 
Table 30-8. Blood sampling time of single-dose and repeated-dose PK studies. ................................... 34 
 
 
List of Figures 
 
Figure 30-1. Semi-logarithmic plot of concentration-time (hours) after different doses of  
F-627 in healthy male subjects........................................................................................... 18 
Figure 30-2. Mean ANC in subjects after administration of different doses of F-627. .......................... 18 
 
 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 10 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 64


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Abbreviations and Terms 
 
Abbreviations and Terms Definitions 
AEs 
Adverse Events 
ALP 
Alkaline Phosphatase 
ANC 
Absolute Neutrophil Count 
AUC 
Area Under Concentration-Time Curve 
CL/F 
Total Clearance 
Cmax 
Maximum Serum Concentration 
DHL 
Lactate Dehydrogenase 
ECG 
Electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
ED50 
Median Effective Dose 
EMEA 
European Medicines Agency 
FDA 
U.S. Food & Drug Administration 
GCP 
Good Clinical Practice 
Kel 
Elimination rate constant 
MRT 
Mean Residence Time 
NCI CTC 
National Cancer Institute Common Terminology Criteria 
NOAEL 
No-Observed-Adverse-Effect Level 
PK/PD 
Pharmacokinetics/Pharmacodynamics 
Pubmed 
PubMed search system developed by the National Institutes of Health 
rhG-CSF-Fc 
Recombinant human granulocyte colony stimulating factor-Fc fusion protein 
SFDA 
State Food and Drug Administration 
Tmax 
Time to Peak 
Vd 
Apparent Volume of Distribution 
Vz/F 
Volume of Distribution 
WBC 
White Blood Cell 
WHO 
World Health Organization 
 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 11 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 65


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
 
1. 
STUDY BACKGROUND 
1.1 
Introduction to F-627 
1.1.1 
Name, structure, and physicochemical properties 
All recombinant human granulocyte colony stimulating factors (rhG-CSF) that have already been 
approved for marketing in China and other countries, and the more than 10 rhG-CSFs in clinical and 
pre-clinical studies, are monomeric G-CSFs (Pharmaproject ref). This rhG-CSF-Fc fusion protein, is a 
rhG-CSF dimer expressed in CHO cells, based on the technology of Fc fusion, whose IP is protected by 
Chinese patents. The Fc fragment is derived from human immunoglobulin with prolonged effects. The 
half-life of IgG immunoglobulins may be up to 3 weeks in human blood. Recombinant protein drugs 
generated using the Fc fusion protein technology such as Enbrel (for rheumatoid arthritis, soluble 
TNFα receptor and IgG1) and chimeric monoclonal antibodies such as Remicade (for rheumatoid 
arthritis, anti-TNFα IgG1) and Abciximab (for platelet aggregation, anti-GPIIb/IIIa IgG1) have been 
successfully marketed. In addition, D-Mab (for osteoporosis, anti-RANKL IgG2) has been approved for 
marketing by FDA. The safety and efficacy of Fc fusion protein have been validated for clinical 
application. 
 
The Fc region of human immunoglobulin mediates effector functions, such as antibody-dependent 
cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and plays an important 
role in the immune defense. ADCC refers to the phagocytosis or killing of target cells, which is 
mediated by the specific binding of antibody or the Fc fusion protein via the Fc region to the Fcγ 
receptor expressed on the surface of effector cells, such as natural killer cells and macrophages. CDC 
refers to the killing of target cells by the activation of complements, which is mediated by the specific 
binding of antibody or the Fc fusion protein via the Fc region to plasma proteins, such as complement 
proteins C1q, C3 and C4. 
 
The effector function of the Fc fragment in rhG-CSF-Fc is reduced and eliminated by two methods 
(U.S. Patent: 6797493, Chinese Patent: 02126839.8). Among the four human IgGs, IgG2 has a weaker 
effector function. In regard to FcγRI and FcγRIIB, the affinity of FcγRI for the four human IgGs is in 
the order of: IgG1, IgG3 > IgG4 >> IgG2. The affinity of FcγRIIB for the four human IgGs is: IgG3 > 
IgG1 > IgG4 > IgG2 (Van Sorge et al 2003, Tissue Antigens. Vol. 61:189–202). Therefore, IgG2 Fc 
was used for the making of the fusion protein. Given the substitution of proline (a proven functional 
residue in CDC) at position 331 of IgG2 with serine, the fusion protein generated by this method no 
longer has any effector function. The above amino acid number (e.g. position 331) was calculated using 
the EU numbering system described by Kabat et al. (Sequence of Proteins of Immunological Interest, 
edition5, United States Department of Health and Human Services, 1991). 
 
 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 12 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 66


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
In the construction of the G-CSF-Fc fusion protein, a peptide linker comprising 16 amino acids was 
added between G-CSF and IgG2-Fc. The sequence of this linker is: 
GlySerGlyGlyGlySerGlyGlyGlyGlySerGlyGlyGlyGlySer. The purpose is to keep the Fc domain of the 
fusion protein away from the G-CSFR binding site and improve its bioactivity. In addition, the peptide 
linker may also allow one G-CSF to be distant from another G-CSF, and produce rhG-CSF in a dimeric 
form with two G-CSF molecules on a single Fc fragment. The rhG-CSF-Fc dimer may cause a stronger 
receptor activation compared with a rhG-CSF monomer, and thereby the bioactivity of the fusion 
protein can be further improved. 
1.1.2 
Mechanism of action 
The human granulocyte colony stimulating factor receptor (G-CSF receptor, G-CSFR) is a specific, 
812-amino acid single-chain receptor with high affinity to G-CSF. During neutrophil development, 
each cell expresses about 50–500 G-CSFR. The more mature neutrophils are, the higher the density of 
G-CSFR on their surfaces Tamada et al. performed a 2.8Ao diffraction analysis of the G-CSF: G-CSFR 
crystal (PNAS, 2008, Vol. 103: 3135-3140) and found that this complex exists in a 2:2 ratio, i.e., 
2 ligands with 2 receptors (Fig. 3-2). Each G-CSF molecule binds to one receptor. Only when two 
receptors binding to the G-CSF ligands interact with each other to form a 2:2 dimer, the C-terminal of 
the G-CSF receptor may activate the downstream signaling molecule, JAK2 (Janus tyrosine kinase). 
JAK2 then initiates gene transcription by activating STAT3, resulting in cell proliferation. 
Theoretically, dimeric ligands may be able to activate downstream signaling pathways faster and 
stronger than monomeric ligands. 
 
G-CSF receptors on neutrophils can not only transmit G-CSF signal, but also regulate the G-CSF 
concentration in the blood. During an infection or a neutropenic period, G-CSF concentrations in the 
blood will increase to stimulate the production of neutrophils. When absolute neutrophil count 
increases, the binding of G-CSF in the blood also increases, thereby maintaining a relatively stable G-
CSF concentration in vivo. 
 
Furthermore, in a clinical study of rhG-CSF (Schwinger et al, 1993, Bone Marrow Transplantation, Vol. 
11:489-492), it was found that peripheral blood precursor cells and peripheral blood stem cells increase 
drastically after the injection of rhG-CSF, which is called peripheral blood precursor cell (PBPC) 
and/or peripheral blood stem cell (PBSC) mobilization. Many hematopoietic growth factors such as 
SCF, FL, GM-CSF, and IL-3, as well as reagents affecting the character of bone marrow matrix 
proteins and adhesion molecules have the similar function of PBPC and/or PBSC mobilization. 
Therefore, peripheral blood cells collected after rhG-CSF injection, are enriched with PBPCs and 
PBSCs, and are widely used as donor cells for conventional bone marrow transplantation in developed 
countries. 
 
 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 13 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 67


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
1.1.3 
Preclinical pharmacokinetics study 
Pharmacokinetics studies of F-627 in rats and cynomolgus monkeys showed that F-627 is a long-acting 
drug in vivo. F-627 demonstrated nonlinear pharmacokinetics. Blood drug concentration and ANC 
increase (PD response) is dose-dependent. In the study of F-627 (100 µg/kg) subcutaneous injection in 
rats, T1/2 was 7.6 ± 1.3 hours, Cmax was 162 ng/mL, and AUC was 4217 ± 641 ng/mL·*hr. In the study 
of pegfilgrastim (Neulasta, 100 µg/kg) in rats, T1/2 was 7.1 hours (Zamboni W.C, 2003, 
Pharmacotherapy, Vol.23 (8 pt2):9S-14S) and AUC was 1600 ng/mL·*hr (FDA IND). In cynomolgus 
monkey models with cyclophosphamide-induced neutropenia, the PK parameters of F-627 and 
pegfilgrastim at the equivalent dose were comparable (as shown in Table 30-1). However, F-627 
resulted in a faster neutrophil recovery compared with pegfilgrastim. 
 
Table 30-1. Comparison of PK parameters between F-627 and pegfilgrastim. 
 
Dose 60 µg/kg 
Tmax (hr) 
Cmax (ng/mL) 
AUC (ng/mL·hr) 
T½ (hr) 
F-627 (Female) 
8.0 
776 ± 155 
21289 ± 5744 
8.9 
F-627 (Male) 
8.0 
566 ± 162 
14515 ± 7324 
11 
Pegfilgrastim (Female) 
12.0 
482 ± 88 
25571 ± 474 
8.2 
Pegfilgrastim (Male) 
8.0 
574 ± 87 
21894 ± 2616 
8.7 
Note: The table shows the PK data after the first dose in the cynomolgus monkey model with cyclophosphamide-induced 
neutropenia. 
1.1.4 
Preclinical toxicology study 
A systematic preclinical safety evaluation of F-627 has been conducted according to SFDA's 
registration categories of biological products and requirements for submission dossiers. Refer to Table 
30-2 for the details of safety evaluation tests. In the repeat dosing toxicity studies in rats and 
cynomolgus monkeys, application requirements of FDA were taken into account by increasing the 
number of animals and the number of organs dissected. Meanwhile, the validation of PK/TK analysis 
method was in accordance with the application requirements of FDA/EMEA. In the 3-month repeat 
dosing toxicity studies, the no-observed-adverse-event-level (NOAEL) of F-627 was 1000 µg/kg in rats 
and 675 µg/kg in cynomolgus monkeys, which were the high dose selected in the dose design. 
 
Table 30-2. Summary of F-627 preclinical safety evaluation tests. 
 
Animal 
Study Title 
Dose (µg/kg) 
Administration 
Observation Time 
NOAEL 
µg/kg 
Rat 
Acute toxicity study 
100,500,2500,7500 
Single 
2 weeks 
 
Rat 
Dose range finding 
toxicity study 
30,100,300,1500 
Repeat 
4 weeks 
 
Rat 
Repeat dosing toxicity 
study 
100,300,1000 
Repeat 
Administration: 
3 months 
Recovery period: 
1 month 
1000 
Cynomolgus 
monkey 
Acute toxicity study 
300,3000 
Single 
2 weeks 
 
Cynomolgus 
Repeat dosing toxicity 
75,225,675 
Repeat 
Administration: 
675 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 14 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 68


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Animal 
Study Title 
Dose (µg/kg) 
Administration 
Observation Time 
NOAEL 
µg/kg 
monkey 
study 
3 months 
Recovery period: 
1 month 
Mouse 
Safety pharmacology 
study - spontaneous 
activity 
30,120,480 
Single 
10 minutes 
 
Mouse 
Safety pharmacology 
study - synergy of 
sodium pentobarbital 
hypnotic effect in mice 
30,120,480 
Single 
30 minutes 
 
Mouse 
Safety pharmacology 
study - hypnotic effect 
of sodium pentobarbital 
of subthreshold dose 
30,120,480 
Single 
30 minutes 
 
Rabbit 
Muscular irritation 
study 
400,1600 
Single 
48 hours, 16 days 
 
Rabbit 
Vascular irritation 
study 
400,1600 
Single 
48 hours, 16 days 
 
Guinea Pig 
Active anaphylaxis test Sensitization phase: 
100, 500; 
Challenge phase: 
sensitization dose × 2 
Sensitization for 
5 times 
once every other 
day 
30 minutes, 3 hours 
Rabbit 
RBC in vitro hemolysis 
test 
1000 µg/mL 
In vitro 
incubation 
3 hours 
 
 
Results from 3-month repeat dosing toxicity studies showed that the no-observed-adverse-effect-level 
(NOAEL) of F-627 was 1000 µg/kg in rats and 675 µg/kg in cynomolgus monkeys. F-627 is a 
recombinant fusion protein with a molecular weight of 95000 Daltons. Results from preclinical studies 
showed that the toxicity of F-627 was due to the exaggerated pharmacology effects, which is closely 
associated with the dose (expressed in mg/kg) in various different species. Based on the guideline 
issued by the FDA in 2005, the maximum safe starting dose of F-627 was calculated to be 67.5 µg/kg 
using mg/kg conversion, which is one-tenth of the NOAEL in cynomolgus monkeys. Based on the dose 
in the phase I clinical trial conducted in Australia, 80 µg/kg is a safe starting dose. 
1.1.5 
Preclinical pharmacodynamic study 
In vitro bioactivity study of F-627 
The in vitro bioactivity study of F-627 showed that the ED50 of F-627 was 0.68 ng/mL (7.58 pM) in the 
proliferative response of M-NFS-60 cell line. The proliferation effects of F-627 on M-NFS-60 was 
neutralized by anti-human G-CSF monoclonal antibodies. The activation of intracellular signaling 
pathways following G-CSF ligand-receptor binding was studied by detecting G-CSF-activated 
phosphorylated STAT3. Similar with filgrastim (Neupogen, Amgen) and pegfilgrastim (Neulasta, 
Amgen; Neulastim, Roche), F-627 can effectively activate phosphorylated STAT3 signaling and 
stimulate cell proliferation in M-NFS-60 cell line. 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 15 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 69


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
In vivo pharmacodynamics study of F-627 
In vivo bioactivity study of F-627 showed that: a single subcutaneous injection of F-627 in mice, rats, 
and cynomolgus monkeys resulted in increases of peripheral blood white blood cell count (WBC) and 
absolute neutrophil count (ANC) in a dose-dependent manner. The minimum effective dose of F-627 in 
rats was 3.0 μg/kg. A single subcutaneous injection of F-627 100 μg /kg in mice showed that, 
phosphorylated STAT3 levels in bone marrow cells increased 17 folds compared to baseline levels. 
Peak ANC in peripheral blood appeared at 48 hr after the dose, and recovered to normal levels at 72 hr. 
F-627 was significantly superior to Neulasta and rhG-CSF, at the same molar dose of G-CSF, in terms 
of ANC increase and duration. 
 
In cynomolgus monkey models with cyclophosphamide-induced neutropenia, F-627 not only shorten 
the recovery time of ANC, but also reduced the ANC decrease compared to filgrastim (rhG-CSF) and 
pegfilgrastim (Neulasta), thereby preventing the occurrence of severe neutropenia. F-627 demonstrated 
superior pharmacodynamic effects over the same dose (60 μg/kg) of pegfilgrastim. 
1.1.6 
Previous clinical studies 
The phase I clinical trial was conducted at the Alfred Medical Center in Melbourne, Australia. The 
clinical study protocol was approved by the Ethics Committee of the hospital on May 4, 2010, and the 
first subject received F-627 treatment on Jun. 1, 2010. 
 
The starting dose of this study was 30 µg/kg, and the dose was escalated sequentially to 60, 120, 240, 
and 360 µg/kg. In each dose cohort, 6 healthy adult male subjects were enrolled, which means totally 
30 subjects in five cohorts. One to three Asian subjects were recruited to each dose cohort except for 
the 360 µg/kg cohort. Each subject received a single-dose of F-627 by subcutaneous injection. Blood 
samples were then collected at multiple time points in the 14-day follow-up visits to evaluate the 
pharmacokinetics, pharmacodynamics (including WBC, ANC, and CD34 analysis), and safety of the 
drug. The starting dose of F-627 was 30 µg/kg. Dose escalation was conducted only after it was 
confirmed to be safe by the principal investigators and medical experts of the sponsor. 
 
All subjects completed dose administration. F-627 subcutaneous injection was well-tolerated. There 
were no serious adverse events (SAEs) or deaths among the 30 subjects. All adverse events are 
summarized in Table 30-3. No abnormalities were observed in the vital signs, electrocardiograms 
(ECGs), abdominal ultrasound, serum biomarkers and urinalysis parameters of subjects in all dose 
cohorts. The most common adverse events were manifested as musculoskeletal disorders, including 
mild to moderate muscle soreness, bone pain and lumbago. 
 
Table 30-3. Summary of adverse events in the phase I clinical trial. 
 
Adverse Events 
30 µg/kg 
60 µg/kg 
120 µg/kg 
240 µg/kg 
360 µg/kg 
Total 
Number 
Description 
Headache 
1 
2 
1 
1 
2 
7 
2 moderate 
events 
Injection-Site Pain 
2 
 
 
0 
 
2 
1 moderate 
events 
Bone Pain 
 
2 
 
3 
 
5 
3 moderate 
events 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 16 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 70


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Adverse Events 
30 µg/kg 
60 µg/kg 
120 µg/kg 
240 µg/kg 
360 µg/kg 
Total 
Number 
Description 
Back Pain 
2 
1 
4 
4 
4 
15 
6 moderate 
events 
Leg Pain 
 
1 
 
1 
2 
4 
3 moderate 
events 
Abdominal 
Discomfort/Pain 
 
1 
 
1 
 
2 
1 moderate 
events 
Dry Skin 
 
1 
 
 
 
1 
1 moderate 
events 
Hunger 
 
 
1 
 
 
1 
 
Urinary Tract 
Infection 
 
 
 
1 
 
2 
 
Diarrhea 
 
 
 
2 
 
2 
 
Feeling Abnormal 
 
 
 
1 
 
1 
 
Tiredness 
 
 
 
 
1 
1 
 
Respiratory 
Tract Irritation 
 
 
 
1 
 
1 
 
Photophobia 
 
 
 
1 
 
1 
 
All moderate adverse events were noted, others were mild events. 
 
Results are shown in Table 30-4. The 5 dose cohorts, 30, 60, 120, 240, and 360 μg/kg, demonstrated 
dose-dependent pharmacodynamics, i.e., WBC, ANC, and CD34 count increased with increasing dose. 
The lowest dose cohort (30 μg/kg) demonstrated significant ANC elevation. The time to initial onset of 
effect was 4 hours for all dose cohorts. In the lowest dose cohort, ANC at 4 hours after administration 
(5.05 ± 2.00) was significantly higher than that before administration (2.79 ± 0.40, p = 0.02). Tmax of 
ANC was 36 hours for two low dose cohorts and 72 hours for two high dose cohorts. The peak ANC in 
these four dose cohorts increased 4.1, 4.4, 5.8, and 8.6 folds compared to the pre-dose ANC. CD34 
peaked at 72–96 hours, respectively. CD34 reached 38.7 ± 11.7 in the 120 μg/kg cohort. Results 
showed a good dose-effect relationship of F-627 in healthy male subjects. 
 
Table 30-4. Human PK parameters in phase I clinical trial. 
 
Parameters 
30 µg/kg 
（n=6） 
60 µg/kg 
（n=6） 
120 µg/kg 
（n=6） 
240 µg/kg 
（n=6） 
360 µg/kg 
（n=6） 
Cmax (ng/mL) 
21.3(10.3) 
44.6(17.7) 
219.9(76.6) 
759(160) 
693(243) 
Tmax (hr) 
8(8-16) 
8(8-16) 
16(16-36) 
36(36) 
16(16-48) 
T1/2 (hr) 
43.9(9.3) 
56.1(23.3) 
59.3(23.5) 
62.8(10.8) 
71.4(27.3) 
AUC(0-∞) (ng·hr/mL) 
720(214) 
1756(673) 
8374(2789) 
46580(17255) 
44009(18266) 
CL/F (mL/hr/kg) 
41.4(12.8) 
36.8(14.6) 
18.5(7.7) 
5.7(2.0) 
12.0/11.9 
 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 17 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 71


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Figure 30-1. Semi-logarithmic plot of concentration-time (hours) after different doses of F-627 in 
healthy male subjects. 
 
 
Table 30-5. Summary of pharmacodynamics in phase I clinical trial. 
 
F-627 Dose 
ANC Elevation (Tmax) 
Peak ANC 
ANC Recovery 
CD34 Tmax 
µg/kg 
hrs 
(Increased Folds) 
hrs 
(CD34 Count) 
30 
4 (36) 
11.52 (4.1) 
144 
96 (7.83 ± 2.32) 
60 
4 (36) 
12.32 (4.4) 
240 
72 (21.5 ± 23.9) 
120 
4 (72) 
22.31 (5.8) 
288 
72 (38.67 ± 11.71) 
240 
4 (72) 
26.98 (8.6) 
240 
96 ( 37.83 ± 9.7) 
360 
5(96) 
34.97(10.9) 
To be 
supplemented 
120(52.7 ± 19.0) 
ANC units: 1 × 109/L; ANC recovery: ANC < 5 × 109/L; CD34 count units: 1 × 103/mL, n = 6. 
 
Figure 30-2. Mean ANC in subjects after administration of different doses of F-627. 
 
 
Time (hours) 
Serum F-627 in healthy adult males 
(ng/mL) 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 18 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 72


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Clinical studies of long-acting rhG-CSF (pegfilgrastim, i.e. PEGylated G-CSF) were primarily 
conducted by Amgen Inc. The new drug approval documents of pegfilgrastim included two phase I 
clinical trials that examined the PK/PD and safety of the drug in healthy human; four phase II clinical 
trials that determined the effective dose of the drug in patients with different cancers, including post-
chemotherapy lymphoma, lung cancer and breast cancer; and two phase III clinical trials that examined 
the efficacy and safety of 100 µg/kg pegfilgrastim. Pegfilgrastim was approved for marketing by the 
FDA in 2002 and is mainly used in Europe, U.S. and other western countries. Pegfilgrastim is a first-
line supportive therapy for post-chemotherapy cancer patients. It is used to treat neutropenia caused by 
radiation therapy and chemotherapy. 
 
There has been a substantial number of clinical studies of pegfilgrastim in recent years. A total of 
107 clinical studies could be found in the Pubmed database using pegfilgrastim or Neulasta as 
keywords for title and abstract. Long-acting pegfilgrastim is favorable for patients as it is administered 
once per chemotherapy cycle and its efficacy is equal to that of the short-acting Filgrastim administered 
daily. However, most blood cancer patients, such as those with lymphoma or acute leukemia, are in a 
state of severe neutropenia for a considerable period of time (2-3 weeks) even with post-chemotherapy 
administration of filgrastim or pegfilgrastim. Therefore, this is the medical challenge facing the 
application of the existing recombinant human G-CSF monomers. 
 
The clinical side effects of long-acting Pegfilgrastim are similar with those of short-acting Filgrastim. 
These side effects are primarily manifested as musculoskeletal disorders including muscle soreness, 
bone pain, lumbago and chest pain, and gastrointestinal disorders including inappetence or increased 
ALT/AST in liver. Some patients may develop fever, headache, asthenia, rash and ALP/LDH elevation, 
and a small fraction of patients may experience shock, interstitial pneumonia, adult respiratory distress 
syndrome, and increased immature granulocyte count. Pegfilgrastim is prohibited for individuals with 
severe liver, kidney, heart and lung disorders. Pegfilgrastim is not recommended for myeloid leukemia 
patients without significant reduction in immature granulocytes in the bone marrow or with immature 
granulocytes in the peripheral blood. 
1.2 
Overall Evaluation of Adjuvant Measures and Efficacy of Chemotherapy for Cancer 
Cancer is currently still a threat to human health and its incidence rate continues to increase (Nature 
Review Cancer, 2006, vol 6: 63-74). In 2002, there were 10.9 million new cancer patients worldwide. 
The number of new cancer patients worldwide is estimated to reach 16.5 million in 2020 and 
27.0 million in 2050. According to the statistics from the Ministry of Health of the PRC, the incidence 
rate of cancer had increased to 127 in 100000 people in the 1990s. In recent years, the number of new 
cancer patients per year has reached 1.6–1.7 million, totaling about 4.5 million cancer patients. In terms 
of cancer treatment, chemotherapeutic and cytotoxic agents are still first-line therapy. Some new small 
molecule targeted drugs still cannot be used as first-line drugs for curing cancer. Therefore, there is still 
much to be done for the adjuvant therapy of chemotherapy. Although first- and second-generation G-
CSF has partially shortened the duration of chemotherapy-induced neutropenia, how to alleviate 
neutropenia and shorten the duration of severe neutropenia are still the challenges in the treatment of 
chemotherapy-induced severe neutropenia. The development and study of F-627 have provided 
theoretical and practical feasibility for the treatment of this problem. As an independent global 
innovation, F-627 is expected to become the best adjuvant therapy for enhancing the efficacy of 
chemotherapy drugs in cancer patients. 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 19 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 73


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
2. STUDY OBJECTIVES 
2.1 
Primary Objective 
To evaluate the safety and tolerability of recombinant human granulocyte colony stimulating factor-Fc 
fusion protein for injection (F-627) in treatment of female postoperative breast cancer patients who 
require adjuvant chemotherapy in a single-center, open-label, single-dose and repeated-dose, dose-
escalation phase I clinical trial. 
2.2 
Secondary Objectives 
1) 
To evaluate the pharmacokinetics (PK) of F-627 by determining the serum drug concentrations of 
F-627 at different time points after dosing; 
2) 
To evaluate the pharmacodynamics of F-627 by analyzing the relationship between serum drug 
concentrations of F-627 and neutrophil counts in blood at different time points after dosing, and to 
provide a recommended dose for phase II clinical trial. 
2.3 
Exploratory Objectives 
1) 
To observe the number of days in which absolute neutrophil count is less than 0.5 × 109/L in cycle 
1 of chemotherapy, the average time of ANC recovery, and the number of days in which absolute 
neutrophil count is less than 1 × 109/L, and to provide insights for phase II clinical trial. 
2) To evaluate the potential immunogenicity of F-627 by testing anti-F-627 antibodies (IgG and IgM) 
in serum. 
3. STUDY PLAN AND METHODOLOGY 
3.1 
Overall Study Design and Schedule of Study Procedures 
This is a single-center, open-label, dose-escalation, single-dose and repeated-dose phase I clinical trial 
in treatment of female postoperative breast cancer patients who require adjuvant chemotherapy. 
Eligible patients are those who have not received chemotherapy. The adjuvant chemotherapy regimen 
for this trial is EC→P or EC→T, that is: epirubicin 100 mg/m2, i.v. + cyclophosphamide 600 mg/m2, 
i.v. on day 1, repeat cycle every 21 days for 4 cycles. After completing the evaluation for all 4 cycles, 
subjects will receive 4 subsequent cycles of sequential chemotherapy (either paclitaxel or docetaxel) 
and supportive care according to routine clinical practice. The investigator must ensure that the first 
cycle of treatment follows the recommended chemotherapy regimen; in chemotherapy cycles 2–4, 
treatment regimen and dose are permitted to be individualized based on subject conditions. Dose delay 
and one dose reduction due to toxicities other than myelotoxicity (such as cardiotoxicity) are permitted 
in this trial. If the subject requires a second dose reduction, the investigator and sponsor must decide 
together whether the subject should continue the treatment with study drug. 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 20 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 74


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Subjects who have signed the informed consent form and have passed the screening are enrolled in the 
trial. 
 
This study includes 3 dose cohorts, 80, 240, and 320 µg/kg, each of which will enroll 6 subjects 
sequentially. Subjects in each cohort will receive a single-dose of F-627 by subcutaneous injection 
approximately 48 hours after the completion of chemotherapy. Blood samples are then collected at 
multiple time points in the subsequent follow-up visits to evaluate the pharmacokinetics, 
pharmacodynamics, and safety of the drug. If dose-limiting toxicities (DLT, see Section 3.4) are not 
observed before the start of cycle 2, then the same dose of F-627 is to be given at approximately 
48 hours after each chemotherapy in cycles 2–4. 
 
Only after 6 subjects in each cohort have completed the treatment and observation of the first cycle will 
the sponsor and investigator determine whether to proceed to the next higher dose based on the safety 
evaluation. 
 
Schedule of study procedures is detailed in Table 30-6. 
 
Table 30-6. Schedule of F-627 study procedures. 
 
1–15 Days 
Before 
Enrollment 
Day 1, Day 22, 
Day 43, and 
Day 64 of 
the Study6 
Day 3, Day 24, 
Day 45, 
and Day 66 of 
the Study1 
Cycle 1 of 
Chemotherapy 
(Day 3– 
Day 21)4 
Cycles 2–4 of 
Chemotherapy 
(Day 3– 
Day 21)5 
End of Study  
(Day 84)7 
Signing Informed 
Consent Form 
X 
 
 
 
 
 
History of Cancer 
X 
 
 
 
 
 
Complete Physical 
Examination 
X 
 
 
 
 
X 
Physical 
Examination 
 
X 
X 
 
 
 
Abdominal 
Ultrasound2 
X 
X 
 
 
 
X 
Chemotherapy 
 
X 
 
 
 
 
Urinalysis2 
X 
X 
 
 
 
X 
Administration1 
 
 
X 
 
 
 
12-Lead ECG3 
X 
 
 
 
 
X 
Color Doppler 
Echocardiography 
X 
 
 
 
 
 
Chest X-Ray 
X 
 
 
 
 
X 
Height and Weight2 
X 
X 
 
 
 
 
Body Temperature 
X 
X 
X 
X 
X 
X 
Routine Blood Test 
(including ANC) 
X 
X 
X 
X 
X 
X 
Clinical Chemistry2 
X 
X 
 
 
 
X 
Serum Pregnancy 
Test 
X 
 
 
 
 
X 
Blood Pressure 
and Heart Rate 
X 
X 
 
 
 
X 
Pharmacokinetics8 
 
 
X 
X 
X 
 
Serum Antibody9 
 
X 
X 
X 
X 
X 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 21 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 75


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
1–15 Days 
Before 
Enrollment 
Day 1, Day 22, 
Day 43, and 
Day 64 of 
the Study6 
Day 3, Day 24, 
Day 45, 
and Day 66 of 
the Study1 
Cycle 1 of 
Chemotherapy 
(Day 3– 
Day 21)4 
Cycles 2–4 of 
Chemotherapy 
(Day 3– 
Day 21)5 
End of Study 
(Day 84)7 
AEs and Combined 
Medications9 
X 
X 
X 
X 
X 
1.
Three dose cohorts for F-627 (80 μg/kg, 240 μg/kg and 320 μg/kg);
2.
Examination should be completed upon enrollment and the start of each chemotherapy cycle. Body height is measured 
upon enrollment only, while body weight is measured on day 1 of each cycle; for abdominal ultrasound, a retest on day 
1 of cycle 1 is not required and the baseline result can be used; for routine blood test and clinical chemistry before the 
start of cycle 1, results of the tests performed within 7 days before cycle 1 are acceptable;
3.
12-lead ECG should be repeated at the last visit of the study;
4.
For chemotherapy cycle 1, starting from day 3, oral temperature measurement and routine blood test will be performed
daily until ANC recovers to > 1.0 × 109/L from nadir, and once every 3 days thereafter until the next cycle;
5.
For chemotherapy cycles 2–4 (day 3–day 21 of each chemotherapy cycle, i.e., day 24–day 84 of the study), starting on
each day 3 of cycles 2–4, oral temperature measurement and routine blood test will be performed every other day until
ANC recovers from its nadir to > 1.0 × 109/L, and once every 3 days thereafter until the next cycle;
6.
Only when ANC of a subject recovers to > 1.0 × 109/L as judged by the investigator, can the next cycle start;
7.
The last visit is on day 84, and the subjects should complete a follow-up visit by telephone on day 114 (30 days after
the last visit);
8.
In cycle 1 and cycle 3, blood samples are collected for PK at time points shown in Table 30-8;
9.
Blood samples will be collected for serum antibody assays during screening or before treatment with the drugs, as well
as on days 8, 13, and 21 of each cycle.
Remark: All laboratory measurements will be performed at a central laboratory assigned by the investigator. In case of any 
toxicities related to chemotherapy, subsequent treatment can be modified according to common diagnosis and treatment 
practice in the judgment of the investigator. 
3.2 
Evidence for Dose Determination 
Results from 3-month repeat dosing toxicity studies showed that the no-observed-adverse-effect-level 
(NOAEL) of F-627 was 1000 µg/kg in rats and 675 µg/kg in cynomolgus monkeys. F-627 is a 
recombinant fusion protein with a molecular weight of 95000 Daltons. Results from preclinical studies 
showed that the toxicity of F-627 was due to the amplification of pharmacodynamics, which is closely 
associated with the dose (expressed in mg/kg) in various different species. Based on the guideline 
issued by the FDA in 2005, the maximum safe starting dose of F-627 was calculated to be 67.5 µg/kg 
using mg/kg conversion, which is one-tenth of the NOAEL in cynomolgus monkeys. Based on the dose 
for healthy volunteers in the phase I clinical trial, 80 µg/kg is a safe starting dose. 
The pharmacokinetic parameters in cynomolgus monkeys, such as T1/2, AUC, CL and MRT, were 
comparable between F-627 and pegfilgrastim. In the 3-month repeat dosing toxicity studies of 
pegfilgrastim and F-627 in rats and cynomolgus monkeys based on subcutaneous injection, the no-
observed-adverse-effect-levels (NOAELs) of drugs in rats were comparable to those in cynomolgus 
monkeys. In addition, the phase I clinical trial involving healthy volunteers used an F-627 dose that is 
less than 5% of the NOAEL in monkeys (Table 30-6). F-627 demonstrated good safety and tolerability 
in all five dose cohorts (30, 60, 120, 240 and 360 µg/kg). For F-627, 240 µg/kg was equivalent to 
96 µg/kg of pegfilgrastim (calculated by the molarity of G-CSF). The phase I of this study plans to 
include three dose cohorts, namely 80, 240 and 320 µg/kg. Firstly, all doses should not exceed the 
maximum dose in the phase I clinical trial. Secondly, the G-CSF molarity of 240 µg/kg F-627 is 
comparable to that of 100 µg/kg pegfilgrastim. Finally, 60 µg/kg of F-627 showed pharmacodynamics 
Confidential Information of Generon (Shanghai) Corporation Ltd. 
Page 22 of 47 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 76


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
superior than 150 µg/kg in the cynomolgus monkey models of chemotherapy-induced neutropenia. 
Therefore, using 80 µg/kg in the low-dose cohort will ensure that the drug may be effective for the 
subjects. The highest dose (320 µg/kg) for subjects is slightly lower than the maximum dose 
(360 µg/kg) tested in healthy subjects. 
 
Table 30-7. Rationale for F-627 doses in clinical trials. 
 
 
Pegfilgrastim 
F-627 
Repeat Dosing Toxicity Study in Rats 
100, 300, and 1000µg/kg, once a week 
for 3/6 months 
100, 300 and 1000 µg/kg, once a week 
for 3 months, followed by a recovery 
period of 1 month 
NOAEL in rats 
1000 µg/kg 
1000 µg/kg 
Repeat Dosing Toxicity Study in 
Monkeys 
75, 250, and 750 µg/kg, once a week for 
1 month, followed by a recovery period 
of 1 month 
75, 225, and 675 µg/kg, once a week for 
3 months, followed by a recovery period 
of 1 month 
NOAEL in Monkeys 
750 µg/kg 
675 µg/kg 
Starting Dose of Healthy Subjects in 
Phase I Clinical Trial 
30 µg/kg 
30 µg/kg 
Dose of Healthy Subjects in Phase I 
Clinical Trial 
30, 60, 100, 300 µg/kg 
30, 60, 120, 240, 360 µg/kg 
Post-Chemotherapy Dose for Breast 
Cancer in Clinical Trial 
60, 100, 300 µg/kg 
Planned: 80, 240 and 320 µg/kg 
Recommended Dose for Clinical Trials 
100 µg/kg 
TBD 
3.3 
Single Dose and Repeated Dose 
This study includes 3 dose cohorts, 80, 240, and 320 µg/kg, each of which will enroll 6 patients with 
breast cancer sequentially receiving adjuvant chemotherapy. Subjects in each cohort will receive a 
single-dose of F-627 by subcutaneous injection approximately 48 hours after the completion of 
chemotherapy. Blood samples are then collected at multiple time points in the subsequent follow-up 
visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. If dose-limiting 
toxicities (DLT, see Section 3.4) are not observed before the start of cycle 2, then the same dose of F-
627 is to be given at approximately 48 hours after each chemotherapy in cycles 2–4. 
3.4 
Dose Escalation 
Doses that will be used in this study are 80, 240 and 320 µg/kg, and 6 subjects will be enrolled in each 
dose cohort. The starting dose is 80 µg/kg. Only after 6 subjects have completed the treatment and 
observation of the first cycle will the sponsor and investigator determine whether to proceed to the next 
higher dose based on the safety evaluation. Likewise, the 240 µg/kg cohort will enroll 6 subjects, and 
only after 6 subjects have completed the treatment and observation of the first cycle will the sponsor 
and investigator determine whether to proceed to the next higher dose based on the safety evaluation. 
The 320 µg/kg cohort will enroll 6 subjects, but dose escalation will not be conducted after all 6 
subjects have completed the treatment and observation. 
 
Dose Cohort 
Dose 
Number of Subjects 
1 
80 µg/kg 
6 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 23 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 77


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
2 
240 µg/kg 
6 
3 
320 µg/kg 
6 
 
Dose escalation should be stopped in each dose cohort if 2 dose-limiting toxicities (DLT, see Section 
3.5 for definition) are observed in subjects in cycle 1 of chemotherapy 
3.5 
Dose-Limiting Toxicity (DLT) 
Dose-limiting toxicity (DLT) refers to an intolerable toxicity that is observed in the treatment with 
investigational drug and limits the further dose escalations. DLT is defined as any grade 3 or greater 
adverse event related to the investigational drug that observed in cycle 1 (21 days). Adverse events will 
be assessed according to NCI CTCAE V4.03 criteria. 
 
After 6 subjects in each F-627 dose cohort have completed the treatment and observation of first cycle, 
the trial may proceed into the next dose cohort only if less than 2 subjects develop DLT. If a grade 3 or 
greater adverse event related to the investigational drug is observed in cycles 2–4, then the investigator 
and sponsor will determine together whether the adverse event would affect further dose escalations. 
3.6 
Risk, Benefit and Ethical Evaluations 
The rhG-CSF-Fc fusion protein is a long-acting rhG-CSF expressed in CHO cells. Each molecule of 
rhG-CSF-Fc fusion protein contains two G-CSF dimer molecules, which may overcome the weak 
bioactivity of pegfilgrastim and produce a stronger receptor activation signal, thereby accelerating the 
differentiation and proliferation of neutrophils in bone marrow. Also, preclinical studies have shown 
that the pharmacokinetic and pharmacodynamic properties of rhG-CSF-Fc is different from or superior 
to pegfilgrastim, and therefore it decreases the severity of neutropenia and reduces the duration of 
severe neutropenia in cancer patients after chemotherapy. For the phase I clinical trial, patients with 
breast cancer will be enrolled as subjects to evaluate the safety, tolerability and pharmacodynamic 
properties of F-627. Phase I clinical trial of pegfilgrastim showed that subcutaneous injection of 30, 60, 
100 and 300 µg/kg of pegfilgrastim resulted in no significant toxicity. The dose of F-627 will also be 
controlled within this range to ensure the safety of the subjects. Phase I clinical trial of F-627 in 
Australia already demonstrated that no serious adverse event is observed within this dose range and 
subjects had good treatment compliance. 
 
In this study, the safety of the subjects will be closely monitored, including clinical symptoms, vital 
signs, routine blood test, clinical chemistry, urinalysis and any adverse event. Once an adverse event is 
observed, it will be handled in accordance with the national regulations. Safety evaluation of the phase 
I clinical trial on healthy subjects showed that adverse events observed under the above doses were all 
within controllable range. Emergency medical events and handling procedures are described in Section 
11 of this document. 
4. STUDY POPULATION 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 24 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 78


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
4.1 
Study Population and Number of Subjects 
Female postoperative patients with breast cancer who receive adjuvant chemotherapy will be enrolled 
in this study. Eligible subject should be chemotherapy naïve patient. 
 
The selection of chemotherapy drug is one of the key considerations in the design of this protocol. 
Among the adjuvant chemotherapy regimens that are recommended by the NCCN 2010 guideline for 
breast cancer, the preferred regimens include TAC, dose-dense AC → dose-dense paclitaxel, AC → 
paclitaxel, TC, EC, and AC. At present, AC/EC→P or AC/EC→T are the commonly used regimens in 
China. 
 
The adjuvant chemotherapy regimen for this trial is EC→P or EC→T, that is: 100 mg/m2 epirubicin i.v. 
+ 600 mg/m2 cyclophosphamide i.v. on day 1, repeat cycle every 21 days for 4 cycles. After 
completing the evaluation for all 4 cycles, subjects will receive 4 subsequent cycles of sequential 
chemotherapy (either paclitaxel or docetaxel) and supportive care according to routine clinical practice. 
 
The investigator must ensure that the first cycle of treatment follows the recommended chemotherapy 
regimen; in chemotherapy cycles 2–4, treatment regimen and dose are permitted to be individualized 
based on subject conditions. Dose delay and one dose reduction due to toxicities other than 
myelotoxicity (such as cardiotoxicity) are permitted in this trial. If the subject requires a second dose 
reduction, the investigator and sponsor must decide together whether the subject should continue the 
treatment with study drug. 
 
This study includes 3 dose cohorts, 80, 240, and 320 µg/kg, each of which will enroll 6 subjects, 
totaling 18 subjects. 
4.2 
Inclusion Criteria 
1) 18-75 years old; 
2) Female postoperative breast cancer patients who require adjuvant chemotherapy, and are planned 
to receive 4 cycles of EC chemotherapy; 
3) ECOG performance status of 0-1; 
4) Absolute neutrophil count (ANC) ≥ 2.0 × 109/L, hemoglobin (Hb) ≥ 11.5 g/dL, and platelet (PLT) 
≥ 100 × 109/L prior to chemotherapy; 
5) Hepatic and renal function within the normal range; 
6) Left ventricular ejection fraction greater than 50% 
7) Willing to sign the informed consent form and able to comply with protocol requirements; 
4.3 
Exclusion Criteria 
Subjects who meet any of the following must be excluded from this study: 
 
1) Women in pregnancy or breastfeeding; women of child–bearing potential have a positive pregnancy 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 25 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 79


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
test result prior to the first dose; 
2) Life expectancy less than 12 months; 
3) Radiation therapy within 4 weeks prior to enrollment; 
4) Patients with breast cancer who have received neoadjuvant chemotherapy before radical 
mastectomy; 
5) Prior bone marrow or stem cell transplant; 
6) With other malignant tumors other than breast cancer; 
7) Have received G-CSF treatment within 6 weeks prior to enrollment; 
8) Diagnosed with acute congestive heart failure, cardiomyopathy, or myocardial infarction by 
clinical diagnosis, ECG or other approaches 
9) With any disease that may cause splenomegaly; 
10) With acute infection, chronic active Hepatitis B within 1 year (unless patients tested negative for 
HBsAg prior to enrollment) or Hepatitis C; 
11) History of tuberculosis (TB); history of TB exposure, unless negative for tuberculin test; TB 
patients undergoing treatment; or suspected TB evaluated by chest x-ray; 
12) Known HIV positive or AIDS; 
13) With sickle cell anemia; 
14) With alcohol or drug abuse that may affect the compliance with the study; 
15) With known hypersensitivity to E. coli derived proteins, G-CSF, or excipients; 
16) Has received any other study drug within 4 weeks prior to enrollment; 
17) Patients with diseases or symptoms unsuitable for participating in the trial based on the 
investigator's judgment; 
4.4 
Criteria for Terminating Study 
1) Incidence rate and severity of serious adverse events (SAEs) indicate the study should be 
terminated early as determined by the investigators and the sponsor; 
2) The dose-limiting toxicity of the subjects does not recover or cannot be relieved; 
3) The investigators question the safety of the drug and believe that the continuation of the study may 
pose serious risks to the subjects; 
4) The maximum dose set in the clinical trial has been reached; 
5) Data fraud, or inaccurate/incomplete collection of data; 
 
4.5 
Criteria for Subject Withdrawal 
Subjects will prematurely withdraw from the study with a written explanation when the following 
conditions occur. 
 
1) Subjects voluntarily withdraw during the study; 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 26 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 80


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
2) The investigator considers that withdrawal is for the best interest of the subject; 
3) The investigator or subject believes that continuing the trial may result in intolerable adverse 
events; 
4) Complications or worsening co-morbidities affecting subject's participation occur; 
5) Safety issues of the study drug in the absence of data, subject will be exposed to potential risks if 
continues the participation in the study; 
6) When a safety concern regarding the study drug arises, but data is yet unknown, resulting in 
potential risks if subjects continue the trial; 
4.6 
Drop-Out Criteria 
Determination of drop-outs: Eligible subjects who have signed the informed consent form and been 
enrolled have the right to withdraw from the study at any time. Subjects who do not complete the entire 
observation are considered drop-outs regardless of the time or reason of the withdrawal. A replacement 
should be implemented immediately according to the original plan when a drop-out occurs. Blood 
samples from drop-out subjects should be retained and tested and processed by the sponsor. 
4.7 
Withdrawal-Related Procedures and Handling 
The investigator should ask the withdrawn subject for the reason of withdrawal and whether there is 
an adverse event, and record the length of treatment and dose. If possible, the investigator should 
perform corresponding observation and evaluation of the withdrawn subject and conduct a follow-up 
for adverse events within 30 days of the last dosing. If a subject withdraws from the study due to 
suspected grade 2, 3 or 4 infection according to WHO risk classification criteria, then his/her 
biological samples must not be sent to a laboratory, and instead, should be destructed as per 
operating practice of the study site. 
5. INVESTIGATIONAL DRUG AND TREATMENT 
5.1 
Source 
F-627 is provided by Generon (Shanghai) Corporation Ltd. 
 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 27 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 81


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
5.2 
Strength and Expiration Date 
The recombinant human granulocyte colony stimulating factor-Fc fusion protein for injection (F-627) 
is securely packaged and sealed by Generon (Shanghai) Corporation Ltd. 
 
Dosage Form 
Strength 
Formulation 
Mode of 
Administration 
Expiration 
Date 
Lyophilized Powder 
for Injection 
1 mg 
F-627 (rhG-CSF-Fc) 
1.0 mg 
Subcutaneous 
injection 
2 years 
(tentative) 
Sucrose  
20.0 mg 
Mannitol 
50.0 mg 
Polysorbate 80 
0.05 mg 
Sodium phosphate dibasic 
0.92 mg 
Sodium phosphate monobasic 
0.42 mg 
Lyophilized Powder 
for Injection 
5 mg 
F-627 (rhG-CSF-Fc) 
5.0 mg 
Subcutaneous 
injection 
2 years 
(tentative) 
Sucrose  
20.0 mg 
Mannitol 
50.0 mg 
Polysorbate 80 
0.05 mg 
Sodium phosphate dibasic 
0.92 mg 
Sodium phosphate monobasic 
0.42 mg 
5.3 
Labeling 
The recombinant human granulocyte colony stimulating factor-Fc fusion protein for injection (F-627) 
is stored as lyophilized powder in tubular vials (1.0 mg/2 mL vial and 5.0 mg/2 mL vial). The drug 
label includes the following information: investigational drug name, study number, study protocol 
number, storage conditions, contents, mode of administration, batch number, expiration date, and the 
standard notes "For clinical trials only" and "Keep out of reach of children". 
5.4 
Storage 
The drug should be stored as specified in a sealed container at 2–8 °C away from light, and under the 
management of designated personnel. If the temperature exceeds the storage condition during transport 
and storage, record and report the incident to the sponsor. 
5.5 
Drug Preparation 
The pharmacist is responsible for preparing the drugs and the nurse is responsible for reviewing. 
During drug preparation, inject 0.5 mL of water for injection slowly into the vial along the wall, let the 
vial stand for 1–2 minutes, and perform subcutaneous injection after the powder is completely 
dissolved. The injection should be used within 1 hour after preparation. The recommended 
concentration for F-627 is 2.0 mg/mL. The drug is generally injected in the morning (08:00 ± 1:00). 
The subject should remain in a sitting or walking position within two hours after the injection. 
 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 28 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 82


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
5.6 
Administration and Precautions 
Subjects must sign the informed consent forms prior to enrollment. After being screened and confirmed 
to be enrolled, subjects will be numbered in strict order. If a subject withdraws from the study, the 
same subject number must not be reused. Subjects who have withdrawn are not allowed to participate 
in this study again. According to the study protocol, subjects are allocated to different dose cohorts and 
will enter the study in the order of enrollment. 
 
The investigator should be present during administration and within 1 hour after administration to 
provide guidance and supervision, and be prepared to administer first aid or emergency treatment 
whenever needed. The specific time and date of dosing, and the drug labels should be documented in 
the subject's source data files and case report forms. 
 
Subjects will receive a chemotherapy of EC on day 1 of each cycle, and a subcutaneous injection of  
F-627 on day 3, that is, 48 ± 2 hours after the start of chemotherapy. During the treatment, subjects 
should avoid strenuous physical activity or long periods of bed rest, and keep relaxed. 
5.7 
Salvage Therapy 
In the study, an approved G-CSF treatment should be given to the patient as salvage therapy in the case 
of febrile neutropenia (defined as ANC < 1.0 × 109/L; a single measurement of body temperature > 
38.3 °C or a fever ≥ 38.0 °C lasting for longer than 1 hour; note: body temperature measurement is 
based on oral temperature or equivalent armpit/rectal temperature) or grade 4 neutropenia for longer 
than 3 days. The sponsor recommends GRAN® (filgrastim) at a dose of 5 µg/kg/day of G-CSF, once 
daily for ≤ 2 weeks or until neutrophil count recovers to 1.0 × 109/L. 
5.8 
Drug Management 
Registration and recording of the investigational drug should be in the charge of designated personnel. 
The study site should establish a set of systematic operating procedures to ensure that the drugs are 
received by designated personnel, the distribution of the drugs is accurately documented, and the drugs 
are used and stored properly. 
 
1) Drug registration form: 
a. The type of drug received from the sponsor; 
b. Dosage form and strength; 
c. Batch number and expiration date; 
d. The dosage form, dose, quantity, and date of drug dispensed to the investigator (signed by both 
dispensers and recipients). 
2) Individual drug administration record: subject name, package number, administration time, dose 
and mode of administration, signature of operator, and return of packaging. 
3) Detailed record of drug administration, loss, scattering, and misuse. 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 29 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 83


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
4) Unused drugs should be stored in accordance with storage requirements. Storage conditions should 
be checked regularly by the same designated personnel. 
5) After the study is completed, all remaining drugs should be returned and recorded, and be disposed 
according to the GCP by the site together with the sponsor. 
5.9 
Principles and Methods for Treatment of Drug Toxicities 
If a subject develops a mild drug toxicity after receiving F-627 injection, symptoms should be 
monitored with the treatment continued. Intervention is usually not required. Toxicities related to 
chemotherapy should be handled according to clinical guidelines and the prescribing information of the 
chemotherapy drugs. Serious or life-threatening symptoms must be treated immediately, and the 
clinical trial for this case must be terminated. 
 
Refer to Table 30-3 for all adverse events observed in phase I clinical trial: these symptoms do not need 
to be treated. At present, serious adverse events have not been observed for F-627. High-risk serious 
adverse events for long-acting G-CSF that have been reported include: 
 
• 
Acute splenomegaly: incidence rate is around 1–10%, while the likelihood of splenic rupture is less 
than 1 in 10000. Patients who develop abdominal pain and were found to have splenomegaly upon 
physical examination or ultrasonic inspection should be treated immediately. The drugs should be 
discontinued. 
• 
Adult respiratory distress syndrome (ARDS): Rare cases have been reported with clinical use of 
long-acting G-CSF. Treat immediately and discontinue the drugs if present. 
5.10 Treatment Compliance 
Administer according to subject's dosage allocation under the guidance and supervision of the 
investigator. The actual time and date of administration should be accurately documented for each 
subject. Any protocol violations should be documented in subject's source data file and case report 
form. 
6. EVALUATIONS AND ENDPOINTS 
6.1 
Evaluations During Screening 
Prior to enrollment, the evaluation carried out within 2 weeks before dose administration (1–14 days 
before enrollment) includes: 
 
1) Record of subject demographics: date of birth, gender, ethnicity, etc.; 
2) Medical history collection, including history of cancer and history of chemotherapy; 
3) Record of concomitant diseases and combined medication, surgical history, etc.; 
4) Record of pathological diagnosis confirmed in tumor histology or cytology; 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 30 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 84


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
5) Tumor staging (TNM); 
 Complete physical examination, height, weight, vital signs (temperature, pulse, respiratory 
rate, blood pressure), and heart rate; 
6) ECOG PS score, weight evaluation; 
7) Hematologic examination: red blood cell, hemoglobin, white blood cell, platelet count, differential 
blood count (neutrophils, lymphocytes, monocytes, basophils and eosinophils), hematocrit, mean 
corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), mean corpuscular hemoglobin 
concentration (MCHC), etc.; 
8) Clinical chemistry: including total protein (TP), albumin (ALB), globulin (G), blood glucose, 
blood urea nitrogen, creatinine, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), 
pancreatic amylase, total bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), Ca, 
P, Mg, K, Na, Cl, etc.; 
9) Urinalysis: including pH, specific gravity, protein, cast, blood cell, urine glucose, ketones, etc.; 
10) 12-lead ECG; 
11) Color doppler echocardiography 
12) Pregnancy test within 7 days before dose administration; 
13) Chest x-ray (PA and lateral); 
14) Signing informed consent form; 
15) Abdominal ultrasound (liver, gallbladder, spleen, kidney, and pancreas) 
Note: Only results of routine blood test and clinical chemistry conducted within 1 week before 
enrollment are accepted. 
6.2 
Clinical Evaluations During and After F-627 Treatment 
Evaluations on day 1 of each chemotherapy cycle (day 1, day 22, day 43, and day 64 of the study) 
include: 
 
1) Abdominal ultrasound; 
2) Chemotherapy; 
3) Urinalysis; 
4) Height, weight; 
5) Body temperature; 
6) Routine blood test (including ANC) 
7) Clinical chemistry; 
8) Blood pressure and heart rate; 
9) Serum antibody assay (IgG and IgM) 
10) Adverse events and combined medication; 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 31 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 85


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Evaluations on day 3 of each chemotherapy cycle (day 3, day 24, day 45, and day 66 of the study) 
include: 
 
1) Physical examination 
2) Investigational Drug; 
3) Temperature; 
4) Routine blood test (including ANC); 
5) Adverse events and combined medication; 
 
According to different time in the chemotherapy cycle, for cycle 1 (days 1–21 of both the cycle and the 
study), starting from day 3, oral temperature measurement and routine blood test will be performed 
daily until ANC recovers from nadir to > 1.0 × 109/L, and once every 3 days thereafter until the next 
cycle. Evaluations include: 
 
1) Temperature; 
2) Routine blood test (including ANC); 
3) Adverse events and combined medication; 
 
For chemotherapy cycles 2–4 (days 3–21 of each chemotherapy cycle, i.e., days 23–84 of the study), 
starting from day 2, oral temperature measurement and routine blood test will be performed every other 
day until ANC recovers from its nadir to > 1.0 × 109/L, and once every 3 days thereafter until the next 
cycle. Evaluations include: 
 
1) Physical examination; 
2) Temperature; 
3) Routine blood test (including ANC); 
4) Serum antibody assay (IgG and IgM); 
5) Adverse events and combined medication 
 
Evaluations upon the end (day 84) or withdrawal include: 
 
1) Physical examination; 
2) Abdominal ultrasound; 
3) Urinalysis; 
4) 12-lead ECG; 
5) Chest x-ray; 
6) Temperature; 
7) Routine blood test (including ANC) 
8) Clinical chemistry; 
9) Serum pregnancy test; 
10) Blood pressure and heart rate; 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 32 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 86


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
11) Antibody test (IgG and IgM);
12) Adverse events and combined medication
Subjects who withdraw from the study should be followed for adverse events 30 days after the last dose. 
The subjects should complete telephone visits (on day 114, i.e., 30 days after the last visits). 
6.3 
Pharmacokinetic (PK) Evaluations 
6.3.1 
Determination and analysis of PK serum samples 
The concentrations of drugs and metabolites in blood samples will be determined by the validated 
central laboratory (Covance Pharmaceutical Research and Development (Shanghai) Co., Ltd.). The 
specific method of determining serum drug concentrations will be decided by the laboratory and will be 
described in detail in the clinical study report. 
6.3.2 
Collection, handling, and storage of PK blood samples 
According to the time points specified in the study protocol, baseline blood samples are collected 
within 1 hour before dose administration. Refer to 30-8 for the blood collection interval. The actual 
blood collection time should be documented after each intravenous blood sampling. The sampling date 
and collection tube number should be documented in the case report form (CRF). The collect tube 
label should include the following information: study number, subject initials, cycle number, day, 
sampling time (hour), etc. Each time a total of 2.5 mL of blood is collected, transferred to a labeled 
serum separator tube, let stand for about 30 minutes, and centrifuged at 1000 g for 15 minutes at room 
temperature. Aliquot the serum into two clean 1.5 mL EP tubes (approximately 0.3 mL of serum each), 
close the lid tightly and immediately transfer to ≤ –70 °C for storage. The entire sampling and serum 
collection process must be completed within 60 minutes. Samples must be transferred in a constant 
temperature box with dry ice. 
6.3.3 
Blood sampling of single-dose and repeated-dose PK studies 
PK analysis of F-627 in the phase I clinical trial showed that mean time to peak was 30–36 hours and 
plasma elimination half-life was 46–72 hours, longer in the high-dose cohort. For example, in the 
240 µg/kg cohort, Tmax  was 36 hours, T1/2  was 62.8 hours, MRT was 43.5 ± 6.0 hours, Cmax  was 758 ± 
160 ng/mL, AUC was 46580 ± 17255 ng/mL*hr, and CLz/F was 5.72 ± 2.0 mL/hr/kg. 
Taking into account the above results from animal PK studies, this phase I clinical trial plans to collect 
blood samples at different time points following single-dose and repeated-dose administration. See 
Table 30-8 for detailed blood sampling time. 
Confidential Information of Generon (Shanghai) Corporation Ltd. 
Page 33 of 47 
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 87


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Table 30-8. Blood sampling time of single-dose and repeated-dose PK studies. 
 
Study Process 
Days of 
Study 
Days of 
Dosing 
Blood Sampling 
Time Point of 
Cycle 1 
(hours: minutes) 
Blood Sample 
Number 
Blood Sampling 
Time Point of 
Cycle 3 
(hours: minutes) 
Blood Sample 
Number 
F-627 PK Study (2.5 
mL) 
F-627 PK 
Study 
(2.5 mL) 
Study Process 
3 
1 
–01:00±0.1:00 
PK 1 
00:00±0.1:00 
PK 1 
 
 
02:00±0.3:00 
PK 2 
02:00±0.3:00 
PK 2 
 
 
06:00±0.5:00 
PK 3 
06:00±0.5:00 
PK 3 
 
 
12:00±0.5:00 
PK 4 
12.00±0.5:00 
PK 4 
4 
2 
24:00±0.5:00 
PK 5 
24:00±0.5:00 
PK 5 
 
 
36:00±0.5:00 
PK 6 
36:00±0.5:00 
PK 6 
5 
3 
48:00±1:00 
PK 7 
48:00±1:00 
PK 7 
6 
4 
72:00±1:00 
PK 8 
72:00±1:00 
PK 8 
7 
5 
96:00±1:00 
PK 9 
96:00±1:00 
PK 9 
8 
6 
120:00±1:00 
PK 10 
120:00±1:00 
PK 10 
9 
7 
144:00±1:00 
PK 11 
144:00±1:00 
PK 11 
11 
9 
192:00±2:00 
PK 12 
192:00±2:00 
PK 12 
 
13 
11 
240:00±2:00 
PK 13 
240:00±2:00 
PK 13 
Number of Blood Samples Collected on Each Subject 
13 
 
13 
Total Volume of Blood Samples Collected on Each Subject 
32.5mL 
 
32.5 mL 
6.4 
Pharmacodynamic Evaluation 
While evaluating the safety, tolerability and pharmacokinetic characteristics of F-627, the ANC-time 
profile after treatment is observed to investigate the effects of different dosages on neutrophil count and 
to determine a recommended dose for phase II trials. 
 
Pharmacodynamic evaluation of F-627 is carried out at the study site. For cycle 1, starting from day 3, 
oral temperature measurement and routine blood test will be performed daily until ANC recovers from 
its nadir to a value not less than 10 × 109/L, and once every 3 days thereafter until the next cycle; for 
chemotherapy cycles 2–4 (days 3–21 of each chemotherapy cycle, i.e., days 24–84 of the study), 
starting from each day 3 of cycles 2–4, oral temperature measurement and routine blood test will be 
performed every other day until ANC recovers from its nadir to > 10 × 109/L, and once every 3 days 
thereafter until the next cycle. Refer to Table 30-6 for specific procedures. 
6.5 
Safety Evaluation 
Safety evaluations include all observed and recorded adverse events and serious adverse events, 
changes in complete physical examinations, vital signs, performance status, routine blood test, routine 
urinalysis, chemistry indicators, echocardiogram, and ECG. 
Refer to Section 7 for the definition of adverse events, which are graded according to NCI CTCAE 
V4.03. The investigator should take appropriate treatment measures on the adverse events, report the 
event in the corresponding form of CRFs, and determine the relationship between the adverse event or 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 34 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 88


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
serious adverse event and the drugs. If a serious safety issue occurs during the trial, the sponsor and 
investigator must decide together whether to terminate the trial. The sponsor may also request to 
terminate the clinical trial according to the situation. 
6.6 
Serum Antibody Assays and Evaluations 
This study will evaluate the potential immunogenicity of F-627 by testing serum anti-F-627 antibodies 
(IgG and IgM) in serum. 
 
Serum antibody assays will be carried out at the laboratory of Generon (Shanghai) Corporation Ltd. 
Specific assay methods will be determined by the laboratory and will be described in detail in the 
clinical study report. 
 
According to the study protocol, blood samples will be collected during screening (baseline value), and 
on days 8, 13, and 21 of each cycle. A total of 2.5 mL of blood will be collected. 
 
Each time a total of 2.5 mL of blood is collected, transferred to a labeled serum separator tube, placed 
for about 30 minutes, and centrifuged at 1000 g for 15 minutes at room temperature. Aliquot the serum 
into two clean 1.5 mL EP tubes (approximately 0.3 mL of serum each), close the lid tightly and 
immediately transfer to ≤ –70 °C for storage. The entire sampling and serum collection process must be 
completed within 60 minutes. Samples must be transferred in a constant temperature box with dry ice. 
The collect tube label should include the following information: study number, subject initials, cycle 
number, day, sampling time (hour), etc. 
7. ADVERSE EVENTS 
7.1 
Adverse Events (AEs) and Abnormal Values of Laboratory Measurements 
7.1.1 
Clinical adverse events 
An AE is defined as any untoward medical condition in a patient or clinical study subject administered 
a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptoms, or disease temporally associated with the use of a medicinal product 
(investigational drug), whether or not considered related to the medicinal product. 
 
If an elective surgery/treatment has been scheduled prior to the study, then it is not considered as an AE. 
However, if the disease worsens during the trial (e.g. surgery/treatment is required earlier than 
scheduled), then the elective surgery/treatment due to disease worsening is considered as an AE. 
 
 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 35 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 89


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
AEs and corresponding severity during the trial should be recorded in the CRFs. Refer to Section 
7.1.1.1 for detailed severity. A causality evaluation between AEs and treatment should also be 
performed. 
7.1.1.1 Severity 
AEs are graded according to NCI CTCAE v4.03. 
 
Investigators should use the following guidelines to assess the severity of AEs that are not graded by 
NCI CTCAE: 
 
Mild 
The AE causes discomfort but does not affect activities of daily living 
Moderate 
The AE causes discomfort and affects activities of daily living 
Severe 
The subject cannot work or perform activities of daily living 
Life-Threatening The AE is life-threatening 
7.1.1.2 Causality 
The investigator will use "probably related", "possibly related", "unlikely related", and "unrelated" to 
assess the causality between adverse events and treatment. The evaluation criteria are shown in 
Appendix 1 (classification of causality between adverse events and drugs). 
7.1.1.3 Serious adverse events 
An AE meeting any one of the followings is considered as an SAE. The investigator should report the 
SAE to the sponsor and regulatory authorities according to relevant regulations within 24 hours of 
learning of the event. 
 
Death 
An adverse event that causes the death (reporting of deaths resulting from progression of 
disease is exempted) 
Life-Threatening 
An AE in which the subject is at immediate risk of death at the time of event if no medical 
interventions are taken as judged by the investigator, not an event that hypothetically might 
cause death or worsening. 
Hospitalization 
An AE that leads to hospitalization, excluding emergency or outpatient visits. 
Prolonged Hospitalization An AE occurs during the hospitalization and results in prolonged hospitalization. 
Congenital Anomaly 
An abnormality present at birth or after birth, or any malformations leading to abortion. 
Permanent or Significant 
Disability/Incapacity 
An AE that has important effect on the subject's daily life. Incapacity does not include 
medical events of relative minor importance, such as headache, nausea, vomiting, diarrhea, 
influenza, or accidental injury (e.g. ankle sprains). 
Important medical events 
requiring pharmaceutical 
or surgical interventions 
to prevent serious medical 
events 
Important medical events may not be immediately life-threatening, or result in death or 
hospitalization, but may jeopardize the subject and require pharmaceutical or surgical 
interventions to prevent any of the above outcomes (i.e., death, life threat, hospitalization 
or prolonged hospitalization, and congenital anomaly). These events may include allergic 
bronchospasm requiring treatment in an emergency room or at home, convulsions not 
requiring hospitalization, or drug dependence or abuse. 
A severe AE refers to the severity of the event, and is not necessarily an SAE, e.g. persistent vomiting 
for several hours is considered as a severe AE, but not an SAE clinically. 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 36 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 90


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
After the initial report of an SAE, medical history, autopsy report, and other necessary documents 
should be provided as required. 
 
The severity, causality with the drugs, interventions taken and outcome of an SAE should be included 
in the report. 
7.1.2 
Treatment and follow-up of adverse events 
An investigational drug-related AE should be followed until it returns to the baseline level or is stabilized. 
If an AE does not return to the baseline level or cannot be stabilized, a reasonable explanation should be 
recorded in the CRF. 
7.1.3 
Abnormal values of laboratory measurements 
7.1.3.1 Laboratory measurements 
Results of laboratory measurement/vital signs should be recorded in the CRF. Abnormal values of 
laboratory measurements that meet the criteria for SAEs should be recorded in the SAE reports and the 
CRFs as AEs simultaneously. 
 
Clinically significant abnormal values of laboratory measurements/vital signs should be recorded in 
CRFs as independent AEs if at least one of the followings are met: 
 
• 
Accompanied by clinical symptoms 
• 
Resulting in changes in administration (such as dose adjustment, treatment suspension, or 
permanent discontinuation) 
• 
Requiring changes in combined treatment (such as the addition, suspension, discontinuation of, or 
changes to combined medication or treatment) 
• 
Resulting in treatment interruption 
• 
The investigator insists on reporting as an adverse event: If an abnormality in laboratory 
measurement/vital signs is associated with clinical symptoms/sign, the corresponding clinical 
symptom/sign should be reported as an adverse event, and the abnormal lab result or vital sign 
should be recorded in the case report form as supplemental information. 
7.1.3.2 Follow-up of abnormal values of laboratory measurements 
Any clinically significant abnormal values of laboratory measurements that cannot be explained should 
be retested and followed until returning to the baseline levels, or provided with a reasonable 
explanation and recorded in the CRFs. 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 37 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 91


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
7.2 
Adverse Event Management 
7.2.1 
Adverse event reporting 
The investigator should closely monitor the clinical and laboratory evidence of each AE in the study. 
All AEs should be evaluated and recorded in detail, including the date of onset, symptoms, severity, 
outcome, duration, result of the event, relationship to the investigational drug, the diagnosis of the AE, 
and measures taken. The investigator should provide other potential information on causes of SAEs 
that are considered possibly unrelated to the investigational drug. 
 
For an AE considered intermittent, the nature and severity should be similar between each occurrence. 
All AEs should be recorded, regardless of whether they are collected from the subject's medical history, 
investigator's observation, or self-reporting by the subject. 
 
All AEs should be followed until satisfactory resolution. 
 
All adverse events and serious adverse events that occur from the signing of the informed consent form 
to 30 days after stopping the investigational drug should be collected, regardless of whether the event is 
observed by the investigator or self-reported by the subject. 
7.2.2 
Serious adverse event reporting (immediate) 
If any clinical AEs or laboratory abnormalities that occur from the study to 30 days after the last dose 
are considered as SAEs, the investigator must report the SAEs to the sponsor and regulatory authorities 
in accordance with applicable regulations within 24 hours after learning of the event, regardless of 
whether interventions are given. 
 
For SAEs occurring within the above-mentioned period, those considered related to the investigational 
drug should also be reported. 
7.2.3 
Special non-serious adverse event reporting 
Progression of Disease 
Tumor progression should not be reported as an AE or SAE. A second cancer can be instead. 
 
Lack of Treatment Efficacy 
When the disease treated by the investigational drug worsens, it may not be possible to determine 
whether it is due to lack of treatment efficacy or an adverse event. In this case, it is generally 
considered to be due to lack of treatment efficacy rather than an adverse event unless the investigator 
believes that the exacerbation is related to the investigational drug. 
 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 38 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 92


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Infusion Reaction 
Other than reporting an "infusion reaction", symptoms and AEs associated with the investigational drug 
or chemotherapy should also be reported. An AE may be related to the infusion if the event occurs 
during or within 24 hours from the chemotherapy infusion. 
The following data should be collected: 
• 
Special symptoms to be recorded in the CRFs; 
• 
Severity of each AE; 
• 
Symptoms that occur within 24 hours from the infusion, e.g. fever, chills, and hypotension. 
 
Overdose 
An overdose (whether accidental or intentional) must be reported according to procedures of treating 
the overdose, regardless of whether there are symptoms related to the overdose. All overdose-related 
symptoms should be reported as AEs. 
7.2.4 
Pregnancy 
Subjects who become pregnant during the study must immediately notify the investigator. The 
investigational drug and chemotherapy drug must be discontinued. Subjects who become pregnant 
within 90 days after the completion of treatment should also notify the investigator. The investigator 
must report the pregnancy to the sponsor within 24 hours. The investigator should discuss with the 
subject about the risks of continuing pregnancy and potential effects on the fetus. The pregnancy 
should be followed until satisfactory resolution. 
8. STATISTICAL METHODS AND ANALYSIS 
Descriptive statistics will be summarized for all variables obtained at various observation time points 
by dose cohorts, unless the protocol specifies that statistical analysis at a particular time point is not 
required. Overall, continuous variables (such as age) will be descriptively summarized with observed 
numbers, mean, median, standard deviation, minimum, and maximum. Categorical variables will be 
descriptively summarized with frequency and percentage based on each category. Continuous safety 
analysis of adverse events related to the investigational drug and other safety endpoints will be 
performed to determine how to achieve dose escalation. 
 
The analysis dataset includes all enrolled subjects who have received at least one dose of the study drug. 
This dataset is available for all analyses. Statistical methods are detailed in the Statistical Analysis Plan. 
8.1 
Pharmacokinetic Evaluation 
Two phases (single-dose and repeated dose); All PK parameters will be summarized using descriptive 
statistics by dose cohorts. The non-compartmental analysis of blood drug concentration data will be 
performed by the central laboratory using WinNonlin Enterprise. 
 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 39 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 93


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
For Cmax (natural logarithm) of the single-dose and repeated-dose phase, AUC(0-inf), AUCt, and AUClast 
will be analyzed by one-way ANOVA, with dose cohort as the fixed factor. The least squares mean 
difference between the two dose cohorts and the 90% confidence intervals are obtained from the 
analysis of variance, and then the least squares geometric means ratio and the 90% confidence intervals 
are obtained by taking the antilog. 
8.2 
Pharmacodynamics Evaluation 
Absolute neutrophil count (ANC) after administration in different dose cohorts, as well as the number 
of days of ANC less than 0.5 × 109/L, the number of days of ANC less than 1.0 × 109/L, and the time of 
ANC recovered to 1.0 × 109/L after the completion of chemotherapy in cycles 1 and 2–4 are observed. 
8.3 
Statistical Analysis of Safety Data 
All adverse events are listed by patient, and coded using MedDRA as per physiologic system and 
standard terminology. Inferential statistics are not required for safety endpoints. Abnormal values 
laboratory measurements, vital signs, ECG, and other safety endpoints need to be noted. 
9. DATA MANAGEMENT 
This study will be monitored in accordance with International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP). The clinical 
research associate will have direct access to source data and will verify the data by comparing data in 
case report forms with the data in the original medical records (patient's permitting the clinical research 
associate to directly access the data is part of the informed consent). This data verification process is an 
important part of ensuring the quality of the study. During this process, the investigator will be urged to 
correct any transcription errors and omissions. Also, the demographic data in case report forms are also 
considered as source data and should be verified before being transferred to the data management 
department. 
9.1 
Data Filling-In by Investigator 
1) All parts of the case report forms should be carefully and detailedly filled in for subjects who 
signed the informed consent forms and are eligible to participate in the trial, with no blanks or 
omissions (blank spaces should be crossed out); 
2) Data in the case report forms should be verified with medical records to ensure accuracy; 
3) Case report forms are considered as source data. When making changes, the investigator should 
cross out incorrect data, write down the correct data, then sign and date the change; 
4) Data that are significantly higher or beyond reference ranges should be verified and explained by 
the investigator; 
5) Refer to the instructions for filling in case report forms (CRFs). 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 40 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 94


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
9.2 
Requirement of Data Monitoring by Clinical Research Associate 
1) The clinical research associate should check subjects' informed consent and screening procedures 
during the course of the trial; 
2) Ensure that case report forms are filled out correctly and consistent with source data; 
3) All errors or omissions have been corrected or noted, and signed and dated by the investigator; 
4) Dose modifications, treatment changes, combined medications, and intercurrent diseases should be 
confirmed and documented for each subject; 
5) Verify that withdrawal and loss to follow-up of enrolled subjects are explained in the case report 
forms; 
6) Ensure that all adverse events have been documented, and serious adverse events have been 
documented and reported; 
7) Verify whether the drugs are supplied, stored, dispensed, and returned in accordance with 
applicable regulations, and documented accordingly; 
8) CRF must be completed for each enrolled patient; 
9) CRF is filled out by the investigator and must be completed for each enrolled patient. After the 
completed CRF is reviewed by the clinical research associate, the original copy is handed over to 
the data management personnel of the statistical teaching and research section for data entry and 
data management, the middle copy is handed over to the sponsor for archiving, and the bottom 
copy is archived at the clinical pharmacological center. 
9.3 
Data Entry, Recording and Management 
This study will use paper case report forms (pCRFs). Subject data will be clearly documented on the 
case report forms using blue or black ink. Correction fluid or tape must not be used. The clinical 
research associate of Generon (Shanghai) Corporation Ltd. will verify data during monitoring visits. 
The investigator should ensure that the data in the case report forms are accurate, complete, and clear. 
Data in the case report forms will be entered into the F-627 clinical study database and validated under 
the direction of data management personnel. Data in the case report forms that are missing, abnormal, 
or inconsistent will be presented to the investigator in data query forms and documented accordingly. 
The database is locked only after all queries have been resolved. The statistics department is 
responsible for data entry and management. The data manager will use software-compiled data entry 
programs for data entry and management. Double entry and proofreading should be performed by two 
data entry personnel independently to ensure the accuracy of data. The clinical research associate 
should submit any queries regarding case report forms to the investigator in data query forms. The 
investigator should respond and return the query as soon as possible. The medical statistician will then 
modify, confirm, and enter the data based on the investigator's response. The data query form can be 
issued again if necessary. 
The revision and inquiry of the data query form should be documented. The data query form is an 
extension to the CRF and must be kept carefully. 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 41 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 95


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
9.4 
Audits and Inspections  
The authorized representative of Generon (Shanghai) Corporation Ltd., regulatory departments, 
independent ethics committee may audit or inspect the study site, including source data verification. 
The purpose of audits or inspections is to systematically and independently check all study-related 
procedures and documents to ensure that procedures have been implemented and data have been 
recorded, analyzed, and accurately reported in accordance with study protocol, GCP, ICH guidelines, 
and other laws and regulations. The investigator should immediately contact Generon (Shanghai) 
Corporation Ltd. when an inspection of the study site has been requested by the regulatory department. 
9.5 
Personnel Training 
The principal investigator should maintain a study work record of study-related personnel (doctors, 
nurses, and other personnel). The principal investigator must ensure that all personnel have received 
appropriate training related to the study, and any new information related to the study has been 
communicated to the relevant personnel. 
10. STUDY PROTOCOL REVISIONS 
The study protocol and study procedures must not be modified without the consent of both the principal 
investigator and Generon (Shanghai) Corporation Ltd. If the study protocol must be modified, the 
amendments or new version of the protocol (revised protocol) must be reviewed and approved in 
writing by the ethics committee prior to being implemented. If applicable, it must be submitted to or 
approved by the local drug regulatory authorities according to local regulations. 
 
If there is an administrative amendment, the change must be submitted to or approved in writing by the 
ethics committee as required. Generon (Shanghai) Corporation Ltd. and the ethics committee of the 
study site must be notified if amendments to the study protocol require changes to the study site's 
informed consent form. The application of the revised informed consent form must be approved by 
Generon (Shanghai) Corporation Ltd. and the ethics committee in writing. 
 
Generon (Shanghai) Corporation Ltd. will distribute the protocol amendments and the new version of 
the study protocol to each principal investigator. The principal investigators will then be responsible for 
providing these documents to the ethics committee and other personnel at the study site. 
11. STUDY MANAGEMENT 
11.1 Clinical Study Agreement 
The principal investigator of the study site must comply with all the terms and responsibilities of this 
clinical study agreement. The investigator must follow the study protocol when there are contradictions 
between the study protocol and the study agreement. 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 42 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 96


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
11.2 Study Schedule and Requirements for Early Termination 
The study is scheduled to begin in December 2012 and end in October 2013. If the sponsor decides to 
terminate or suspend the study, the investigator and regulatory authorities must be notified in writing 
and the reason for early termination or suspension must be provided. The principal 
investigator/investigator must immediately explain the situation to subjects in this study, provide 
appropriate treatment, take necessary measures, and document the treatment measures in the source 
documents and case report forms. 
12. ETHICS 
12.1 Ethics of Clinical Study 
The study must not be initiated before the protocol is approved by the Institutional Review Board (IRB) 
or ethics committee (EC). The composition of the IRB or EC must be in accordance with State Food 
and Drug Administration (SFDA) requirements and fulfill all duties required by the SFDA. The ethics 
committee approval should include comments on the review or approval, as well as the name, gender, 
and occupation of the committee members. The clinical research associate must first receive a copy of 
the ethics committee approval before distributing the drugs to the investigator. The investigator must 
receive the ethics committee approval before enrolling subjects. 
 
According to applicable regulations of national regulatory authorities, in case of any amendments to the 
study protocol, the principal investigator is responsible for submitting to and obtaining written approval 
from the ethics committee for all study protocol amendments. The ethics committee must review 
advertisements for subject recruitment. The ethics committee must also re-approve the study protocol 
annually as required by local regulations. All SAEs or unexpected events that occur in the study must 
be reported to the EC as subject safety and the conduct of the trial may be affected. Consult the EC if 
the ethical aspects of the study need to be re-evaluated. 
 
This study must be conducted in strict accordance with the requirements of SFDA "Good Clinical 
Practice" and the "Declaration of Helsinki". 
12.2 Independent Ethics Committee (IEC) 
Before the clinical study can begin, the trial protocol, informed consent form, and other materials 
provided to subjects must be reviewed and approved by the ethics committee. Relevant approvals must 
be provided to the sponsor. 
 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 43 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 97


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
12.3 Informed Consent Form (ICF) 
The principal investigator of the study site must ensure that subjects receive adequate oral and written 
information regarding the nature, purpose, potential risks and benefits of the study, and must inform 
subjects that they may voluntarily withdraw from the study at any time. Subjects must be given the 
opportunity to ask questions and time to consider these information. The informed consent form must 
be signed and dated by each subject before the trial is initiated. The original copy must be kept by the 
investigator as part of the trial documents. A copy of the signature page is retained by the subject. The 
subject must be informed that the sponsor's designee may review the relevant medical records. 
12.4 Privacy Protection 
The informed consent form will state (or sometimes with separate documents) compliance with 
applicable data protection and privacy regulations. Based on this statement, subjects are required to 
authorize the investigator or other personnel who need to know the information to collect, use, and 
publish their data. The informed consent form will state that the study data are stored in a computer 
database and kept confidential in accordance with the applicable laws. In the database, subjects are 
only identified based on random number/study number/subject name initials. The informed consent 
form will also state that for the purpose of data verification, the sponsor's designee, regulatory 
authorities, and the ethics committee have direct access to hospital or medical records related to this 
study, including patient medical records. 
13. QUALITY CONTROL OF CLINICAL TRIAL 
In the study, the clinical research associate assigned by the sponsor will regularly conduct on-site 
monitoring visits to the study hospital to ensure that all parts of the study protocol are strictly 
implemented and the accuracy of study data. 
 
The personnel participating in the study must receive uniform training, make unified records and adopt 
the same evaluation criteria. The investigator must fill out all parts of the CRF truthfully, detailedly, 
and carefully according to requirements to ensure that the contents of the case report form is authentic 
and reliable. The evaluation criteria for abnormalities in laboratory measurement should be based on 
the normal reference ranges provided by the measurer. 
 
All observations and findings in the trial should be verified to ensure data reliability and to ensure that 
conclusions from the trial are derived from source data. Appropriate data management measures should 
be set in place during the clinical trial and data processing phases. Active measures should be taken to 
maintain a drop-out rate of < 20%. 
 
 
 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 44 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 98


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
14. Data Storage and Use 
The investigator must agree to store all study data, including confirmation of all participating subjects 
(different records, such as CRFs and hospital source data, can be effectively verified), original 
informed consent forms of all patients, CRFs, and detailed drug dispensation records. 
 
All data from this clinical trial are owned by Generon (Shanghai) Corporation Ltd. and must not be 
provided to persons unrelated to this trial in any form without the consent of the sponsor. Data from 
this study may be published only after the consent of the sponsor. 
15. REFERENCES 
1 
National Comprehensive Cancer Network(NCCN), Version 2010. 
2 
L Roskos, B B Yang et al. Pharmacokinetic/Pharmacodynamic Modeling of Pegfilgrastim in 
Healthy Subjects. J. Clin Pharmacol 2006; 46: 747-757 
3 
F. A. Holmes, S. E. Jones, J. O’Shaughnessy et al. Comparable efficacy and safety profiles of 
once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: 
a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002 ;13:903-9. 
4 
Stephen E. Jones, Michael A. Savin et al. Phase III Trial Comparing Doxorubicin Plus 
Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable 
Breast Cancer. J Clin Oncol. 2006;24:5381-5387. 
5 
Martin M, Pienkowski P, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. 
N Engl J Med 2005;352:2302-2313. 
6 
Nobuyuki Yamamoto, Ikuo Sekine, Kazuhiko Nakagawa, et al. A Pharmacokinetic and Dose 
Escalation Study of Pegfilgrastim (KRN 125) in Lung Cancer Patients with Chemotherapy-induced 
Neutropenia. Jpn J Clin Oncol 2009;39(7):425-430 
 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 45 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 99


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Appendix 
Appendix 1 Analysis of Causality Between Drugs and Adverse Events 
1) Probably related: 
 
This category applies to AEs that are considered highly likely to be caused by the drugs. The event is 
considered probably related if three of the followings are met: 
 
a) Plausible time relationship to administration. 
b) Cannot be reasonably explained by known signs and symptoms, environmental or toxic 
factors, or other treatments received. 
c) The AE resolved or improved after treatment suspension or dose reduction (with one 
exception where the AE does not resolve while drug-related toxicities persists after 
suspending treatment, such as (1) myelosuppression, (2) delayed dyskinesia). 
d) Consistent with the recognized toxicity of the suspected drug. 
e) Positive rechallenge. 
 
2) Possibly related 
 
This category applies to AEs that are not likely to be caused by the drugs, but cannot be ruled out with 
certainty. The AE is considered possibly related if two of the followings are met: 
 
a) Plausible time relationship to administration. 
b) Can be explained by disease, environmental or toxic factors, or other treatments received. 
c) Consistent with the recognized toxicity of the suspected drug. 
 
3) Unlikely related (meet 2 criteria) 
 
This category of adverse events generally meet the following criteria: 
 
a) Implausible time relationship to administration. 
b) Plausibly explained by disease, environmental or toxic factors, or other treatments received. 
c) Not consistent with the recognized toxicity of the suspected drug. 
d) Negative rechallenge. 
 
4) Unrelated 
 
This category applies to AEs that are clearly caused by other factors (disease, environment, etc.) and 
does not meet the criteria for "unlikely related", "possibly related", or "probably related". 
 
 
Probably Related 
Possibly Related Unlikely related 
Unrelated 
Clearly Caused by Other Factors 
– 
– 
– 
+ 
Plausible Time Relationship to Administration 
+ 
+ 
– 
– 
May be Explained by Disease 
– 
+ 
+ 
+ 
Recognized Toxicity of the Suspected Drug 
+ 
+ 
– 
– 
Positive Dechallenge 
+ 
– 
– 
– 
Positive Rechallenge 
+ 
– 
– 
– 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 46 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 100


F-627 Phase I Clinical Study Protocol 
Biological Product Category: Category 1 
 
Appendix 2 ECOG Performance Status Scoring Standard 
Score 
Performance Status 
0 
Fully active, able to carry on all pre-disease performance without restriction 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light nature or office 
work 
2 
Ambulatory and capable of all self care but unable to carry out any work activities; confined to bed for no more 
than 50% of waking hours 
3 
Capable of only limited self care; confined to bed or chair for more than 50% of waking hours 
4 
Completely disabled; cannot carry on any self care; totally confined to bed or chair 
5 
Death 
 
Confidential Information of Generon (Shanghai) Corporation Ltd.  
Page 47 of 47  
Generon F-627
2012-F-627-CH1: Study Protocol and Protocol Amendment - Page 101

SAP_001.pdf: 
Sponsor:  
Generon (Shanghai) Corporation Ltd. 
Protocol Number: 
2012-F-627-CH1 
Version and Date: 
Final 1.0, Dec. 6, 2013 
 
Statistical Analysis Plan 
 
 
 
 
Statistical Analysis Plan 
 
 
Generon (Shanghai) Corporation Ltd. 
 
Building 9, No.787 Kangqiao Road, 
Shanghai, 
the People's Republic of China 
 
 
Protocol Number: 2012-F-627-CH1 
 
 
A Single-Center, Open-Label, Dose-Escalation Phase I Clinical Trial of 
Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein 
for Injection as an Adjuvant to Chemotherapy in Subjects with Breast Cancer 
 
 
 
Miao Rui 
Fountain Medical Development Ltd. 
 
 
 
 
 
Statistical Analysis Plan 
Page 1 of 18 
 
2195 of 3559 
 


Sponsor:  
Generon (Shanghai) Corporation Ltd. 
Protocol Number: 
2012-F-627-CH1 
Version and Date: 
Final 1.0, Dec. 6, 2013 
 
 
Statistical Analysis Plan 
 
Sponsor: Generon (Shanghai) Corporation Ltd. 
Protocol Title: A Single-Center, Open-Label, Dose-Escalation Phase I Clinical Trial of 
Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein for 
Injection as an Adjuvant to Chemotherapy in Subjects with Breast Cancer 
 
 
Author: 
 
Miao Rui 
Statistician 
_______________ 
Fountain Medical Development Ltd. 
Signature 
 
Date: 
 
 
 
Reviewed by: 
 
Wu Yu  
Director of Statistics/Data Management 
_______________ 
Fountain Medical Development Ltd. 
Signature 
 
Date:  
 
 
 
Approved By:  
Huang Cheng  
Medical Director 
__
___ 
Generon (Shanghai) Corporation Ltd. 
Signature 
 
Date:  
 
 
 
 
 
Statistical Analysis Plan 
Page 2 of 18 
 
2196 of 3559 
 


Sponsor:  
Generon (Shanghai) Corporation Ltd. 
Protocol Number: 
2012-F-627-CH1 
Version and Date: 
Final 1.0, Dec. 6, 2013 
 
 
Table of Contents 
 
 
Page 
Statistical Analysis Plan ......................................................................................................................................... 1 
List of Abbreviations .............................................................................................................................................. 5 
1 
INTRODUCTION ........................................................................................................................................ 6 
2 
OBJECTIVES AND ENDPOINTS .............................................................................................................. 6 
2.1 
Objectives ......................................................................................................................................... 6 
2.1.1 
Primary objective .................................................................................................................. 6 
2.1.2 
Secondary objectives ............................................................................................................ 6 
2.1.3 
Exploratory objectives .......................................................................................................... 6 
2.2 
Endpoints .......................................................................................................................................... 6 
2.2.1 
Primary endpoints ................................................................................................................. 6 
2.2.2 
Secondary endpoints ............................................................................................................. 6 
2.2.3 
 ........................................................................................................... 7 
2.3 
Hypothesis Test ................................................................................................................................ 7 
3 
STUDY DESIGN ......................................................................................................................................... 7 
3.1 
Number of Study Sites ...................................................................................................................... 7 
3.2 
Sample Size ...................................................................................................................................... 7 
3.3 
Inclusion/Exclusion Criteria ............................................................................................................. 7 
3.4 
Dosage .............................................................................................................................................. 7 
3.4.1 
Single dose and repeated doses ............................................................................................. 7 
3.4.2 
Dose escalation ..................................................................................................................... 8 
3.5 
Study Duration .................................................................................................................................. 8 
3.6 
Blinding and Randomization .......................................................................................................... 11 
3.7 
Subject Withdrawal ........................................................................................................................ 11 
3.8 
Subject Replacement ...................................................................................................................... 11 
4 
Analysis Plan .............................................................................................................................................. 11 
4.1 
Interim Analysis ............................................................................................................................. 11 
4.2 
Final Analysis ................................................................................................................................. 11 
5 
SAMPLE SIZE ESTIMATION .................................................................................................................. 11 
5.1 
Sample Size Assumption ................................................................................................................ 11 
5.2 
Sensitivity Analysis for Sample Size .............................................................................................. 11 
6 
Analysis Sets .............................................................................................................................................. 12 
6.1 
Safety Analysis Set ......................................................................................................................... 12 
6.2 
PD Analysis Set .............................................................................................................................. 12 
6.3 
PK Analysis Set .............................................................................................................................. 12 
6.4 
Immunogenicity Analysis Set ......................................................................................................... 12 
Statistical Analysis Plan 
Page 3 of 18 
 
2197 of 3559 
 


Sponsor:  
Generon (Shanghai) Corporation Ltd. 
Protocol Number: 
2012-F-627-CH1 
Version and Date: 
Final 1.0, Dec. 6, 2013 
 
7 
COMPARISON OF TREATMENT REGIMENS ..................................................................................... 12 
7.1 
Data Presentation (description of dose cohorts and other subgroups) ............................................ 12 
8 
GENERAL PRINCIPLES OF DATA PROCESSING ............................................................................... 12 
8.1 
Multi-Center Study ......................................................................................................................... 12 
8.2 
Other Stratifications and Covariates ............................................................................................... 12 
8.3 
Subgroup Analysis .......................................................................................................................... 13 
8.4 
Multiple Comparison and Diversity ............................................................................................... 13 
9 
DATA PROCESSING PRINCIPLES ........................................................................................................ 13 
9.1 
Withdrawal and Missing Data ........................................................................................................ 13 
9.2 
Derived Variables ........................................................................................................................... 13 
9.2.1 
Baseline .............................................................................................................................. 13 
9.2.2 
Age ...................................................................................................................................... 13 
9.2.3 
Evaluation window ............................................................................................................. 13 
9.3 
Dictionaries for Coding .................................................................................................................. 13 
9.4 
Normal Ranges for Laboratory Measurements ............................................................................... 13 
10 
STUDY POPULATION ............................................................................................................................. 14 
10.1 
Description of Subjects ................................................................................................................... 14 
10.2 
Protocol Deviations and Violations ................................................................................................ 14 
10.3 
Demographics and Baseline Characteristics ................................................................................... 14 
10.4 
Prior Medications and Concomitant Medications .......................................................................... 15 
10.5 
Medications .................................................................................................................................... 15 
11 
EFFICACY ANALYSIS ............................................................................................................................ 15 
12 
Safety ANALYSIS ..................................................................................................................................... 15 
12.1 
Adverse Events ............................................................................................................................... 15 
12.2 
Laboratory Measurements .............................................................................................................. 16 
12.3 
Vital Signs ...................................................................................................................................... 16 
12.4 
12-Lead ECG .................................................................................................................................. 17 
12.5 
Other Safety Indicators ................................................................................................................... 17 
12.5.1 
Physical examination ....................................................................................................... 17 
12.5.2 
Abdominal ultrasound ..................................................................................................... 17 
12.5.3 
Chest X-ray ...................................................................................................................... 17 
13 
PK ANALYSIS .......................................................................................................................................... 17 
14 
PD ANALYSIS .......................................................................................................................................... 17 
15 
IMMUNOGENICITY ANALYSIS ........................................................................................................... 18 
16 
CHANGES FROM METHODS PLANNED IN THE PROTOCOL ......................................................... 18 
17 
REFERENCES ........................................................................................................................................... 18 
 
 
 
Statistical Analysis Plan 
Page 4 of 18 
 
2198 of 3559 
 


Sponsor:  
Generon (Shanghai) Corporation Ltd. 
Protocol Number: 
2012-F-627-CH1 
Version and Date: 
Final 1.0, Dec. 6, 2013 
 
List of Abbreviations 
Abbreviations 
Definitions 
AE 
Adverse Event 
ANC 
Absolute Neutrophil Count 
ATC 
Anatomical Therapeutic Chemical (ATC) Classification System 
BMI 
Body Mass Index 
CRF 
Case Report Form 
DLT 
Dose-Limiting Toxicity 
ECOG 
Eastern Cooperative Oncology Group 
LOQ 
Limit of Quantitation 
MedDRA 
ICH Medical Dictionary for Regulatory Activities 
NCI CTC 
National Cancer Institute Common Terminology Criteria 
PD 
Pharmacodynamics 
PK 
Pharmacokinetics 
PT 
Preferred Term 
SAE 
Serious Adverse Event 
SOC 
System Organ Class 
TEAE 
Treatment-Emergent Adverse Event 
WHO 
World Health Organization 
WHODD 
World Health Organization Drug Dictionary 
 
 
 
Statistical Analysis Plan 
Page 5 of 18 
 
2199 of 3559 
 






Sponsor:  
Generon (Shanghai) Corporation Ltd. 
Protocol Number: 
2012-F-627-CH1 
Version and Date: 
Final 1.0, Dec. 6, 2013 
 
3.4.2 Dose escalation 
The starting dose of F-627 is 80 μg/kg. If no or one DLT is observed in 6 subjects at the end of cycle 1, 
escalation to 240 μg/kg dose level may commence. If any grade 3 or greater AEs related to F-627 are 
observed in cycles 2–4, the investigator and the sponsor will jointly determine whether the AE may 
affect further dose escalations. The same rule applies to 240 μg/kg cohort. The maximum dose of F-627 
is 320 μg/kg. Dose escalation is not pursued after 6 subjects in the 320 µg/kg cohort complete the 
evaluation. Any DLTs observing in 320 μg/kg cohort in cycle 1 may represent a maximum dose of 
240 μg/kg for the investigational drug. 
3.5 Study Duration 
Subjects should sign an informed consent form and undergo the screening procedure, the screening 
procedure will be completed within 2 weeks prior to the initiation of treatment (1–14 days prior to 
enrollment), and eligible subjects will be enrolled. After enrollment, each subject will undergo a total 
of 4 cycles of chemotherapy with 21 days each, and will receive a chemotherapy of Epirubicin + 
Cyclophosphamide (EC) on day 1 of each cycle. A single subcutaneous injection of F-627 will be 
given 48 ± 2 hr after the completion of chemotherapy. 
The whole study will require for 84 days, and blood samples will be collected at a series of time points 
as specified in the protocol for safety assessment and PK, PD and immunogenicity analyses. Each 
subject shall complete a telephone visit 30 days (day 114) after the end of study. 
The schedule of study procedures are detailed in Table 1. 
 
 
Statistical Analysis Plan 
Page 8 of 18 
 
2202 of 3559 
 


Sponsor:  
Generon (Shanghai) Corporation Ltd. 
Protocol Number: 
2012-F-627-CH1 
Version and Date: 
Final 1.0, Dec. 6, 2013 
 
Table 1. Schedule of F-627 study procedures. 
 
Screening 
Before 
Enrollment 
Day 1, day 22, 
day 43, and 
day 64 of the 
Study6 
Day 3, day 24, 
day 45, and 
day 66 of the 
Study1 
Cycle 1 of 
Chemotherapy  
(day 3–day 21)4 
Cycles 2–4 of 
Chemotherapy  
(day 3–day 21)5 
End of 
Study 
Day 847 
Signing Informed 
Consent Form 
X 
 
 
 
 
 
History of Cancer 
X 
 
 
 
 
 
Complete Physical 
Examination 
X 
 
 
 
 
X 
Physical 
Examination 
 
X 
X 
 
 
 
Abdominal 
Ultrasound2 
X 
X 
 
 
 
 
Chemotherapy 
 
X 
 
 
 
 
Urinalysis2 
X 
X 
 
 
 
X 
Administration1 
 
 
X 
 
 
 
12-Lead ECG3 
X 
 
 
 
 
X 
Color Doppler 
Echocardiography 
X 
 
 
 
 
 
Chest X-Ray 
X 
 
 
 
 
X 
Height and 
Weight2 
X 
X 
 
 
 
 
Body Temperature 
X 
X 
X 
X 
X 
X 
Routine Blood 
Test (ANC) 
X 
X 
X 
X 
X 
X 
Clinical 
Chemistry2 
X 
X 
 
 
 
X 
Serum Pregnancy 
Test 
X 
 
 
 
 
X 
Blood Pressure 
and Heart Rate 
X 
X 
 
 
 
X 
Pharmacokinetics8 
 
 
X 
X 
X 
 
Serum Anti-Drug 
Antibody9 
 
X 
X 
X 
X 
X 
AEs and 
Combined 
Medications9 
 
 
X 
 
X 
 
X 
 
X 
 
X 
1. Three dose cohorts for F-627 (80 μg/kg, 240 μg/kg and 320 μg/kg); 
2. Examination should be completed upon enrollment and the start of each chemotherapy cycle. Body height is measured 
upon enrollment only, while body weight is measured on day 1 of each cycle; for abdominal ultrasound, a retest on day 1 of 
cycle 1 is not required and the baseline result can be used; for routine blood test and clinical chemistry before the start of 
cycle 1, results within 7 days are acceptable; 
3. 12-lead ECG should be repeated at the last visit of the study; 
Statistical Analysis Plan 
Page 9 of 18 
 
2203 of 3559 
 


Sponsor:  
Generon (Shanghai) Corporation Ltd. 
Protocol Number: 
2012-F-627-CH1 
Version and Date: 
Final 1.0, Dec. 6, 2013 
 
4. Starting on day 3 of cycle 1, oral temperature measurement and routine blood test will be performed daily until ANC 
recovers from its nadir to > 1.0 × 109/L, and once every 3 days thereafter until the next cycle; 
5. For chemotherapy cycles 2–4 (day 3–day 21 of each chemotherapy cycle, i.e., day 24–day 84 of the study), starting on 
each day 3 of cycles 2–4, oral temperature measurement and routine blood test will be performed every other day until ANC 
recovers from its nadir to > 1.0 × 109/L, and once every 3 days thereafter until the next cycle; 
6. Only when ANC of a subject recovers to > 1.0 × 109/L as judged by the investigator, can the next cycle start; 
7. The last visit is on day 84, and the subjects should complete a telephone visit on day 114 (30 days after the last visit); 
8. In cycle 1 and cycle 3, blood samples are collected for PK at time points shown in Table 30-8 in "Clinical Study 
Protocol"; 
9. In the screening period or prior to treatment with F-627, and on day 8, day 13 and day 21 of each cycle, blood samples 
will be collected for serum antibody assay. 
 
Note: All laboratory measurements will be performed at a central laboratory assigned by the investigator. In case of any 
toxicities related to chemotherapy, subsequent treatment can be modified according to common diagnosis and treatment 
practice in the judgment of the investigator. 
 
Statistical Analysis Plan 
Page 10 of 18 
 
2204 of 3559 
 


Sponsor:  
Generon (Shanghai) Corporation Ltd. 
Protocol Number: 
2012-F-627-CH1 
Version and Date: 
Final 1.0, Dec. 6, 2013 
 
3.6 Blinding and Randomization 
This is an open-label, non-randomized phase I clinical study. 
3.7 Subject Withdrawal 
Subjects meeting any of the following circumstances will withdraw from the study: 
y 
Subjects voluntarily withdraw during the study; 
y 
The investigator considers that withdrawal is for the best interest of the subject; 
y 
The investigator or subject believes that continuing the trial may result in intolerable adverse 
events; 
y 
Complications or worsening comorbidities affecting subject's participation occur; 
y 
Subject is found to violate protocol after enrollment, or a major protocol violation occurs in the 
study; 
y 
Safety issues of the study drug in the absence of data, subject will be exposed to potential risks if 
continues the participation in the study; 
3.8 Subject Replacement 
For any withdrawal from the study, corresponding remedy should be promptly performed as planned to 
ensure that there are 6 subjects per cohort completing the whole clinical trial, and acquired blood 
samples of each withdrawer should be retained for the sponsor to analyze and dispose of. If a subject 
withdraws from the study due to suspected grade 2, 3 or 4 infection according to WHO risk 
classification criteria, then his/her biological samples must not be sent to a laboratory, and instead, 
should be destructed as per operating practice of the study site. 
4 
Analysis Plan 
4.1 Interim Analysis 
This study has no formal interim analysis. 
4.2 Final Analysis 
Final analysis will be performed after all subjects have completed the clinical trial. 
5 
SAMPLE SIZE ESTIMATION 
5.1 Sample Size Assumption 
This study is a phase I clinical study, for which sample size is calculated mainly according to 
acceptance criteria in similar studies. In this study, at least 18 female subjects are required (3 dose 
cohorts), and there is no formal algorithm for sample size. 
5.2 Sensitivity Analysis for Sample Size 
This analysis does not apply to this study. 
Statistical Analysis Plan 
Page 11 of 18 
 
2205 of 3559 
 


Sponsor:  
Generon (Shanghai) Corporation Ltd. 
Protocol Number: 
2012-F-627-CH1 
Version and Date: 
Final 1.0, Dec. 6, 2013 
 
6 
Analysis Sets 
Analysis sets should be defined prior to final analysis after database locking. 
6.1 Safety Analysis Set 
Safety analysis set is defined as a set of all subjects who have received at least one dose of study drug 
in actual practice, and is mainly used in assessment of demographics and baseline characteristics and 
safety evaluation. 
6.2 PD Analysis Set 
PD analysis set is defined as a set of all subjects who have received at least one dose of study drug in 
actual practice with at least one valid PD measurement, and is mainly used in PD analysis. 
6.3 PK Analysis Set 
PK analysis set is defined as a set of all subjects who have received at least one dose of study drug in 
actual practice with at least one valid serum F-627 concentration, and is mainly used in PK analysis. 
6.4 Immunogenicity Analysis Set 
Immunogenicity analysis set is defined as a set of all subjects who have received at least one dose of 
study drug in actual practice with at least one valid serum antibody (IgG) concentration, and is mainly 
used in immunogenicity analysis. 
7 
COMPARISON OF TREATMENT REGIMENS 
7.1 Data Presentation (description of dose cohorts and other subgroups) 
Data will be presented by dose cohort in the following order: 
y 
80 µg/kg 
y 
240 µg/kg 
y 
320 µg/kg 
8 
GENERAL PRINCIPLES OF DATA PROCESSING 
All statistical analyses should be performed using SAS 9.1 or later version. 
All data in the database will be presented in tables. Unless otherwise stated, data will be sorted in 
tables by dose cohort, subject number and test time point. In general, continuous variables (e.g., age) 
will be descriptively summarized using numbers of observations, means, medians, standard deviations, 
minimums and maximums. The minimum and maximum values shall be rounded to the same decimal 
place as CRF record, and 1 more decimal place than corresponding source data is required for means 
and medians, and 2 more for standard deviations. Categorical variables will be descriptively summarized 
with frequencies and percentages by category. Percentages shall be rounded to 1 decimal place. 
8.1 Multi-Center Study 
This is a single-center study.  
8.2 Other Stratifications and Covariates  
This analysis is not considered in this study. 
Statistical Analysis Plan 
Page 12 of 18 
 
2206 of 3559 
 


Sponsor:  
Generon (Shanghai) Corporation Ltd. 
Protocol Number: 
2012-F-627-CH1 
Version and Date: 
Final 1.0, Dec. 6, 2013 
 
8.3 Subgroup Analysis 
Subgroup analysis is not specified in the clinical study protocol. 
8.4 Multiple Comparison and Diversity 
Descriptive statistics are used in this study, for which multiple comparison and diversity are not 
considered. 
9 
DATA PROCESSING PRINCIPLES 
9.1 Withdrawal and Missing Data 
For a subject withdraws from the study, all data prior to the withdrawal will be included in all analyses.  
In safety analysis set, if the CTCAE (v4.03) grade of an AE is missing, then it is categorized as 
a grade 5 AE in statistical analysis. If the causality assessment of an AE is missing, then it is 
categorized as "related to F-627" in statistical analysis. If the start time of an AE is missing, 
then it is considered a TEAE in statistical analysis. 
9.2 Derived Variables 
9.2.1 Baseline 
Baseline for the entire treatment is defined as the last effective value measured prior to first chemotherapy 
of the treatment. Baseline for a cycle is defined as the last effective value measured prior to the 
chemotherapy cycle. Baseline characteristics are based on a population without missing results. 
9.2.2 Age 
The equation for calculating age is as follows: 
Age (years) = (Date of signing informed consent form - Date of birth + 1)/365.25, rounded down. 
Days since diagnosis = Date of signing informed consent form - Date of breast cancer diagnosis 
9.2.3 Evaluation window  
This analysis does not apply to this study. 
9.3 Dictionaries for Coding 
Combined medications are coded using the Anatomical Therapeutic Chemical (ATC) Classification 
System of the WHO Drug Dictionary (WHODD). 
Adverse events, medical history and surgical history are coded according to system organ class (SOC) 
and preferred term (PT) in ICH Medical Dictionary for Regulatory Activities Terminology (MedDRA) 
Chinese version 16.0. 
9.4 Normal Ranges for Laboratory Measurements 
Normal ranges for laboratory measurements involved in this study will be provided by Fudan 
University Shanghai Cancer Center. Based on the normal ranges provided by the laboratory, 
results will be classified as low (below the lower limit of normal range), normal (within the normal 
range), or high (above the upper limit of normal range). 
Normal ranges of laboratory measurements involved in this study will be listed by tabulation, 
and laboratory measurements in tables will be marked with H or L to indicate high or low levels. 
Statistical Analysis Plan 
Page 13 of 18 
 
2207 of 3559 
 


Sponsor:  
Generon (Shanghai) Corporation Ltd. 
Protocol Number: 
2012-F-627-CH1 
Version and Date: 
Final 1.0, Dec. 6, 2013 
 
10 STUDY POPULATION 
10.1 Description of Subjects 
Information of subject screening for all dose cohorts, status of dose cohorts in various analysis sets, 
screening failures, study completions and withdrawals will be summarized, and causes of 
withdrawals will be summarized by category. 
Information of all subjects withdrawing from the study will be tabulated, with their subject numbers, 
ages, time of the first chemotherapy, time of first administration of F-627, time of withdrawal, and 
causes of premature discontinuation indicated by dose cohort. 
Distribution in data analysis sets will be tabulated, with subject numbers, presence in safety analysis set, 
presence in PD analysis set, presence in PK analysis set, and presence in immunogenicity analysis set 
listed by dose cohort. 
10.2 Protocol Deviations and Violations 
To determine if the protocol has been well followed, data of all subjects in CRF will be checked for any 
protocol deviation or violation after database locking. All potential protocol deviations and violations 
will be independently reviewed and assessed by Generon (Shanghai) Corporation Ltd. 
No data will be excluded from any analysis set due to protocol deviation or violation.  
All protocol deviations and violations will be summarized by category and will be tabulated for 
analysis. 
All protocol deviations and violations are accidental, unconscious changes of or incompliances with the 
clinical study protocol. A protocol deviation will neither increase risks nor decrease benefits, will not 
adversely affect the right, safety or welfare of a subject, and will not damage data integrity, either; 
whereas a protocol violation will go the opposite way. 
Protocol deviations in the following categories should be summarized for analysis: 
y 
Inconsistency between actual treatment time and planned treatment time, e.g., out of time 
window, etc. 
Protocol violations in the following categories should be summarized for analysis: 
y 
Subjects who do not meet the inclusion/exclusion criteria but are enrolled in the study 
y 
Subjects receiving incorrect treatment regimens or doses 
y 
Subjects taking any other prohibited drugs 
y 
Withdrawal from the study 
10.3 Demographics and Baseline Characteristics 
All demographics and baseline data obtained in the screening will be provided as tabulate. 
Demographics of subjects [age, sex, ethnicity, height, and body mass index (BMI)] in the screening 
will be statistically described by dose cohort. 
Diagnostic characteristics (presence of breast cancer, histopathological diagnosis, days since diagnosis, 
and TNM staging), performance status, chemotherapy history, smoking history (current smoker, former 
smoker and never smoker), surgical history, and medical history of subjects will be statistically 
described by dose cohort respectively. 
Statistical Analysis Plan 
Page 14 of 18 
 
2208 of 3559 
 


Sponsor:  
Generon (Shanghai) Corporation Ltd. 
Protocol Number: 
2012-F-627-CH1 
Version and Date: 
Final 1.0, Dec. 6, 2013 
 
Medical history and surgical history are coded according to system organ class (SOC) and preferred 
term (PT) in ICH Medical Dictionary for Regulatory Activities Terminology (MedDRA) Chinese 
version 16.0. 
10.4 Prior Medications and Concomitant Medications 
Combined medications are coded using the Anatomical Therapeutic Chemical (ATC) Classification 
System of the WHO Drug Dictionary (WHODD). 
Prior medications and concomitant medications are classified and summarized according to ATC Level 
1 and Level 2. In the summary, a medication (based on ATC classification) will be recorded only once 
when the subject uses the same medication more than once. 
Prior medication is defined as a medication that has already been discontinued before the first dose of 
the investigational drug F-627. Concomitant medication is defined as a medication that initiates after 
the first dose of the investigational drug F-627 or a medication that starts before and continues after the 
first dose of investigational drug F-627. A medication is considered a prior medication if its end date 
coincides with the date the investigational drug F-627 starts. 
All combined medications should be tabulated for analysis. 
10.5 Medications 
All information of investigational drug F-627 will be tabulated by dose cohort, subject code, treatment 
stage, dosing date, total dose of actual medication, and route of administration respectively. 
Similarly, data of adjuvant chemotherapy medications (epirubicin, cyclophosphamide, etc.) will be 
tabulated. 
11 EFFICACY ANALYSIS 
This study has no efficacy endpoint. 
12 Safety ANALYSIS 
All safety analyses should be based on safety analysis set. 
12.1 Adverse Events 
Adverse events (AEs) are coded according to system organ class (SOC) and preferred term (PT) in ICH 
Medical Dictionary for Regulatory Activities Terminology (MedDRA) 16.0. 
During the entire course of treatment, TEAE is defined as any AE occurring or worsening after starting 
treatment with F-627. For each cycle, TEAE is defined as any AE occurring or worsening after starting 
treatment with F-627 in the cycle.  
In statistical summary of TEAEs, if a subject experiences the same TEAE at least once in a stage, then 
he/she will be considered to experience this TEAE in the stage. TEAE incidence rate is based on the 
number of subjects experiencing a TEAE, rather than the number of TEAE. 
Firstly, AEs, TEAEs, study drug-related TEAEs, grade 3 or greater (as per NCI CTCAE V4.03) TEAEs, 
study drug-related grade 3 or greater TEAEs, TEAEs leading to permanent discontinuation, serious 
adverse events (SAEs), study drug-related SAEs, grade 3 or greater SAEs, study drug-related grade 3 
or greater SAEs, and mortality throughout the treatment and in each cycle will be summarized by dose 
cohort respectively. 
Secondly, the following AEs occurring in various dose cohorts throughout the treatment and in each 
Statistical Analysis Plan 
Page 15 of 18 
 
2209 of 3559 
 


Sponsor:  
Generon (Shanghai) Corporation Ltd. 
Protocol Number: 
2012-F-627-CH1 
Version and Date: 
Final 1.0, Dec. 6, 2013 
 
cycle will be described in detail by SOC and PT respectively: 
• 
TEAE 
• 
Study drug-related TEAEs 
• 
Grade 3 or greater TEAEs 
• 
Study drug-related grade 3 or greater TEAEs 
• 
TEAEs classified as per NCI CTCAE V4.03 
• 
Drug-related TEAEs classified as per NCI CTCAE V4.03 
y 
TEAEs leading to permanent discontinuation 
y 
SAE 
y 
Study drug-related SAEs 
y 
Grade 3 or greater SAEs 
y 
Study drug-related grade 3 or greater SAEs 
y 
Death. 
All AEs and SAEs will be listed in detail. 
12.2 Laboratory Measurements 
Laboratory measurements include routine blood test, clinical chemistry, and urinalysis. 
Results of laboratory measurements (quantitative parameters of routine blood test, clinical chemistry 
and urinalysis) at baseline and at post-baseline time points (day 22, day 43, day 64, and day 84) will be 
descriptively analyzed respectively, and changes of laboratory measurement results from baseline will 
be given. Baseline is defined as the last effective value measured prior to the first chemotherapy. 
Based on the normal ranges provided by the laboratory, results of laboratory measurements 
(quantitative parameters of routine blood test, clinical chemistry and urinalysis) will be classified as 
low (below the lower limit of normal range), normal (within the normal range), high (above the upper 
limit of normal range) and not detected (missing). Changes from baseline of laboratory measurements 
results (quantitative parameters of routine blood test, clinical chemistry and urinalysis, and qualitative 
parameters of urinalysis) at various post-baseline time points will be summarized by category using 
SHIFT TABLE. 
Similarly, results of routine blood test in each chemotherapy cycle will be summarized. Baseline for 
a cycle is defined as the last effective value measured prior to the chemotherapy cycle. 
All laboratory measurements results will be tabulated. 
12.3 Vital Signs 
Parameters of vital signs (heart rate, respiratory rate, systolic pressure, diastolic pressure, body weight 
and body temperature) measured at baseline and at post-baseline time points (day 22, day 43, day 64, 
and day 84) will be descriptively analyzed respectively, and changes from baseline of each parameter at 
post-baseline time points will be given. Baseline is defined as the last effective value measured prior to 
the first chemotherapy. 
Similarly, body temperatures in each chemotherapy cycle will be summarized, and body temperature 
Statistical Analysis Plan 
Page 16 of 18 
 
2210 of 3559 
 


Sponsor:  
Generon (Shanghai) Corporation Ltd. 
Protocol Number: 
2012-F-627-CH1 
Version and Date: 
Final 1.0, Dec. 6, 2013 
 
profiles over time in cycle 1 and cycles 2–4 will be plotted by dose cohort. Baseline for a cycle is 
defined as the last effective value measured prior to the chemotherapy cycle. 
Results of vital signs at various time points will be tabulated. 
12.4 12-Lead ECG 
Results of 12-lead ECG (normal, clinically insignificant abnormality, or clinically insignificant 
abnormality) at baseline and on day 84 will be descriptively analyzed. In addition, changes from 
baseline of 12-lead ECG results on day 84 will be summarized by category using shift table. 
Results of 12-lead ECG will be tabulated. 
12.5 Other Safety Indicators 
Results of physical examination, abdominal ultrasound and chest X-ray will be descriptively 
summarized and tabulated respectively, while pregnancy test results will be tabulated only. 
12.5.1 Physical examination 
Changes from baseline of physical examination results (normal, abnormal or not detected) at post-baseline 
time points (day 22, day 43, day 64 and day 84) will be summarized by category using shift table. 
Results of physical examination will be tabulated. 
12.5.2 Abdominal ultrasound 
Changes from baseline of abdominal ultrasound results (normal, abnormal without clinical significance, 
and abnormal with clinical significance) at post-baseline time points (day 22, day 43, day 64 and 
day 84) will be summarized by category using shift table. 
Results of abdominal ultrasound will be tabulated. 
12.5.3 Chest X-ray 
Changes from baseline of chest X-ray results on day 84 (normal, abnormal without clinical significance, 
and abnormal with clinical significance) will be summarized by category using shift table. 
Results of chest X-ray will be tabulated. 
13 PK ANALYSIS 
Serum F-627 concentrations after dosing will be descriptively analyzed by dose cohort. In addition, 
serum F-627 concentrations after dosing will be tabulated by dose cohort. 
Any other PK data and reports will be provided by Covance Pharmaceutical R&D (Shanghai) Co., Ltd. 
authorized by the sponsor. 
14 PD ANALYSIS 
All PD analyses are based on PD analysis set.  
For cycle 1, starting on day 3, routine blood test will be performed daily until ANC recovers from 
its nadir to a value not less than 1.0×109/L, and once every 3 days thereafter until the next cycle; 
for chemotherapy cycles 2–4 (day 3–day 21 of each chemotherapy cycle, i.e., day 24–day 84 of the 
study), starting on each day 3 of cycles 2–4, routine blood test will be performed every other day until 
ANC recovers from its nadir to > 1.0 × 109/L, and once every 3 days thereafter until the next cycle. 
Number of days when ANC is less than 0.5 × 109/L, number of days when ANC is less than 1.0 × 109/L, 
Statistical Analysis Plan 
Page 17 of 18 
 
2211 of 3559 
 


Sponsor:  
Generon (Shanghai) Corporation Ltd. 
Protocol Number: 
2012-F-627-CH1 
Version and Date: 
Final 1.0, Dec. 6, 2013 
 
ANC nadir, time to ANC nadir, and time of ANC recovery from nadir to 1.0 × 109/L in cycle 1 and 
in cycles 2–4 after study drug administration will be descriptively analyzed by dose cohort, and the 
logarithm of mean ANC profiles over time for each dose cohort in cycle 1 and in cycles 2–4 after study 
drug administration will be provided respectively. 
ANC nadir, time to ANC nadir, and time of ANC recovery from nadir to 1.0 × 109/L after study drug 
administration throughout the treatment will be descriptively analyzed by dose cohort.  
PK/PD profiles of F-627 in cycle 1 and in cycle 3 will be given by dose cohort. 
15 IMMUNOGENICITY ANALYSIS 
All immunogenicity analyses are based on immunogenicity analysis set. 
In the screening period or prior to treatment with F-627, and on day 8, day 13 and day 21 of each cycle, 
blood samples will be collected for serum antibody assay. 
Results of serum antibody assay at baseline and at post-baseline time points (day 22, day 43, day 64, 
and day 84) will be descriptively analyzed respectively, and changes from baseline of serum antibody 
assay results (negative, positive or false-positive) will be given using shift table. Baseline is defined as 
the last effective value measured prior to the first chemotherapy. 
Similarly, results of serum antibody assay in each chemotherapy cycle will be summarized. Baseline 
for a cycle is defined as the last effective value measured prior to the chemotherapy cycle. 
Results of serum antibody (IgG) assay will be tabulated by dose cohort, subject number, and test time 
point. 
16 CHANGES FROM METHODS PLANNED IN THE PROTOCOL 
This statistical analysis plan is consistent with the clinical study protocol in terms of statistical analysis 
method. This statistical analysis plan shall prevail. 
17 REFERENCES 
Not available. 
Statistical Analysis Plan 
Page 18 of 18 
 
2212 of 3559